Peptidomimetics for the treatment of coronavirus and picornavirus infections

ABSTRACT

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional 62/857,674 filedJun. 5, 2019, entitled “PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUSAND PICORNAVIRUS INFECTIONS”.

FIELD OF THE INVENTION

The present invention is directed to compounds, methods and compositionsfor preventing, treating and/or curing Coronavirus infections, includingEnterovirus infections. More specifically, the invention describesspecifically modified peptidomimetics, pharmaceutically acceptablesalts, or other derivatives thereof, and the use thereof in thetreatment of these infections.

BACKGROUND OF THE INVENTION

Coronaviruses are a species of virus belonging to the subfamilyCoronavirinae in the family Coronaviridae, and are enveloped viruseswith a positive-sense single-stranded RNA genome and with a nucleocapsidof helical symmetry.

Coronaviruses primarily infect the upper respiratory andgastrointestinal tract of mammals and birds, though several knownstrains infect humans as well. Coronaviruses are believed to cause asignificant percentage of all common colds in human adults and children.

Coronaviruses, including the OC43 virus, cause colds with majorsymptoms, e.g., fever, throat congestion and adenoids, in humansprimarily in the winter and early spring seasons. Coronaviruses can alsocause pneumonia, either direct viral pneumonia or a secondary bacterialpneumonia, bronchitis, either direct viral bronchitis or a secondarybacterial bronchitis, and severe acute respiratory syndrome (SARS).

Coronaviruses also cause a range of diseases in farm animals anddomesticated pets, some of which can be serious and are a threat to thefarming industry. In chickens, the infectious bronchitis virus (IBV), acoronavirus, targets not only the respiratory tract but also theuro-genital tract. The virus can spread to different organs throughoutthe chicken.

Economically significant coronaviruses of farm animals include porcinecoronavirus (transmissible gastroenteritis coronavirus, TGE) and bovinecoronavirus, which both result in diarrhea in young animals. FelineCoronavirus: two forms, Feline enteric coronavirus is a pathogen ofminor clinical significance, but spontaneous mutation of this virus canresult in feline infectious peritonitis (FIP), a disease associated withhigh mortality. There are two types of canine coronavirus (CCoV), onethat causes mild gastrointestinal disease and one that has been found tocause respiratory disease. Mouse hepatitis virus (MHV) is a coronavirusthat causes an epidemic murine illness with high mortality, especiallyamong colonies of laboratory mice.

Some strains of MHV cause a progressive demyelinating encephalitis inmice which has been used as a murine model for multiple sclerosis.

More recently a coronavirus pandemic has caused a dual threat to thehealth and the economy of the U.S. and the world. COVID-19 was firstidentified in December 2019 in Wuhan, Hubei province, China, resultingin the ongoing 2019-2020 pandemic. COVID-19 is caused by the severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2). Common symptomsof the disease include fever (88%), dry cough (68%), shortness of breath(19%), and loss of smell (15 to 30%). Complications may includepneumonia, viral sepsis, acute respiratory distress syndrome, diarrhea,renal disease, cardiac issues and encephalitis. As of June, 2020, thetotal number of infected worldwide stood at over 4 million and at least102,753 had died, and, according to the Johns Hopkins UniversityCoronavirus Resource Center, almost two million people had testedpositive for coronavirus in the U.S. and over one hundred thousandpeople had died of the disease. Local transmission of the disease hasbeen recorded in over 200 countries. Risk factors include travel andviral exposure, and prevention is assisted by social distancing andquarantine.

Enteroviruses are members of the picornavirus family, a large anddiverse group of small RNA viruses characterized by a singlepositive-strand genomic RNA, and are associated with several human andmammalian diseases. Enteroviruses are named by their transmission-routethrough the intestine (enteric meaning intestinal). On the basis oftheir pathogenesis in humans and animals, enteroviruses were originallyclassified into four groups, polioviruses, Coxsackie A viruses (CA),Coxsackie B viruses (CB), and echoviruses, though Enteroviruses isolatedmore recently are named with a system of consecutive numbers, forexample, EV68, EV69, EV70, EV71, etc.

Enteroviruses affect millions of people worldwide each year and areoften found in the respiratory secretions (e.g., saliva, sputum, ornasal mucus) and stool of an infected person. Historically,poliomyelitis was the most significant disease caused by an enterovirus,namely poliovirus.

Poliovirus, as well as coxsackie and echovirus, is spread through thefecal-oral route. Infection can result in a wide variety of symptoms,including those of: mild respiratory illness (the common cold), hand,foot and mouth disease, acute hemorrhagic conjunctivitis, asepticmeningitis, myocarditis, severe neonatal sepsis-like disease, acuteflaccid paralysis, and the related acute flaccid myelitis.

Current treatments for these infections are mainly supportive,minimizing the symptoms rather than treating the underlying viralinfection. For example, patients may be treated with analgesics torelieve pain, and patients with enteroviral carditis can be treated forcomplications such as arrhythmias, pericardial effusion, and cardiacfailure.

It would be advantageous to provide new antiviral agents, compositionsincluding these agents, and methods of treatment using these agents totreat coronaviruses and picornaviruses. The present invention providessuch agents, compositions and methods.

SUMMARY OF THE INVENTION

The present invention provides compounds, methods and compositions forpreventing, treating and/or curing infections caused by coronaviruses,picornaviruses (e.g., an enterovirus or a rhinovirus) and/or viruses inthe hepeviridae family (e.g., hepatitis E) in a host, or reducing theactivity of these viral infections in the host. In some embodiments, thehost is a human, and in others, is an animal such as a cat or dog. Bothhuman and veterinary embodiments are within the scope of the methodsdescribed herein.

The methods involve administering a therapeutically orprophylactically-effective amount of at least one compound as describedherein to treat, cure or prevent an infection by, or an amountsufficient to reduce the biological activity of, a coronavirus,picornavirus, and/or hepeviridae infection.

In one embodiment, the compounds are used to treat a patient sufferingfrom multiple virus infections, such as hepatitis E and enterovirus(EV). The compounds can also be used to treat norovirus (noV)infections, so the combination of viral infections can include noV inaddition to a coronavirus, picornovirus, and/or hepeviridae virus.

The pharmaceutical compositions include one or more of the compoundsdescribed herein, in combination with a pharmaceutically acceptablecarrier or excipient, for treating a host infected with coronaviruses,picornaviruses, and/or hepeviridae viruses. The formulations can furtherinclude at least one other therapeutic agent. In addition, the presentinvention includes processes for preparing such compounds.

In one embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R¹ is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy,arylalkoxy, or heteroarlalkoxy,

R³ is an optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈alkoxyalkyl, arylalkyl, alkylaryl, heteroarylalkyl, or alkylheteroaryl,specifically including —CH₂-napthyl, —CH₂-(hydroxy)phenyl, such as—CH₂-(4-hydroxy)phenyl, and —CH₂-(halo)phenyl, such as—CH₂-(4-halo)phenyl, including —CH₂-(fluoro)phenyl, specifically,—CH₂-(4-fluoro)phenyl. Alkylaryl and alkylheteroaryl are preferredvariables.

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —C(O)H, CH═C(CN)C(O)NH₂, —C(O)CF₃, —CH(OH)CF₃, —C(OH)SO₃ ⁻ (and anassociated cation, such as Na⁺), or an optionally-substituted epoxidering, and is preferably —C(O)H,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl, and in one embodiment, are allH,

X is, independently, a bond, O or NH,

m, n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom.

In yet another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein p, X, R¹, R², R^(2′), R³, R⁴ and R⁵ are as defined above.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein p, X, R¹, R², R^(2′), R³, R⁴ and R⁵ are as defined above.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein R⁴, R⁵, R⁷, R^(7′), R¹⁰, and R^(10′) are as defined above, andR¹ is an optionally-substituted C₆₋₁₂ cycloalkyl, anoptionally-substituted five or six membered ring heteroaryl, such as

and is preferably an optionally-substituted five or six membered ringheteroaryl.

In another embodiment, the compounds have the following formula:

where R³, R⁴, R⁵, R⁶, R^(6′), R⁷, R^(7′), R¹⁰, R^(10′), m and n are asdefined above, and R1 is a five or six membered ring heteroaryl,

and pharmaceutically-acceptable salts and prodrugs thereof.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically-acceptable salt or prodrug thereof,

wherein Cbz=carbobenzoxy, and R³, R⁴, R⁵, R⁶, R^(6′), R⁷, R^(7′), R¹⁰,R^(10′), m and n are as defined above.

In another embodiment of the compounds of Formulas I-VI,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

where R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl,C₂₋₁₀ alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl.

In yet another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R³ is an optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈alkoxyalkyl, arylalkyl, alkylaryl, heteroarylalkyl, or alkylheteroaryl,—CH₂-(hydroxy)phenyl, and —CH₂-(halo)phenyl,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In yet another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

m=2

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R³ is an optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈alkoxyalkyl, arylalkyl, alkylaryl, heteroarylalkyl, or alkylheteroaryl,—CH₂-(hydroxy)phenyl, and —CH₂-(halo)phenyl,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

m=2 or 3

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In certain embodiments of any of Formulas I-X, X is O, R² and R^(2′) areH, and R¹ is an optionally substituted phenyl.

In certain embodiments of any of Formulas I-X, X=a covalent bond, p=0,and R1 is an optionally substituted aryl or heteroaryl.

In certain embodiments of any of Formulas I-X, the heteroaryl ring is apyrazine, thiophene, isoxazole, or oxazole ring.

In certain embodiments of any of Formulas I-X, R³ is phenyl,halo-substituted phenyl, or naphthyl.

Representative compounds include the following:

and pharmaceutically-acceptable salts and prodrugs thereof.

DETAILED DESCRIPTION

In one embodiment, compounds and compositions useful in treating,preventing, or curing coronavirus, picornavirus, and/or hepeviridaevirus infections are disclosed. Methods for treating, preventing, orcuring coronavirus, picornavirus, and/or hepeviridae virus infectionsare also disclosed.

The compounds described herein show inhibitory activity againstenterovirus infections in cell-based assays. Therefore, the compoundscan be used to treat or prevent an enterovirus infection in a host, orreduce the biological activity of the virus. The host can be a mammal,and in particular, a human, infected with an enteroviral infection. Themethods involve administering an effective amount of one or more of thecompounds described herein.

Pharmaceutical formulations including one or more compounds describedherein, in combination with a pharmaceutically acceptable carrier orexcipient, are also disclosed. In one embodiment, the formulationsinclude at least one compound described herein and at least one furthertherapeutic agent.

The present invention will be better understood with reference to thefollowing definitions:

I. Definitions

The term “independently” is used herein to indicate that the variable,which is independently applied, varies independently from application toapplication. Thus, in a compound such as R″XYR″, wherein R″ is“independently carbon or nitrogen,” both R″ can be carbon, both R″ canbe nitrogen, or one R″ can be carbon and the other R″ nitrogen.

As used herein, the term “enantiomerically pure” refers to a compoundcomposition that comprises at least approximately 95%, and, preferably,approximately 97%, 98%, 99% or 100% of a single enantiomer of thatcompound.

As used herein, the term “substantially free of” or “substantially inthe absence of” refers to a compound composition that includes at least85 to 90% by weight, preferably 95% to 98% by weight, and, even morepreferably, 99% to 100% by weight, of the designated enantiomer of thatcompound. In a preferred embodiment, the compounds described herein aresubstantially free of enantiomers.

Similarly, the term “isolated” refers to a compound composition thatincludes at least 85 to 90% by weight, preferably 95% to 98% by weight,and, even more preferably, 99% to 100% by weight, of the compound, theremainder comprising other chemical species or enantiomers.

The term “alkyl,” as used herein, unless otherwise specified, refers toa saturated straight, branched, or cyclic, primary, secondary, ortertiary hydrocarbons, including both substituted and unsubstitutedalkyl groups. The alkyl group can be optionally substituted with anymoiety that does not otherwise interfere with the reaction or thatprovides an improvement in the process, including but not limited to butlimited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl,sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid,phosphonate, either unprotected, or protected as necessary, as known tothose skilled in the art, for example, as taught in Greene, et al.,Protective Groups in Organic Synthesis, John Wiley and Sons, SecondEdition, 1991, hereby incorporated by reference. Specifically includedare CF₃ and CH₂CF₃.

In the text, whenever the term C(alkyl range) is used, the termindependently includes each member of that class as if specifically andseparately set out. The term “alkyl” includes C₁₋₂₂ alkyl moieties, andthe term “lower alkyl” includes C₁₋₆ alkyl moieties. It is understood tothose of ordinary skill in the art that the relevant alkyl radical isnamed by replacing the suffix “-ane” with the suffix “-yl”.

As used herein, a “bridged alkyl” refers to a bicyclo- or tricycloalkane, for example, a 2:1:1 bicyclohexane.

As used herein, a “spiro alkyl” refers to two rings that are attached ata single (quaternary) carbon atom.

The term “alkenyl” refers to an unsaturated, hydrocarbon radical, linearor branched, in so much as it contains one or more double bonds. Thealkenyl group disclosed herein can be optionally substituted with anymoiety that does not adversely affect the reaction process, includingbut not limited to but not limited to those described for substituentson alkyl moieties. Non-limiting examples of alkenyl groups includeethylene, methylethylene, isopropylidene, 1,2-ethane-diyl,1,1-ethane-diyl, 1,3-propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl,and 1,4-butane-diyl.

The term “alkynyl” refers to an unsaturated, acyclic hydrocarbonradical, linear or branched, in so much as it contains one or moretriple bonds. The alkynyl group can be optionally substituted with anymoiety that does not adversely affect the reaction process, includingbut not limited to those described above for alkyl moieties.Non-limiting examples of suitable alkynyl groups include ethynyl,propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl,pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylbutyn-1-yl, hexyn-1-yl,hexyn-2-yl, and hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals.

The term “alkylamino” or “arylamino” refers to an amino group that hasone or two alkyl or aryl substituents, respectively.

The term “protected” as used herein and unless otherwise defined refersto a group that is added to an oxygen, nitrogen, or phosphorus atom toprevent its further reaction or for other purposes. A wide variety ofoxygen and nitrogen protecting groups are known to those skilled in theart of organic synthesis, and are described, for example, in Greene etal., Protective Groups in Organic Synthesis, supra.

The term “aryl”, alone or in combination, means a carbocyclic aromaticsystem containing one, two or three rings wherein such rings can beattached together in a pendent manner or can be fused. Non-limitingexamples of aryl include phenyl, biphenyl, or naphthyl, or otheraromatic groups that remain after the removal of a hydrogen from anaromatic ring. The term aryl includes both substituted and unsubstitutedmoieties. The aryl group can be optionally substituted with any moietythat does not adversely affect the process, including but not limited tobut not limited to those described above for alkyl moieties.Non-limiting examples of substituted aryl include heteroarylamino,N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, heteroaralkoxy,arylamino, aralkylamino, arylthio, monoarylamidosulfonyl,arylsulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl,arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl,heteroarylsulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,hydroxyaralkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl,aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partiallysaturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl,arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl, andcarboaralkoxy.

The terms “alkaryl” or “alkylaryl” refer to an alkyl group with an arylsubstituent. The terms “aralkyl” or “arylalkyl” refer to an aryl groupwith an alkyl substituent.

The term “halo,” as used herein, includes chloro, bromo, iodo andfluoro.

The term “acyl” refers to a carboxylic acid ester in which thenon-carbonyl moiety of the ester group is selected from the groupconsisting of straight, branched, or cyclic alkyl or lower alkyl,alkoxyalkyl, including, but not limited to methoxymethyl, aralkyl,including, but not limited to, benzyl, aryloxyalkyl, such asphenoxymethyl, aryl, including, but not limited to, phenyl, optionallysubstituted with halogen (F, Cl, Br, or I), alkyl (including but notlimited to C₁, C₂, C₃, and C₄) or alkoxy (including but not limited toC₁, C₂, C₃, and C₄), sulfonate esters such as alkyl or aralkyl sulphonylincluding but not limited to methanesulfonyl, the mono, di ortriphosphate ester, trityl or monomethoxytrityl, substituted benzyl,trialkylsilyl (e.g., dimethyl-t-butylsilyl) or diphenylmethylsilyl. Arylgroups in the esters optimally comprise a phenyl group. The term “loweracyl” refers to an acyl group in which the non-carbonyl moiety is loweralkyl.

The terms “alkoxy” and “alkoxyalkyl” embrace linear or branchedoxy-containing radicals having alkyl moieties, such as methoxy radical.The term “alkoxyalkyl” also embraces alkyl radicals having one or morealkoxy radicals attached to the alkyl radical, that is, to formmonoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy” radicals can befurther substituted with one or more halo atoms, such as fluoro, chloroor bromo, to provide “haloalkoxy” radicals. Examples of such radicalsinclude fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy,trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, andfluoropropoxy.

The term “alkylamino” denotes “monoalkylamino” and “dialkylamino”containing one or two alkyl radicals, respectively, attached to an aminoradical. The terms arylamino denotes “monoarylamino” and “diarylamino”containing one or two aryl radicals, respectively, attached to an aminoradical. The term “aralkylamino”, embraces aralkyl radicals attached toan amino radical. The term aralkylamino denotes “monoaralkylamino” and“diaralkylamino” containing one or two aralkyl radicals, respectively,attached to an amino radical. The term aralkylamino further denotes“monoaralkyl monoalkylamino” containing one aralkyl radical and onealkyl radical attached to an amino radical.

The term “heteroatom,” as used herein, refers to oxygen, sulfur,nitrogen and phosphorus.

The terms “heteroaryl” or “heteroaromatic,” as used herein, refer to anaromatic that includes at least one sulfur, oxygen, nitrogen orphosphorus in the aromatic ring.

The term “heterocyclic,” “heterocyclyl,” and cycloheteroalkyl refer to anonaromatic cyclic group wherein there is at least one heteroatom, suchas oxygen, sulfur, nitrogen, or phosphorus in the ring.

Nonlimiting examples of heteroaryl and heterocyclic groups includefuryl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl,tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl,isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl,isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl,isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl,cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan,pyrrole, isopyrrole, pyrazole, imidazole, 1,2,3-triazole,1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, pyrimidine orpyridazine, and pteridinyl, aziridines, thiazole, isothiazole,1,2,3-oxadiazole, thiazine, pyridine, pyrazine, piperazine, pyrrolidine,oxaziranes, phenazine, phenothiazine, morpholinyl, pyrazolyl,pyridazinyl, pyrazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl,pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl,imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, adenine,N⁶-alkylpurines, N⁶-benzylpurine, N⁶-halopurine, N⁶-vinypurine,N⁶-acetylenic purine, N⁶-acyl purine, N⁶-hydroxyalkyl purine,N⁶-thioalkyl purine, thymine, cytosine, 6-azapyrimidine,2-mercaptopyrmidine, uracil, N⁵-alkylpyrimidines, N⁵-benzylpyrimidines,N⁵-halopyrimidines, N⁵-vinylpyrimidine, N⁵-acetylenic pyrimidine,N⁵-acyl pyrimidine, N⁵-hydroxyalkyl purine, and N⁶-thioalkyl purine, andisoxazolyl. The heteroaromatic group can be optionally substituted asdescribed above for aryl. The heterocyclic or heteroaromatic group canbe optionally substituted with one or more substituents selected fromthe group consisting of halogen, haloalkyl, alkyl, alkoxy, hydroxy,carboxyl derivatives, amido, amino, alkylamino, and dialkylamino. Theheteroaromatic can be partially or totally hydrogenated as desired. As anonlimiting example, dihydropyridine can be used in place of pyridine.Functional oxygen and nitrogen groups on the heterocyclic or heteroarylgroup can be protected as necessary or desired. Suitable protectinggroups are well known to those skilled in the art, and includetrimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, andt-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acylgroups such as acetyl and propionyl, methanesulfonyl, andp-toluenelsulfonyl. The heterocyclic or heteroaromatic group can besubstituted with any moiety that does not adversely affect the reaction,including but not limited to but not limited to those described abovefor aryl.

The term “host,” as used herein, refers to a unicellular ormulticellular organism in which the virus can replicate, including butnot limited to cell lines and animals, and, preferably, humans.Alternatively, the host can be carrying a part of the viral genome,whose replication or function can be altered by the compounds of thepresent invention. The term host specifically refers to infected cells,cells transfected with all or part of the viral genome and animals, inparticular, primates (including but not limited to chimpanzees) andhumans. In most animal applications of the present invention, the hostis a human being. Veterinary applications, in certain indications,however, are clearly contemplated by the present invention (such as foruse in treating chimpanzees).

The term “peptide” refers to a natural or synthetic compound containingtwo to one hundred amino acids linked by the carboxyl group of one aminoacid to the amino group of another.

The term “pharmaceutically acceptable salt or prodrug” is usedthroughout the specification to describe any pharmaceutically acceptableform (such as an ester) compound which, upon administration to apatient, provides the compound.

The compounds can also be prepared in the form of water-solubleprodrugs. Water-soluble prodrugs are well-known to those of skill in theart, and include, for example, those disclosed in Bundgaard et al., “Anovel solution-stable, water-soluble prodrug type for drugs containing ahydroxyl or an NH-acidic group,” J. Med. Chem. 32(12):2503-2507, 1989,Matsumoto et al., Bioorganic & Medicinal Chemistry Letters, Vol. 11,Issue 4, 26 Feb. 2001, Pages 605-609, and Stella et al., “Prodrugstrategies to overcome poor water solubility,” Advanced Drug DeliveryReviews, Volume 59, Issue 7, 30 Jul. 2007, Pages 677-694.

As the name suggests, water-soluble prodrugs are formulated using theaqueous solubility of the drug and for enhancing the oral drug delivery,generally includes the addition of an ionizable progroup to the parentcompound (such as phosphate, carboxylate, or sulfonate group).Water-soluble ester prodrugs can improve the aqueous solubility ofpoorly soluble drugs that contain a hydroxyl group. The most commonlyused esters for forming prodrugs are those containing ionizable groupssuch as dicarboxylic acid hemiesters. Phosphate esters, such asoxymethylphosphate (OMP) and oxyethylphosphate (OEP) prodrugs, offer oneway to increase the oral bioavailability of many sparingly water solubledrugs. Pegylated prodrugs, either added to directly, or via a spacer,such as an amino acid spacer (Feng et al., Bioorganic & MedicinalChemistry Letters, Volume 12, Issue 22, 18 Nov. 2002, Pages 3301-3303),can also increase water-solubility.

Pharmaceutically-acceptable salts include those derived frompharmaceutically acceptable inorganic or organic bases and acids.Suitable salts include those derived from alkali metals such aspotassium and sodium, alkaline earth metals such as calcium andmagnesium, among numerous other acids well known in the pharmaceuticalart.

The term “pharmaceutically acceptable salt or prodrug” is usedthroughout the specification to describe any pharmaceutically acceptableform (such as an ester) compound which, upon administration to apatient, provides the compound. Pharmaceutically acceptable saltsinclude those derived from pharmaceutically acceptable inorganic ororganic bases and acids. Suitable salts include those derived fromalkali metals such as potassium and sodium, alkaline earth metals suchas calcium and magnesium, among numerous other acids well known in thepharmaceutical art. Pharmaceutically acceptable prodrugs refer to acompound that is metabolized, for example hydrolyzed or oxidized, in thehost to form the compound of the present invention. Typical examples ofprodrugs include compounds that have biologically labile protectinggroups on functional moieties of the active compound. Prodrugs includecompounds that can be oxidized, reduced, aminated, deaminated,hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated,dealkylated, acylated, deacylated, phosphorylated, or dephosphorylatedto produce the active compound. The prodrug forms of the compounds ofthis invention can possess antiviral activity, can be metabolized toform a compound that exhibits such activity, or both.

II. Active Compounds

Coronaviruses are a species of virus belonging to the subfamilyCoronavirinae in the family Coronaviridae, and are enveloped viruseswith a positive-sense single-stranded RNA genome and with a nucleocapsidof helical symmetry.

Picornaviruses belong to the family Picornaviridae, and arenon-enveloped positive strand RNA viruses. Representative Picornavirusesinclude Enterovirus (including Rhinovirus and Poliovirus), Aphthovirus,Cardiovirus, and Hepatovirus genera.

Viruses of the hepeviridae family are single, positive stranded RNAviruses, and the family includes hepatitis E virus.

The compounds described herein are active against each of these viruses.

Enteroviral infections are believed to be associated with multiplesclerosis (MS), as infection by these viruses can cause demylenation.Accordingly, the compounds described herein can be used to treat orprevent multiple sclerosis which results, in whole or in part, fromenteroviral infection.

While not wishing to be bound to a particular theory, it is believedthat the compounds are effective at inhibiting a viral protease (e.g., acoronavirus 3CL protease, Picornavirus 3C protease, or Picornain 3C),and this is at least partially responsible for their effectivenessagainst these viruses.

In one embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R¹ is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy,arylalkoxy, or heteroarlalkoxy,

R³ is an optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈alkoxyalkyl, arylalkyl, alkylaryl, heteroarylalkyl, or alkylheteroaryl,specifically including —CH₂-napthyl, —CH₂-(hydroxy)phenyl, such as—CH₂-(4-hydroxy)phenyl, and —CH₂-(halo)phenyl, such as—CH₂-(4-halo)phenyl, including —CH₂-(fluoro)phenyl, specifically,—CH₂-(4-fluoro)phenyl.

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —C(O)H, CH═C(CN)C(O)NH₂, —C(O)CF₃, —CH(OH)CF₃, —C(OH)SO₃ ⁻ (and anassociated cation, such as Na⁺), or an optionally-substituted epoxidering, and is preferably —C(O)H,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl, and in one embodiment, are allH,

X is, independently, a bond, O or NH,

m, n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom.

In yet another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein p, X, R¹, R², R^(2′), R³, R⁴ and R⁵ are as defined above.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein p, X, R¹, R², R^(2′), R³, R⁴ and R⁵ are as defined above.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein R⁴, R⁵, R⁷, R^(7′), R¹⁰, and R^(10′) are as defined above, andR¹ is an optionally-substituted C₆₋₁₂ cycloalkyl, anoptionally-substituted five or six membered ring heteroaryl,

such as

and is preferably an optionally-substituted five or six membered ringheteroaryl.

In another embodiment, the compounds have the following formula:

where R³, R⁴, R, R⁶, R^(6′), R⁷, R^(7′), R¹⁰, R^(10′), m and n are asdefined above, and R1 is a five or six membered ring heteroaryl,

and pharmaceutically-acceptable salts and prodrugs thereof.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically-acceptable salt or prodrug thereof,

wherein Cbz=carbobenzoxy, and R³, R⁴, R⁵, R⁶, R^(6′), R⁷, R^(7′), R¹⁰,R^(10′), m and n are as defined above.

In another embodiment of the compounds of Formulas I-VI,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

where R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl,C₂₋₁₀ alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl, and R⁹ is an optionally substitutedC₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl,alkylaryl, heteroarylalkyl, or alkylheteroaryl.

In yet another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R³ is an optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈alkoxyalkyl, arylalkyl, alkylaryl, heteroarylalkyl, or alkylheteroaryl,—CH₂-(hydroxy)phenyl, and —CH₂-(halo)phenyl,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In yet another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

m=2

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R³ is an optionally substituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈alkoxyalkyl, arylalkyl, alkylaryl, heteroarylalkyl, or alkylheteroaryl,—CH₂-(hydroxy)phenyl, and —CH₂-(halo)phenyl,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

m=2 or 3

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In still another embodiment, the compounds have the following formula:

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R¹ is optionally substituted C₁₋₁₀ alkyl, aryl, heteroaryl, aryloxy,heteroaryloxy, arylalkoxy, or heteroarlalkoxy,

R⁴ is an optionally substituted C₁₋₆ alkyl,

R⁵ is —(CH₂)_(q)—SH,

—CH(OH)CF₃, —CH(OH)CN,

R⁸ is independently H, an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀alkene, C₂₋₁₀ alkyne, aryl, heteroaryl, arylalkyl, alkylaryl,heteroarylalkyl, or alkylheteroaryl,

R⁹ is an optionally substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkene, C₂₋₁₀ alkyne,aryl, heteroaryl, arylalkyl, alkylaryl, heteroarylalkyl, oralkylheteroaryl,

q is 1, 2 or 3,

R², R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆alkyl, C₁₋₆ haloalkyl, or C₂₋₆ alkenyl,

X is, independently, a bond, O or NH,

n and p are, independently, 0, 1, 2, or 3;

R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃, hydroxy,N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano,C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆ haloalkyl,heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′), together withthe carbon to which they are attached, form a carbonyl,

each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl,

the R′ groups can optionally be substituted with one or moresubstituents, which substituents are, independently, halo, C₁₋₆haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy,amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid, thiol, imine,sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide,phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether,acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, orphosphonate;

two R′ residing on the same carbon or nitrogen atom can come together toform a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁶ and R^(6′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom;

R⁷ and R^(7′) are, independently, hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′,S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C₁₋₆ alkyl,arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆hydroxyalkyl; and

R⁷ and R^(7′) can come together to form an optionally substituted doublebond or a C₃₋₆ ring optionally containing a N, O, or S heteroatom, andpharmaceutically-acceptable salts and prodrugs thereof.

In certain embodiments of any of Formulas I-X, X is O, R² and R^(2′) areH, and R¹ is an optionally substituted phenyl.

In certain embodiments of any of Formulas I-X, X=a covalent bond, p=0,and R1 is an optionally substituted aryl or heteroaryl.

In certain embodiments of any of Formulas I-X, the heteroaryl ring is apyrazine, thiophene, isoxazole, or oxazole ring.

In certain embodiments of any of Formulas I-X, R³ is phenyl,halo-substituted phenyl, or naphthyl.

Representative compounds include the following:

and pharmaceutically-acceptable salts and prodrugs thereof.

Representative compounds also include the following:

and pharmaceutically acceptable salts or prodrugs thereof.

Preferred compounds include the following:

Additional compounds include the following:

and pharmaceutically-acceptable salts and prodrugs thereof.

III. Stereoisomerism and Polymorphism

The compounds described herein can have asymmetric centers and occur asracemates, racemic mixtures, individual diastereomers or enantiomers,with all isomeric forms being included in the present invention.Compounds of the present invention having a chiral center can exist inand be isolated in optically active and racemic forms. Some compoundscan exhibit polymorphism. The present invention encompasses racemic,optically-active, polymorphic, or stereoisomeric forms, or mixturesthereof, of a compound of the invention, which possess the usefulproperties described herein. The optically active forms can be preparedby, for example, resolution of the racemic form by recrystallizationtechniques, by synthesis from optically-active starting materials, bychiral synthesis, or by chromatographic separation using a chiralstationary phase or by enzymatic resolution. One can either purify therespective compound, then derivatize the compound to form the compoundsdescribed herein, or purify the compound themselves.

Optically active forms of the compounds can be prepared using any methodknown in the art, including but not limited to by resolution of theracemic form by recrystallization techniques, by synthesis fromoptically-active starting materials, by chiral synthesis, or bychromatographic separation using a chiral stationary phase.

Examples of methods to obtain optically active materials include atleast the following.

i) physical separation of crystals: a technique whereby macroscopiccrystals of the individual enantiomers are manually separated. Thistechnique can be used if crystals of the separate enantiomers exist,i.e., the material is a conglomerate, and the crystals are visuallydistinct;

ii) simultaneous crystallization: a technique whereby the individualenantiomers are separately crystallized from a solution of the racemate,possible only if the latter is a conglomerate in the solid state;

iii) enzymatic resolutions: a technique whereby partial or completeseparation of a racemate by virtue of differing rates of reaction forthe enantiomers with an enzyme;

iv) enzymatic asymmetric synthesis: a synthetic technique whereby atleast one step of the synthesis uses an enzymatic reaction to obtain anenantiomerically pure or enriched synthetic precursor of the desiredenantiomer;

v) chemical asymmetric synthesis: a synthetic technique whereby thedesired enantiomer is synthesized from an achiral precursor underconditions that produce asymmetry (i.e., chirality) in the product,which can be achieved using chiral catalysts or chiral auxiliaries;

vi) diastereomer separations: a technique whereby a racemic compound isreacted with an enantiomerically pure reagent (the chiral auxiliary)that converts the individual enantiomers to diastereomers. The resultingdiastereomers are then separated by chromatography or crystallization byvirtue of their now more distinct structural differences and the chiralauxiliary later removed to obtain the desired enantiomer;

vii) first- and second-order asymmetric transformations: a techniquewhereby diastereomers from the racemate equilibrate to yield apreponderance in solution of the diastereomer from the desiredenantiomer or where preferential crystallization of the diastereomerfrom the desired enantiomer perturbs the equilibrium such thateventually in principle all the material is converted to the crystallinediastereomer from the desired enantiomer. The desired enantiomer is thenreleased from the diastereomer;

viii) kinetic resolutions: this technique refers to the achievement ofpartial or complete resolution of a racemate (or of a further resolutionof a partially resolved compound) by virtue of unequal reaction rates ofthe enantiomers with a chiral, non-racemic reagent or catalyst underkinetic conditions;

ix) enantiospecific synthesis from non-racemic precursors: a synthetictechnique whereby the desired enantiomer is obtained from non-chiralstarting materials and where the stereochemical integrity is not or isonly minimally compromised over the course of the synthesis;

x) chiral liquid chromatography: a technique whereby the enantiomers ofa racemate are separated in a liquid mobile phase by virtue of theirdiffering interactions with a stationary phase (including but notlimited to via chiral HPLC). The stationary phase can be made of chiralmaterial or the mobile phase can contain an additional chiral materialto provoke the differing interactions;

xi) chiral gas chromatography: a technique whereby the racemate isvolatilized and enantiomers are separated by virtue of their differinginteractions in the gaseous mobile phase with a column containing afixed non-racemic chiral adsorbent phase;

xii) extraction with chiral solvents: a technique whereby theenantiomers are separated by virtue of preferential dissolution of oneenantiomer into a particular chiral solvent;

xiii) transport across chiral membranes: a technique whereby a racemateis placed in contact with a thin membrane barrier. The barrier typicallyseparates two miscible fluids, one containing the racemate, and adriving force such as concentration or pressure differential causespreferential transport across the membrane barrier. Separation occurs asa result of the non-racemic chiral nature of the membrane that allowsonly one enantiomer of the racemate to pass through.

Chiral chromatography, including but not limited to simulated moving bedchromatography, is used in one embodiment. A wide variety of chiralstationary phases are commercially available.

IV. Salt or Prodrug Formulations

In cases where compounds are sufficiently basic or acidic to form stablenontoxic acid or base salts, administration of the compound as apharmaceutically acceptable salt may be appropriate. Examples ofpharmaceutically acceptable salts are organic acid, which form aphysiological acceptable anion, for example, tosylate, methanesulfonate,acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate,α-ketoglutarate and α-glycerophosphate. Suitable inorganic salts canalso be formed, including but not limited to, sulfate, nitrate,bicarbonate and carbonate salts. For certain transdermal applications,it can be preferred to use fatty acid salts of the compounds describedherein. The fatty acid salts can help penetrate the stratum corneum.Examples of suitable salts include salts of the compounds with stearicacid, oleic acid, lineoleic acid, palmitic acid, caprylic acid, andcapric acid.

Pharmaceutically acceptable salts can be obtained using standardprocedures well known in the art, for example by reacting a sufficientlybasic compound such as an amine with a suitable acid, affording aphysiologically acceptable anion. In those cases where a compoundincludes multiple amine groups, the salts can be formed with any numberof the amine groups. Alkali metal (e.g., sodium, potassium or lithium)or alkaline earth metal (e.g., calcium) salts of carboxylic acids canalso be made.

A prodrug is a pharmacological substance that is administered in aninactive (or significantly less active) form and subsequentlymetabolized in vivo to an active metabolite. Getting more drug to thedesired target at a lower dose is often the rationale behind the use ofa prodrug and is generally attributed to better absorption,distribution, metabolism, and/or excretion (ADME) properties. Prodrugsare usually designed to improve oral bioavailability, with poorabsorption from the gastrointestinal tract usually being the limitingfactor. Additionally, the use of a prodrug strategy can increase theselectivity of the drug for its intended target thus reducing thepotential for off target effects.

V. Isotopes

Compounds described herein include isotopically-labeled compounds, whichare identical to those recited in the various formulae and structurespresented herein, but for the fact that one or more atoms are replacedby an atom having an atomic mass or mass number different from theatomic mass or mass number usually found in nature. In other embodimentsare examples of isotopes that are incorporated into the presentcompounds including isotopes of hydrogen, carbon, nitrogen, oxygen,fluorine and chlorine, such as, for example, ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O,¹⁷O, ³⁵S, ¹⁸F, ³⁶Cl, respectively. Certain isotopically-labeledcompounds described herein, for example those into which radioactiveisotopes such as ²H are incorporated, are useful in drug and/orsubstrate tissue distribution assays. Further, in some embodiments,substitution with isotopes such as deuterium, i.e., ²H, can affordscertain therapeutic advantages resulting from greater metabolicstability, such as, for example, increased in vivo half-life or reduceddosage requirements.

VI. Methods of Treatment

In one embodiment, the compounds described herein can be used toprevent, treat or cure coronavirus, picornavirus infections,specifically including enterovirus infections, and/or hepeviridaeinfections, specifically including hepatitis E infections.

The methods involve administering a therapeutically orprophylactically-effective amount of at least one compound as describedherein to treat, cure or prevent an infection by, or an amountsufficient to reduce the biological activity of, a coronavirus,picornavirus, and/or hepeviridae infection.

In one embodiment, the compounds are used to treat a patient sufferingfrom multiple virus infections, such as hepatitis E and enterovirus(EV). The compounds can also be used to treat norovirus (noV)infections, so the combination of viral infections can include noV inaddition to a coronavirus, picornovirus, and/or hepeviridae virus.

In another embodiment, the compounds described herein can be used toinhibit a coronoviral and/or picornaviral protease (e.g., an enteroviralprotease or a rhinoviral 3C protease) in a cell. The method includescontacting the cell with an effective amount of a compound describedherein,

Hosts, including but not limited to humans infected with a coronavirus,picornavirus, hepeviridae virus, or a gene fragment thereof, includinghumans co-infected with norovirus, can be treated by administering tothe patient an effective amount of the active compound or apharmaceutically acceptable prodrug or salt thereof in the presence of apharmaceutically acceptable carrier or diluent. The active materials canbe administered by any appropriate route, for example, orally,parenterally, intravenously, intradermally, transdermally,subcutaneously, or topically, in liquid or solid form.

VII. Combination of Alternation Therapy

In one embodiment, the compounds of the invention can be employedtogether with at least one other active agent, which can be an antiviralagent. In one aspect of this embodiment, the at least one other activeagent is selected from the group consisting of fusion inhibitors, entryinhibitors, protease inhibitors, polymerase inhibitors, antiviralnucleosides, such as remdesivir, GS-441524, N4-hydroxycytidine, andother compounds disclosed in U.S. Pat. No. 9,809,616, and theirprodrugs, viral entry inhibitors, viral maturation inhibitors, JAKinhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors,SARS-CoV-specific human monoclonal antibodies, including CR3022, andagents of distinct or unknown mechanism.

Umifenovir (also known as Arbidol) is a representative fusion inhibitor.

Representative entry inhibitors include Camostat, luteolin, MDL28170,SSAA09E2, SSAA09E1 (which acts as a cathepsin L inhibitor), SSAA09E3,and tetra-O-galloyl-β-D-glucose (TGG). The chemical formulae of certainof these compounds are provided below:

Other entry inhibitors include the following:

Remdesivir, Sofosbuvir, ribavirin IDX-184 and GS-441524 have thefollowing formulas:

Additionally, one can administer compounds which inhibit the cytokinestorm, anti-coagulants and/or platelet aggregation inhibitors thataddress blood clots, compounds which chelate iron ions released fromhemoglobin by viruses such as COVID-19, cytochrome P-450 (CYP450)inhibitors and/or NOX inhibitors.

Representative NOX inhibitors are disclosed in PCT/US2018/067674, andinclude AEBSF, Apocyanin, DPI, GK-136901, ML171, Plumbagin, S17834,VAS2870, VAS3947, GKT-831, GKT771, GTL003 or amido thiadiazolederivatives thereof, as described in AU2015365465, EP20140198597; andWO2015/59659, Schisandrin B, as described in CN104147001 andCN20131179455), bi-aromatic and tri-aromatic compounds described in U.S.Publication No. 2015045387, GB 20110016017, and WO201200725,methoxyflavone derivatives described in JP 2015227329, JP 20140097875,and JP 20150093939, peptides, such as NOX2ds-tat and PR-39, as describedin U.S. Publication No. 2015368301, TN 2015000295, U.S. Publication No.201514689803, U.S. Publication No. 201462013916, PCT WO 201450063, andEP 20130150187, piperazine derivatives described in U.S. Publication No.2014194422, U.S. Pat. No. 9,428,478, U.S. Publication No. 201214123877,U.S. Publication No. 201161496161, and PCT WO 2012US41988, pyrazolederivatives disclosed in KR101280198, KR20110025151, and KR20090082518,pyrazoline dione derivatives disclosed in HK1171748, PCT WO201054329,and EP 20090171466, pyrazolo piperidine derivatives disclosed inKR20130010109, KR20130002317, EP20100153927, PCT WO201150667,EP20100153929, and PCT WO2011IB50668, pyrazolo pyridine derivativesdescribed in KR20170026643, HK1158948, HK1141734, HK1159096, HK1159092,EP20080164857, PCT WO200954156, PCT WO200954150, EP20080164853, PCTWO200853390, U.S. Publication No. 20070896284, EP20070109555, PCT WO200954148, EP20080164847, PCT WO200954155, and EP20080164849,quinazoline and quinoline derivatives disclosed in EP2886120, U.S.Publication No. 2014018384, U.S. Publication No. 20100407925,EP20110836947, GB20110004600, and PCT WO 201250586, tetrahydroindolederivatives disclosed in U.S. Publication No. 2010120749, U.S. Pat. No.8,288,432, U.S. Publication No. 20080532567, EP20070109561, U.S.Publication No. 20070908414, and PCT WO 200853704,tetrahydroisoquinoline derivatives disclosed in U.S. Publication No.2016083351, U.S. Publication No. 201414888390, U.S. Publication No.201361818726, and PCT WO 201436402, Scopoletin, described in TW201325588and TW20110147671, and 2,5-disubstituted benzoxazole and benzothiazolederivatives disclosed in TW201713650 and PCT WO 201554662.Representative NOX inhibitors also include those disclosed in PCTWO2011062864.

Exemplary Nox inhibitors also include2-phenylbenzo[d]isothiazol-3(2H)-one,2-(4-methoxyphenyl)benzo[d]isothiazol-3(2H)-one,2-(benzo[d][1,3]dioxol-5-yl)benzo[d]isothiazol-3(2H)-one,2-(2,4-dimethylphenyl)benzo[d]isothiazol-3(2H)-one,2-(4-fluorophenyl)benzo[d]isothiazol-3(2H)-one,2-(2,4-dimethylphenyl)-5-fluorobenzo[d]isothiazol-3(2H)-one,5-fluoro-2-(4-fluorophenyl)benzo[d]isothiazol-3(2H)-one,2-(2-chloro-6-methylphenyl)-5-fluorobenzo[d]isothiazol-3(2H)-one,5-fluoro-2-phenylbenzo[d]isothiazol-3(2H)-one,2-(benzo[d][1,3]dioxol-5-yl)-5-fluorobenzo[d]isothiazol-3(2H)-one,methyl 4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, methyl4-(5-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, ethyl4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, tert-butyl4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, methyl2-methoxy-4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, methyl3-chloro-4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate,4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzonitrile, methyl2-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate,2-(4-acetylphenyl)benzo[d]isothiazol-3(2H)-one,2-(4-nitrophenyl)benzo[d]isothiazol-3(2H)-one,2-(4-hydroxyphenyl)benzo[d]isothiazol-3(2H)-one, methyl6-(3-oxobenzo[d]isothiazol-2(3H)-yl)nicotinate,6-(3-oxobenzo[d]isothiazol-2(3H)-yl)nicotinonitrile,2-(4-(hydroxymethyl)phenyl)benzo[d]isothiazol-3(2H)-one,2-benzylbenzo[d]isothiazol-3(2H)-one,N-methyl-4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzamide,2-(4-hydroxyphenyl)benzo[d]isothiazol-3(2H)-one,2-(2,4-dimethylphenyl)-1-methyl-1H-indazol-3(2H)-one,2-(4-fluorophenyl)-1-methyl-1H-indazol-3 (2H)-one,2-(2,4-dimethylphenyl)-1H-indazo-3(2H)-one,1-methyl-2-phenyl-1H-indazol-3 (2H)-one,2-(1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(5-phenyl-1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(5-(ethylthio)-1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(5-(methylthio)-1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one,5-fluoro-2-(1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(5-(tert-butyl)-1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)benzo[d]isothiazol-3(2H)-one2-(4-methylthiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(4,5-dimethylthiazol-2-yl)benzo[d]isothiazol-3(2H)-one,2-(benzo[d][1,3]dioxol-5-yl)-4,5-difluorobenzo[d][1,2]selenazol-3(2H)-one,2-(benzo[d][1,3]dioxol-5-yl)-5-fluorobenzo[d][1,2]selenazol-3(2H)-one,2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-fluorobenzo[d][1,2]selenazol-3(2H)-2-(4-(1,3-dioxolan-2-yl)phenyl)benzo[d][1,2]selenazol-3(2H)-one,2-(benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxybenzo[d][1,2]selenazol-3(2H)-one, methyl4-(3-oxobenzo[d][1,2]selenazol-2(3H)-yl)benzoate, methyl4-(3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)benzoate, and ethyl4-(3-oxoisothiazol-2(3H)-yl)benzoate, and pharmaceutically acceptablesalts and prodrugs thereof.

Additional representative NOX inhibitors include:

wherein

Z is selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₁₋₆ alkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl,heteroaryl, heterocyclic, alkylaryl, arylalkyl, hydroxyl, nitro, cyano,cyanoalkyl, azido, azidoalkyl, formyl, hydrazino, halo (F, Cl, Br, or1), OR′, NHR′, SR′, S(O)R′, S(O)₂R′, S(O)₂NHR′, S(O)₂N(R′)R′, SFs,COOR′, COR′, OCOR′, NHCOR′, N(COR′)COR′, SCOR′, OCOOR′, and NHCOOR′,wherein each R′ is independently H, a C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆alkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl, wherein the groups can be substituted with oneor more substituents as defined above,

and n is an integer from 0-4,

or a pharmaceutically acceptable salt or prodrug thereof.

Specific examples of these compounds include

deuterated analogs thereof, or a pharmaceutically acceptable salt orprodrug thereof.

In one embodiment, the NOX inhibitor is Ebselen, Neopterin, APBA,Diapocynin, or a deuterated analog thereof, or apharmaceutically-acceptable salt or prodrug thereof.

In another embodiment, the NOX compounds are those disclosed in PCT WO2010/035221.

In still another embodiment, the compounds are NOX inhibitors disclosedin PCT WO 2013/068972, which are selected from the group consisting of:

-   4-(2-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(4-methoxyphenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(4-chlorophenyl)-2-(2-methoxyphenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2-fluoro-4-methoxyphenyl)-5-[(1-methyl-1H-pyrazol-3-yl)    methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(2-fluoro-5-methoxyphenyl)-2-(2-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-5-[(2-methoxypyridin-4-yl)methyl]-4-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-methoxyphenyl)-4-methyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(4-chloro-2-fluorophenyl)-2-(2-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(5-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-5-[(6-methoxypyridin-3-yl)methyl]-4-methyl-1H-pyrazolo[4,3-c]pyridine-3,6    (2H,5H)-dione;-   4-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(5-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(2-fluoro-5-methoxyphenyl)-2-(2-methoxyphenyl)-5-[(1-methyl-1H-pyrazo-1-3-yl)    methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(5-chloro-2-fluorophenyl)-2-(2-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-methyl-5-(pyridin-3-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6    (2H,5H)-dione;-   2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6    (2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2-fluorophenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-(pyridin-4-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-methoxyphenyl)-4-(3-methoxyphenyl)-5-[(1-methyl-1H-pyrazo-1-3-yl)methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2-fluoro-4-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(2-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-5-[(1-methyl-1H-pyrazo-1-3-yl)    methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-methoxyphenyl)-4-(4-methoxyphenyl)-5-[(1-methyl-1H-pyrazo-1-3-yl)methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-methoxyphenyl)-4-(3-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-[(2-methoxypyridin-4-yl)methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2-fluoro-4-methoxyphenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2,6-difluorophenyl)-5-(pyridin-4-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2-fluorophenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-methyl-5-[(1-methyl-1H-pyrazol-3-yl)methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(3-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-5-methyl-4-[3-(methylamino)phenyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-methoxyphenyl)-4-(4-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2,5-difluorophenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(4-chlorophenyl)-5-(1,3-thiazol-2-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-[(1-methyl-1H-pyrazol-3-yl)    methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(3,5-dichlorophenyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(3-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-5-(pyridin-3-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2,6-difluorophenyl)-5-(pyridin-3-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   4-(2-fluoro-5-methoxyphenyl)-2-(2-methoxyphenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;-   2-(2-chlorophenyl)-4-(2,5-difluorophenyl)-5-(pyridin-3-ylmethyl)-H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;    and-   2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-[(1-methyl-1H-pyrazol-3-yl)    methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione.

Representative CYP450 inhibitors include, but are not limited to,amiodarone, amlodipine, apigenin, aprepitant, bergamottin (grapefruit),buprenorphine, bupropion, caffeine, cafestol, cannabidiol, celecoxib,chloramphenicol, chlorphenamine, chlorpromazine, cimetidine, cinacalcet,ciprofloxacin, citalopram, clarithromycin, clemastine, clofibrate,clomipramine, clotrimazole, cobicistat, cocaine, curcumin (turmeric),cyclizine, delavirdine, desipramine, disulfiram, diltiazem,diphenhydramine, dithiocarbamate, domperidone, doxepin, doxorubicin,duloxetine, echinacea, entacapone, erythromycin, escitalopram,felbamate, fenofibrate, flavonoids (grapefruit), fluoroquinolones (e.g.,ciprofloxacin), fluoxetine, fluvoxamine, fluconazole, fluvastatin,gabapentin, gemfibrozil, gestodene, halofantrine, haloperidol,hydroxyzine, imatinib, indomethacin, indinavir, interferon, isoniazid,itraconazole, JWH-018, ketoconazole, letrozole, lovastatin,levomepromazine, memantine, methylphenidate, metoclopramide, methadone,methimazole, methoxsalen, metyrapone, mibefradil, miconazole, midodrine,mifepristone, milk thistle, moclobemide, modafinil, montelukast,moclobemide, naringenin (grapefruit), nefazodone, nelfinavir, niacin,niacinamide, nicotine, nicotinamide, nilutamide, norfloxacin,orphenadrine, paroxetine, perphenazine, pilocarpine, piperine,phenylbutazone, probenecid, promethazine, proton pump inhibitors (e.g.,lansoprazole, omeprazole, pantoprazole, rabeprazole), quercetin,quinidine, ranitidine, risperidone, ritonavir, saquinavir, selegiline,sertraline, star fruit, St. John's wort, sulconazole, sulfamethoxazole,sulfaphenazole, telithromycin, teniposide, terbinafine,thiazolidinediones, thioridazine, ticlopidine, tioconazole, thiotepa,trimethoprim, topiramate, tranylcypromine, tripelennamine, valerian,valproic acid, verapamil, voriconazole, zafirlukast, and zuclopenthixol.

Representative ACE-2 inhibitors include sulfhydryl-containing agents,such as alacepril, captopril (capoten), and zefnopril,dicarboxylate-containing agents, such as enalapril (vasotec), ramipril(altace), quinapril (accupril), perindopril (coversyl), lisinopril(listril), benazepril (lotensin), imidapril (tanatril), trandolapril(mavik), and cilazapril (inhibace), and phosphonate-containing agents,such as fosinopril (fositen/monopril).

For example, when used to treat or prevent infection, the activecompound or its prodrug or pharmaceutically acceptable salt can beadministered in combination or alternation with another antiviral agentincluding, but not limited to, those of the formulae above. In general,in combination therapy, effective dosages of two or more agents areadministered together, whereas during alternation therapy, an effectivedosage of each agent is administered serially. The dosage will depend onabsorption, inactivation and excretion rates of the drug, as well asother factors known to those of skill in the art. It is to be noted thatdosage values will also vary with the severity of the condition to bealleviated. It is to be further understood that for any particularsubject, specific dosage regimens and schedules should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of thecompositions.

A number of agents for combination with the compounds described hereinare disclosed in Ghosh et al., “Drug Development and Medicinal ChemistryEfforts Toward SARS-Coronavirus and Covid-19 Therapeutics,” ChemMedChem10.1002/cmdc.202000223.

Nonlimiting examples of antiviral agents that can be used in combinationwith the compounds disclosed herein include those listed below.

Compounds for Inhibiting the Cytokine Storm

Throughout its activation, the inflammatory response must be regulatedto prevent a damaging systemic inflammation, also known as a “cytokinestorm.” A number of cytokines with anti-inflammatory properties areresponsible for this, such as IL-10 and transforming growth factor β(TGF-β). Each cytokine acts on a different part of the inflammatoryresponse. For example, products of the Th2 immune response suppress theTh1 immune response and vice versa.

By resolving inflammation, one can minimize collateral damage tosurrounding cells, with little or no long-term damage to the patient.Accordingly, in addition to using the compounds described herein toinhibit the viral infection, one or more compounds which inhibit thecytokine storm can be co-administered.

Compounds which inhibit the cytokine storm include compounds that targetfundamental immune pathways, such as the chemokine network and thecholinergic anti-inflammatory pathway.

JAK inhibitors, such as JAK 1 and JAK 2 inhibitors, can inhibit thecytokine storm, and in some cases, are also antiviral. RepresentativeJAK inhibitors include those disclosed in U.S. Pat. No. 10,022,378, suchas Jakafi, Tofacitinib, and Baricitinib, as well as LY3009104/INCB28050,Pacritinib/SB1518, VX-509, GLPG0634, INC424, R-348, CYT387, TG 10138,AEG 3482, and pharmaceutically acceptable salts and prodrugs thereof.

Still further examples include CEP-701 (Lestaurtinib), AZD1480, INC424,R-348, CYT387, TG 10138, AEG 3482,7-iodo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,7-(4-aminophenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acrylamide,7-(3-aminophenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acrylamide, N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, methyl2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidine-7-carboxylate,N-(4-morpholinophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine,7-(4-amino-3-methoxyphenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzene-sulfonamide,N,N-dimethyl-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,1-ethyl-3-(2-methoxy-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)urea,N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)metha-nesulfonamide,2-methoxy-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)pheno-1,2-cyano-N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide,N-(cyanomethyl)-2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidine-7-carboxamide,N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide,1-ethyl-3-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)-2-(trifluoromethoxy)phenyl)urea,N-(3-nitrophenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine,7-iodo-N-(3-nitrophenyl)thieno[3,2-d]pyrimidin-2-amine,N1-(7-(2-ethylphenyl)thieno[3,2-d]pyrimidin-2-yl)benzene-1,3-diamine,N-tert-butyl-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,N1-(7-iodothieno[3,2-d]pyrimidin-2-yl)benzene-1,3-diamine,7-(4-amino-3-(trifluoromethoxy)phenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,7-(2-ethylphenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)aceta-mide,N-(cyanomethyl)-N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide,N-(cyanomethyl)-N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide,N-(3-(5-methyl-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide,4-(5-methyl-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)b-enzenesulfonamide,N-(4-(5-methyl-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-y-1)phenyl)methanesulfonamide,7-iodo-N-(4-morpholinophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine,7-(2-isopropylphenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,7-bromo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,N7-(2-isopropylphenyl)-N2-(4-morpholinophenyl)thieno[3,2-d]pyrimidine-2,7-diamine,N7-(4-isopropylphenyl)-N2-(4-morpholinophenyl)thieno[3,2-d]pyrimidine-2,7-diamine,7-(5-amino-2-methylphenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide,7-iodo-N-(3-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,7-(4-amino-3-nitrophenyl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,7-(2-methoxypyridin-3-yl)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine,(3-(7-iodothieno[3,2-d]pyrimidin-2-ylamino)phenyl)methanol,N-tert-butyl-3-(2-(3-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,N-tert-butyl-3-(2-(3-(hydroxymethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,N-(4-morpholinophenyl)-7-(4-nitrophenylthio)-5H-pyrrolo[3,2-d]pyrimidin-2-amine,N-tert-butyl-3-(2-(3,4,5-trimethoxyphenylamino)thieno[3,2-d]pyrimi-din-7-yl)benzenesulfonamide,7-(4-amino-3-nitrophenyl)-N-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine,N-(3,4-dimethoxyphenyl)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine,N-tert-butyl-3-(2-(3,4-dimethoxyphenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,7-(2-aminopyrimidin-5-yl)-N-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine,N-(3,4-dimethoxyphenyl)-7-(2,6-dimethoxypyridin-3-yl)thieno[3,2-d]-pyrimidin-2-amine,N-(3,4-dimethoxyphenyl)-7-(2,4-dimethoxypyrimidin-5-yl)thieno[3,2-d]pyrim-idin-2-amine,7-iodo-N-(4-(morpholinomethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine,N-tert-butyl-3-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,2-cyano-N-(4-methyl-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide,ethyl3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzoate,7-bromo-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-2-amine,N-(3-(2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide,N-(cyanomethyl)-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide,N-tert-butyl-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide,N-tert-butyl-3-(2-(4-(1-ethylpiperidin-4-yloxy)phenylamino)thieno-[3,2-d]pyrimidin-7-yl)benzenesulfonamide,tert-butyl-4-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)-1H-pyrazole-1-carboxylate,7-bromo-N-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)thieno[3,2-d]pyrimidin-2-amine,N-tert-butyl-3-(2-(4-((4-ethylpiperazin-1-yl)methyl)phenylamino)-thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,N-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-7-(1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-2-amine,N-(cyanomethyl)-3-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimi-din-7-yl)benzamide,N-tert-butyl-3-(2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]-pyrimidin-7-yl)benzenesulfonamide,tert-butylpyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzylcarb-amate,3-(2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide,7-(3-chloro-4-fluorophenyl)-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno-[3,2-d]pyrimidin-2-amine,tert-butyl4-(2-(4-(1-ethylpiperidin-4-yloxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl-)-1H-pyrazole-1-carboxylate,7(benzo[d][1,3]dioxol-5-yl)-N-(4-(morpholinomethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine,tert-butyl5-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)-1H-indole-1-carboxylate,7-(2-aminopyrimidin-5-yl)-N-(4-(morpholinomethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine,tert-butyl4-(2-(-4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)-5,6-di-hydropyridine-1(2H)-carboxylate,tert-butylmorpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzylcarbamate,N-(3-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phen-yl)acetamide,N-(4-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phen-yl)acetamide,N-(3-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phen-yl)methanesulfonamide,7-(4-(4-methylpiperazin-1-yl)phenyl)-N-(4-(morpholinomethyl)phenyl)thieno-[3,2-d]pyrimidin-2-amine,N-(2-methoxy-4-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide,7-bromo-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine,(3-(2-(3,4,5-trimethoxyphenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)met-hanol,(4-(2-(3,4,5-trimethoxyphenylamino)thieno[3,2-d]pyrimidin-7-yl)phen-yl)methanol,(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methano-1,(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanol,N-(pyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzyl)methanesulfonamide,tert-butylmorpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzylcarbamate,N-(4-(morpholinomethyl)phenyl)-7-(3-(piperazin-1-yl)phenyl)thieno[3,2-d]pyrimidin-2-amine,7-(6-(2-morpholinoethylamino)pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine,7-(2-ethylphenyl)-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-2-amine,7-(4-(aminomethyl)phenyl)-N-(4-(morpholinomethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine,N-(4-(1-ethylpiperidin-4-yloxy)phenyl)-7-(1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-2-amine,N-(2,4-dimethoxyphenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine,7-bromo-N-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine,N-(3,4-dimethoxyphenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine, andpharmaceutically acceptable salts and prodrugs thereof.

HMGB1 antibodies and COX-2 inhibitors can be used, which downregulatethe cytokine storm. Examples of such compounds include Actemra (Roche).Celebrex (celecoxib), a COX-2 inhibitor, can be used. IL-8 (CXCL8)inhibitors can also be used.

Chemokine receptor CCR2 antagonists, such as PF-04178903 can reducepulmonary immune pathology.

Selective α7Ach receptor agonists, such as GTS-21 (DMXB-A) and CNI-1495,can be used. These compounds reduce TNF-α. The late mediator of sepsis,HMGB1, downregulates IFN-γ pathways, and prevents the LPS-inducedsuppression of IL-10 and STAT 3 mechanisms.

Compounds for Treating or Preventing Blood Clots

Viruses that cause respiratory infections, including Coronaviruses suchas Covid-19, can be associated with pulmonary blood clots, and bloodclots that can also do damage to the heart.

The compounds described herein can be co-administered with compoundsthat inhibit blood clot formation, such as blood thinners, or compoundsthat break up existing blood clots, such as tissue plasminogen activator(TPA), Integrilin (eptifibatide), abciximab (ReoPro) or tirofiban(Aggrastat).

Blood thinners prevent blood clots from forming, and keep existing bloodclots from getting larger. There are two main types of blood thinners.Anticoagulants, such as heparin or warfarin (also called Coumadin), slowdown biological processes for producing clots, and antiplateletaggregation drugs, such as Plavix, aspirin, prevent blood cells calledplatelets from clumping together to form a clot.

By way of example, Integrilin® is typically administered at a dosage of180 mcg/kg intravenous bolus administered as soon as possible followingdiagnosis, with 2 mcg/kg/min continuous infusion (following the initialbolus) for up to 96 hours of therapy.

Representative platelet aggregation inhibitors include glycoproteinIIB/IIIA inhibitors, phosphodiesterase inhibitors, adenosine reuptakeinhibitors, and adenosine diphosphate (ADP) receptor inhibitors. Thesecan optionally be administered in combination with an anticoagulant.

Representative anti-coagulants include coumarins (vitamin Kantagonists), heparin and derivatives thereof, including unfractionatedheparin (UFH), low molecular weight heparin (LMWH), andultra-low-molecular weight heparin (ULMWH), synthetic pentasaccharideinhibitors of factor Xa, including Fondaparinux, Idraparinux, andIdrabiotaparinux, directly acting oral anticoagulants (DAOCs), such asdabigatran, rivaroxaban, apixaban, edoxaban and betrixaban, andantithrombin protein therapeutics/thrombin inhibitors, such as bivalentdrugs hirudin, lepirudin, and bivalirudin and monovalent argatroban.

Representative platelet aggregation inhibitors include pravastatin,Plavix (clopidogrel bisulfate), Pletal (cilostazol), Effient(prasugrel), Aggrenox (aspirin and dipyridamole), Brilinta (ticagrelor),caplacizumab, Kengreal (cangrelor), Persantine (dipyridamole), Ticlid(ticlopidine), Yosprala (aspirin and omeprazole).

Small Molecule Covalent CoV 3CLpro Inhibitors

Representative small molecule covalent CoV 3CLpro inhibitors include thefollowing compounds:

Non-Covalent CoV 3CLpro Inhibitors

Representative non-covalent CoV 3CLpro inhibitors include the following:

SARS-CoV PLpro Inhibitors

Representative SARS-Cov PLpro inhibitors include the following:

Additional compounds include the following:

Additional Compounds that can be Used

Additional compounds and compound classes that can be used incombination therapy include the following: Antibodies, includingmonoclonal antibodies (mAb), Arbidol (umifenovir), Actemra(tocilizumab), APN01 (Aperion Biologics), ARMS-1 (which includesCetylpyridinium chloride (CPC)), ASC09 (Ascletis Pharma), AT-001(Applied Therapeutics Inc.) and other aldose reductase inhibitors (ARI),ATYR1923 (aTyr Pharma, Inc.), Aviptadil (Relief Therapeutics), Azvudine,Bemcentinib, BLD-2660 (Blade Therapeutics), Bevacizumab, Brensocatib,Calquence (acalabrutinib), Camostat mesylate (a TMPRSS2 inhibitor),Camrelizumab, CAP-1002 (Capricor Therapeutics), CD24Fcm, Clevudine,(Oncolmmune), CM4620-IE (CalciMedica Inc., CRAC channel inhibitor),Colchicine, convalescent plasma, CYNK-001 (Sorrento Therapeutics),DAS181 (Ansun Pharma), Desferal, Dipyridamole (Persantine), Dociparstatsodium (DSTAT), Duvelisib, Eculizumab, EIDD-2801 (RidgebackBiotherapeutics), Emapalumab, Fadraciclib (CYC065) and seliciclib(roscovitine) (Cyclin-dependent kinase (CDK) inhibitors), Farxiga(dapagliflozin), Favilavir/Favipiravir/T-705/Avigan, Galidesivir, Ganovo(danoprevir), Gilenya (fingolimod) (sphingosine 1-phosphate receptormodulator), Gimsilumab, IFX-1, Ilaris (canakinumab), intravenousimmunoglobulin, Ivermectin (importin α/β inhibitor), Kaletra/Aluvia(lopinavir/ritonavir), Kevzara (sarilumab), Kineret (anakinra), LAU-7b(fenretinide), Lenzilumab, Leronlimab (PRO 140), LY3127804 (an anti-Ang2antibody), Leukine (sargramostim, a granulocyte macrophage colonystimulating factor), Losartan, Valsartan, and Telmisartan (AngiotensinII receptor antagonists), Meplazumab, Metablok (LSALT peptide, a DPEP1inhibitor), Methylprednisolone and other corticosteroids, MN-166(ibudilast, Macrophage migration inhibitory factor (MIF) inhibitor),MRx-4DP0004 (a strain of Bifidobacterium breve, 4D Pharma), Nafamostat(a serine protease inhibitor), Neuraminidase inhibitors like Tamiflu(oseltamivir), Nitazoxanide (nucleocapsid (N) protein inhibitor),Nivolumab, OT-101 (Mateon), Novaferon (man-made Interferon), Opaganib(yeliva) (Sphingosine kinase-2 inhibitor), Otilimab, PD-1 blockingantibody, peginterferons, such as peginterferon lambda, Pepcid(famotidine), Piclidenoson (A3 adenosine receptor agonist), Prezcobix(darunavir), PUL-042 (Pulmotect, Inc., toll-like receptor (TLR) binder),Rebif (interferon beta-1a), RHB-107 (upamostat) (serine proteaseinhibitor, RedHill Biopharma Ltd.), Selinexor (selective inhibitor ofnuclear export (SINE)), SNG001 (Synairgen, inhaled interferon beta-1a),Solnatide, stem cells, including mesenchymal stem cells, MultiStem(Athersys), and PLX (Pluristem Therapeutics), Sylvant (siltuximab),Thymosin, TJM2 (TJ003234), Tradipitant (neurokinin-1 receptorantagonist), Truvada (emtricitabine and tenofovir), Ultomiris(ravulizumab-cwvz), Vazegepant (CGRP receptor antagonist or blocker),and Xofluza (baloxavir marboxil).

Repurposed Antiviral Agents

A number of pharmaceutical agents, including agents active against otherviruses, have been evaluated against Covid-19, and found to haveactivity. Any of these compounds can be combined with the compoundsdescribed herein. Representative compounds include lopinavir, ritonavir,niclosamide, promazine, PNU, UC2, cinanserin (SQ 10,643), Calmidazolium(C3930), tannic acid, 3-isotheaflavin-3-gallate,theaflavin-3,3′-digallate, glycyrrhizin,S-nitroso-N-acetylpenicillamine, nelfinavir, niclosamide, chloroquine,hydroxychloroquine, 5-benzyloxygramine, ribavirin, Interferons, such asInterferon (IFN)-α, IFN-β, and pegylated versions thereof, as well ascombinations of these compounds with ribavirin, chlorpromazinehydrochloride, triflupromazine hydrochloride, gemcitabine, imatinibmesylate, dasatinib, and imatinib.

VIII. Pharmaceutical Compositions

Hosts, including but not limited to humans, infected with a coronavirus,picornavirus, including enterovirus, and/or hepeviridae virus, includinghepatitis E virus, and, optionally, co-infected with norovirus, can betreated by administering to the patient an effective amount of theactive compound or a pharmaceutically acceptable prodrug or salt thereofin the presence of a pharmaceutically acceptable carrier or diluent. Theactive materials can be administered by any appropriate route, forexample, orally, parenterally, intravenously, intradermally,subcutaneously, topically, or by inhalation or other form of delivery tothe pulmonary tract, in liquid or solid form.

A preferred dose of the compound for will be in the range of betweenabout 0.01 and about 10 mg/kg, more generally, between about 0.1 and 5mg/kg, and, preferably, between about 0.5 and about 2 mg/kg, of bodyweight of the recipient per day. The effective dosage range of thepharmaceutically acceptable salts and prodrugs can be calculated basedon the weight of the parent compound to be delivered. If the salt orprodrug exhibits activity in itself, the effective dosage can beestimated as above using the weight of the salt or prodrug, or by othermeans known to those skilled in the art.

The compound is conveniently administered in unit any suitable dosageform, including but not limited to but not limited to one containing 7to 600 mg, preferably 70 to 600 mg of active ingredient per unit dosageform. An oral dosage of 1-400 mg is usually convenient.

The concentration of active compound in the drug composition will dependon absorption, inactivation and excretion rates of the drug as well asother factors known to those of skill in the art. It is to be noted thatdosage values will also vary with the severity of the condition to bealleviated. It is to be further understood that for any particularsubject, specific dosage regimens should be adjusted over time accordingto the individual need and the professional judgment of the personadministering or supervising the administration of the compositions, andthat the concentration ranges set forth herein are exemplary only andare not intended to limit the scope or practice of the claimedcomposition. The active ingredient can be administered at once, or canbe divided into a number of smaller doses to be administered at varyingintervals of time.

Oral Formulations

A preferred mode of administration of the active compound is oral,although for certain patients a sterile injectable form can be given sc,ip or iv. Oral compositions will generally include an inert diluent oran edible carrier. They can be enclosed in gelatin capsules orcompressed into tablets. For the purpose of oral therapeuticadministration, the active compound can be incorporated with excipientsand used in the form of tablets, troches or capsules. Pharmaceuticallycompatible binding agents, and/or adjuvant materials can be included aspart of the composition.

The tablets, pills, capsules, troches and the like can contain any ofthe following ingredients, or compounds of a similar nature: a bindersuch as microcrystalline cellulose, gum tragacanth or gelatin; anexcipient such as starch or lactose, a disintegrating agent such asalginic acid, Primogel or corn starch; a lubricant such as magnesiumstearate or Sterotes; a glidant such as colloidal silicon dioxide; asweetening agent such as sucrose or saccharin; or a flavoring agent suchas peppermint, methyl salicylate, or orange flavoring. When the dosageunit form is a capsule, it can contain, in addition to material of theabove type, a liquid carrier such as a fatty oil. In addition, unitdosage forms can contain various other materials that modify thephysical form of the dosage unit, for example, coatings of sugar,shellac, or other enteric agents.

The compound can be administered as a component of an elixir,suspension, syrup, wafer, chewing gum or the like. A syrup can contain,in addition to the active compound(s), sucrose as a sweetening agent andcertain preservatives, dyes and colorings and flavors.

The compound or a pharmaceutically acceptable prodrug or salts thereofcan also be mixed with other active materials that do not impair thedesired action, or with materials that supplement the desired action,such as antibiotics, antifungals, anti-inflammatories or other antiviralcompounds. Solutions or suspensions used for parenteral, intradermal,subcutaneous, or topical application can include the followingcomponents: a sterile diluent such as water for injection, salinesolution, fixed oils, polyethylene glycols, glycerine, propylene glycolor other synthetic solvents; antibacterial agents such as benzyl alcoholor methyl parabens; antioxidants such as ascorbic acid or sodiumbisulfite; chelating agents, such as ethylenediaminetetraacetic acid;buffers, such as acetates, citrates or phosphates, and agents for theadjustment of tonicity, such as sodium chloride or dextrose. Theparental preparation can be enclosed in ampoules, disposable syringes ormultiple dose vials made of glass or plastic.

If administered intravenously, preferred carriers are physiologicalsaline or phosphate buffered saline (PBS).

Transdermal Formulations

In some embodiments, the compositions are present in the form oftransdermal formulations, such as that used in the FDA-approved agonistrotigitine transdermal (Neupro patch). Another suitable formulation isthat described in U.S. Publication No. 20080050424, entitled“Transdermal Therapeutic System for Treating Parkinsonism.” Thisformulation includes a silicone or acrylate-based adhesive, and caninclude an additive having increased solubility for the activesubstance, in an amount effective to increase dissolving capacity of thematrix for the active substance.

The transdermal formulations can be single-phase matrices that include abacking layer, an active substance-containing self-adhesive matrix, anda protective film to be removed prior to use. More complicatedembodiments contain multiple-layer matrices that may also containnon-adhesive layers and control membranes. If a polyacrylate adhesive isused, it can be crosslinked with multivalent metal ions such as zinc,calcium, aluminum, or titanium ions, such as aluminum acetylacetonateand titanium acetylacetonate.

When silicone adhesives are used, they are typicallypolydimethylsiloxanes. However, other organic residues such as, forexample, ethyl groups or phenyl groups may in principle be presentinstead of the methyl groups. Because the active compounds are amines,it may be advantageous to use amine-resistant adhesives. Representativeamine-resistant adhesives are described, for example, in EP 0 180 377.

Representative acrylate-based polymer adhesives include acrylic acid,acrylamide, hexylacrylate, 2-ethylhexylacrylate, hydroxyethylacrylate,octylacrylate, butylacrylate, methylacrylate, glycidylacrylate,methacrylic acid, methacrylamide, hexylmethacrylate,2-ethylhexylmethacrylate, octylmethacrylate, methylmethacrylate,glycidylmethacrylate, vinylacetate, vinylpyrrolidone, and combinationsthereof.

The adhesive must have a suitable dissolving capacity for the activesubstance, and the active substance most be able to move within thematrix, and be able to cross through the contact surface to the skin.Those of skill in the art can readily formulate a transdermalformulation with appropriate transdermal transport of the activesubstance.

Certain pharmaceutically acceptable salts tend to be more preferred foruse in transdermal formulations, because they can help the activesubstance pass the barrier of the stratum corneum. Examples includefatty acid salts, such as stearic acid and oleic acid salts. Oleate andstearate salts are relatively lipophilic, and can even act as apermeation enhancer in the skin.

Permeation enhancers can also be used. Representative permeationenhancers include fatty alcohols, fatty acids, fatty acid esters, fattyacid amides, glycerol or its fatty acid esters, N-methylpyrrolidone,terpenes such as limonene, alpha-pinene, alpha-terpineol, carvone,carveol, limonene oxide, pinene oxide, and 1,8-eucalyptol.

The patches can generally be prepared by dissolving or suspending theactive agent in ethanol or in another suitable organic solvent, thenadding the adhesive solution with stirring. Additional auxiliarysubstances can be added either to the adhesive solution, the activesubstance solution or to the active substance-containing adhesivesolution. The solution can then be coated onto a suitable sheet, thesolvents removed, a backing layer laminated onto the matrix layer, andpatches punched out of the total laminate.

Formulations for Pulmonary Administration

In some embodiments, the compounds are administered to the pulmonarytract (i.e., via pulmonary administration). In one specific embodiment,pulmonary administration comprises inhalation of the compounds,typically in the form of particles or droplets, such as by nasal, oralinhalation, or both. The particles or droplets can be administered intwo or more separate administrations (doses).

In one aspect of this embodiment, particles may be formulated as anaerosol (i.e.: liquid droplets of a stable dispersion or suspension ofparticles which include one or more of the compounds described herein ina gaseous medium). Particles delivered by aerosol may be deposited inthe airways by gravitational sedimentation, inertial impaction, and/ordiffusion. Any suitable device for generating the aerosol may be used,including but not limited to pressured meter inhalers (pMDI),nebulizers, dry powder inhalers (DPI), and soft-mist inhalers.

In one specific embodiment, the methods comprise inhalation of particlesincluding one or more of the compounds described herein aerosolized vianebulization. Nebulizers generally use compressed air or ultrasonicpower to create inhalable aerosol droplets of the particles orsuspensions thereof. In this embodiment, the nebulizing results inpulmonary delivery to the subject of aerosol droplets of the particlesor suspension thereof.

In another embodiment, the methods comprise inhalation of particlesaerosolized via a pMDI, wherein the particles or suspensions thereof aresuspended in a suitable propellant system (including but not limited tohydrofluoroalkanes (HFAs) containing at least one liquefied gas in apressurized container sealed with a metering valve. Actuation of thevalve results in delivery of a metered dose of an aerosol spray of theparticles or suspensions thereof.

Biodegradable particles can be used for the controlled-release anddelivery of the compounds described herein. Aerosols for the delivery oftherapeutic agents to the respiratory tract have been developed. Adjei,A. and Garren, J. Pharm Res. 7, 565-569 (1990); and Zanen, P. and Lamm,J.-W. J. Int. J. Pharm. 114, 111-115 (1995).

The respiratory tract encompasses the upper airways, including theoropharynx and larynx, followed by the lower airways, which include thetrachea followed by bifurcations into the bronchi and bronchioli. Theupper and lower airways are called the conducting airways. The terminalbronchioli then divide into respiratory bronchioli which then lead tothe ultimate respiratory zone, the alveoli, or deep lung. Gonda, I.“Aerosols for delivery of therapeutic and diagnostic agents to therespiratory tract,” in Critical Reviews in Therapeutic Drug CarrierSystems 6:273-313, 1990. The deep lung, or alveoli, are the primarytarget of inhaled therapeutic aerosols for systemic drug delivery.

Accordingly, it can be important to deliver antiviral particles to thedeep lung (i.e., the alveolar regions of the lung). Relatively largeparticles tend to get trapped in the oropharyngeal cavity, which canlead to excessive loss of the inhaled drug. Relatively smaller particlescan be delivered to the deep lung, but can be phagocytosed. One way todeliver relatively large particles (sized to avoid phagocytosis), whichare light enough to avoid excessive entrapment in the oropharyngealcavity, is to use porous particles.

In one embodiment, the particles for delivering the compounds describedherein to the alveolar regions of the lung are porous,“aerodynamically-light” particles, as described in U.S. Pat. No.6,977,087. Aerodynamically light particles can be made of abiodegradable material, and typically have a tap density less than 0.4g/cm³ and a mass mean diameter between 5 μm and 30 μm. The particles maybe formed of biodegradable materials such as biodegradable polymers. Forexample, the particles may be formed of a functionalized polyester graftcopolymer consisting of a linear alpha-hydroxy-acid polyester backbonehaving at least one amino acid group incorporated herein and at leastone poly(amino acid) side chain extending from an amino acid group inthe polyester backbone. In one embodiment, aerodynamically lightparticles having a large mean diameter, for example greater than 5 m,can be used for enhanced delivery of one or more of the compoundsdescribed herein to the alveolar region of the lung.

Nanoparticulate Compositions

The compounds described herein can also be administered in the form ofnanoparticulate compositions.

In one embodiment, the controlled release nanoparticulate formulationscomprise a nanoparticulate active agent to be administered and arate-controlling polymer which functions to prolong the release of theagent following administration. In this embodiment, the compositions canrelease the active agent, following administration, for a time periodranging from about 2 to about 24 hours or up to 30 days or longer.Representative controlled release formulations including ananoparticulate form of the active agent are described, for example, inU.S. Pat. No. 8,293,277.

Nanoparticulate compositions comprise particles of the active agentsdescribed herein, having a non-crosslinked surface stabilizer adsorbedonto, or associated with, their surface.

The average particle size of the nanoparticulates is typically less thanabout 800 nm, more typically less than about 600 nm, still moretypically less than about 400 nm, less than about 300 nm, less thanabout 250 nm, less than about 100 nm, or less than about 50 nm. In oneaspect of this embodiment, at least 50% of the particles of active agenthave an average particle size of less than about 800, 600, 400, 300,250, 100, or 50 nm, respectively, when measured by light scatteringtechniques.

A variety of surface stabilizers are typically used with nanoparticulatecompositions to prevent the particles from clumping or aggregating.Representative surface stabilizers are selected from the groupconsisting of gelatin, lecithin, dextran, gum acacia, cholesterol,tragacanth, stearic acid, benzalkonium chloride, calcium stearate,glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifyingwax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylenecastor oil derivatives, polyoxyethylene sorbitan fatty acid esters,polyethylene glycols, polyoxyethylene stearates, colloidal silicondioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulosecalcium, carboxymethylcellulose sodium, methylcellulose,hydroxyethylcellulose, hydroxypropylcellulose,hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose,magnesium aluminum silicate, triethanolamine, polyvinyl alcohol,polyvinylpyrrolidone, tyloxapol, poloxamers, poloxamines, poloxamine908, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate,an alkyl aryl polyether sulfonate, a mixture of sucrose stearate andsucrose distearate, p-isononylphenoxypoly-(glycidol), SA9OHCO,decanoyl-N-methylglucamide, n-decyl-D-glucopyranoside,n-decyl-D-maltopyranoside, n-dodecyl-D-glucopyranoside,n-dodecyl-D-maltoside, heptanoyl-N-methylglucamide,n-heptyl-D-glucopyranoside, n-heptyl-D-thioglucoside,n-hexyl-D-glucopyranoside, nonanoyl-N-methylglucamide,n-nonyl-D-glucopyranoside, octanoyl-N-methylglucamide,n-octyl-D-glucopyranoside, and octyl-D-thioglucopyranoside. Lysozymescan also be used as surface stabilizers for nanoparticulatecompositions. Certain nanoparticles such as poly(lactic-co-glycolicacid) (PLGA)-nanoparticles are known to target the liver when given byintravenous (IV) or subcutaneously (SQ).

In one embodiment, the nanoparticles or other drug delivery vehicles aretargeted to the liver. One such type of liver-targeted drug deliveryvehicle is described in Park, et al., Mol Imaging. February 2011; 10(1):69-77, and uses Glypican-3 (GPC3) as a molecular target. Park taughtusing this target for hepatocellular carcinoma (HCC), a primary livercancer frequently caused by chronic persistent hepatitis.

In one aspect of this embodiment, this drug delivery vehicle is alsoused to target therapeutics to the liver to treat viral infections.Further, since the compounds described herein have anti-cancer uses,this type of system can target the compounds to the liver and treatliver cancers. GPC3 is a heparan sulfate proteoglycan that is notexpressed in normal adult tissues, but significantly over-expressed inup to 80% of human HCC's. GPC3 can be targeted, for example, usingantibody-mediated targeting and binding (See Hsu, et al., Cancer Res.1997; 57:5179-84).

Another type of drug delivery system for targeting the liver isdescribed in U.S. Pat. No. 7,304,045. The '045 patent discloses adual-particle tumor or cancer targeting system that includes a firstligand-mediated targeting nanoparticle conjugated with galactosamine,with the ligand being on a target cell. The first nanoparticle includespoly(γ-glutamic acid)/poly(lactide) block copolymers and n antiviralcompound, which in this case is a compound described herein, and in the'045 patent, was gancyclovir. A second nanoparticle includespoly(γ-glutamic acid)/poly(lactide) block copolymers, an endothelialcell-specific promoter, and a (herpes-simplex-virus)-(thymidine kinase)gene constructed plasmid, and provides enhanced permeability andretention-mediated targeting. The first and said second nanoparticlesare mixed in a solution configured for delivering to the liver. When thedisorder to be treated is a liver tumor or cancer, the delivery can bedirectly to, or adjacent to, the liver tumor or cancer.

Representative rate controlling polymers into which the nanoparticlescan be formulated include chitosan, polyethylene oxide (PEO), polyvinylacetate phthalate, gum arabic, agar, guar gum, cereal gums, dextran,casein, gelatin, pectin, carrageenan, waxes, shellac, hydrogenatedvegetable oils, polyvinylpyrrolidone, hydroxypropyl cellulose (HPC),hydroxyethyl cellulose (HEC), hydroxypropyl methylcelluose (HPMC),sodium carboxymethylcellulose (CMC), poly(ethylene) oxide, alkylcellulose, ethyl cellulose, methyl cellulose, carboxymethyl cellulose,hydrophilic cellulose derivatives, polyethylene glycol,polyvinylpyrrolidone, cellulose acetate, cellulose acetate butyrate,cellulose acetate phthalate, cellulose acetate trimellitate, polyvinylacetate phthalate, hydroxypropylmethyl cellulose phthalate,hydroxypropylmethyl cellulose acetate succinate, polyvinylacetaldiethylamino acetate, poly(alkylmethacrylate), poly(vinylacetate), polymers derived from acrylic or methacrylic acid and theirrespective esters, and copolymers derived from acrylic or methacrylicacid and their respective esters.

Methods of making nanoparticulate compositions are described, forexample, in U.S. Pat. Nos. 5,518,187 and 5,862,999, both for “Method ofGrinding Pharmaceutical Substances;” U.S. Pat. No. 5,718,388, for“Continuous Method of Grinding Pharmaceutical Substances;” and U.S. Pat.No. 5,510,118 for “Process of Preparing Therapeutic CompositionsContaining Nanoparticles.”

Nanoparticulate compositions are also described, for example, in U.S.Pat. No. 5,298,262 for “Use of Ionic Cloud Point Modifiers to PreventParticle Aggregation During Sterilization;” U.S. Pat. No. 5,302,401 for“Method to Reduce Particle Size Growth During Lyophilization;” U.S. Pat.No. 5,318,767 for “X-Ray Contrast Compositions Useful in MedicalImaging;” U.S. Pat. No. 5,326,552 for “Novel Formulation ForNanoparticulate X-Ray Blood Pool Contrast Agents Using High MolecularWeight Non-ionic Surfactants;” U.S. Pat. No. 5,328,404 for “Method ofX-Ray Imaging Using Iodinated Aromatic Propanedioates;” U.S. Pat. No.5,336,507 for “Use of Charged Phospholipids to Reduce NanoparticleAggregation;” U.S. Pat. No. 5,340,564 for Formulations Comprising Olin10-G to Prevent Particle Aggregation and Increase Stability;” U.S. Pat.No. 5,346,702 for “Use of Non-Ionic Cloud Point Modifiers to MinimizeNanoparticulate Aggregation During Sterilization;” U.S. Pat. No.5,349,957 for “Preparation and Magnetic Properties of Very SmallMagnetic-Dextran Particles;” U.S. Pat. No. 5,352,459 for “Use ofPurified Surface Modifiers to Prevent Particle Aggregation DuringSterilization;” U.S. Pat. Nos. 5,399,363 and 5,494,683, both for“Surface Modified Anticancer Nanoparticles;” U.S. Pat. No. 5,401,492 for“Water Insoluble Non-Magnetic Manganese Particles as Magnetic ResonanceEnhancement Agents;” U.S. Pat. No. 5,429,824 for “Use of Tyloxapol as aNanoparticulate Stabilizer;” U.S. Pat. No. 5,447,710 for “Method forMaking Nanoparticulate X-Ray Blood Pool Contrast Agents Using HighMolecular Weight Non-ionic Surfactants;” U.S. Pat. No. 5,451,393 for“X-Ray Contrast Compositions Useful in Medical Imaging;” U.S. Pat. No.5,466,440 for “Formulations of Oral Gastrointestinal Diagnostic X-RayContrast Agents in Combination with Pharmaceutically Acceptable Clays;”U.S. Pat. No. 5,470,583 for “Method of Preparing NanoparticleCompositions Containing Charged Phospholipids to Reduce Aggregation;”U.S. Pat. No. 5,472,683 for “Nanoparticulate Diagnostic Mixed CarbamicAnhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic SystemImaging;” U.S. Pat. No. 5,500,204 for “Nanoparticulate Diagnostic Dimersas X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;”U.S. Pat. No. 5,518,738 for “Nanoparticulate NSAID Formulations;” U.S.Pat. No. 5,521,218 for “Nanoparticulate Iododipamide Derivatives for Useas X-Ray Contrast Agents;” U.S. Pat. No. 5,525,328 for “NanoparticulateDiagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool andLymphatic System Imaging;” U.S. Pat. No. 5,543,133 for “Process ofPreparing X-Ray Contrast Compositions Containing Nanoparticles;” U.S.Pat. No. 5,552,160 for “Surface Modified NSAID Nanoparticles;” U.S. Pat.No. 5,560,931 for “Formulations of Compounds as NanoparticulateDispersions in Digestible Oils or Fatty Acids;” U.S. Pat. No. 5,565,188for “Polyalkylene Block Copolymers as Surface Modifiers forNanoparticles;” U.S. Pat. No. 5,569,448 for “Sulfated Non-ionic BlockCopolymer Surfactant as Stabilizer Coatings for NanoparticleCompositions;” U.S. Pat. No. 5,571,536 for “Formulations of Compounds asNanoparticulate Dispersions in Digestible Oils or Fatty Acids;” U.S.Pat. No. 5,573,749 for “Nanoparticulate Diagnostic Mixed CarboxylicAnydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic SystemImaging;” U.S. Pat. No. 5,573,750 for “Diagnostic Imaging X-Ray ContrastAgents;” U.S. Pat. No. 5,573,783 for “Redispersible Nanoparticulate FilmMatrices With Protective Overcoats;” U.S. Pat. No. 5,580,579 for“Site-specific Adhesion Within the GI Tract Using NanoparticlesStabilized by High Molecular Weight, Linear Poly(ethylene Oxide)Polymers;” U.S. Pat. No. 5,585,108 for “Formulations of OralGastrointestinal Therapeutic Agents in Combination with PharmaceuticallyAcceptable Clays;” U.S. Pat. No. 5,587,143 for “Butylene Oxide-EthyleneOxide Block Copolymers Surfactants as Stabilizer Coatings forNanoparticulate Compositions;” U.S. Pat. No. 5,591,456 for “MilledNaproxen with Hydroxypropyl Cellulose as Dispersion Stabilizer;” U.S.Pat. No. 5,593,657 for “Novel Barium Salt Formulations Stabilized byNon-ionic and Anionic Stabilizers;” U.S. Pat. No. 5,622,938 for “SugarBased Surfactant for Nanocrystals;” U.S. Pat. No. 5,628,981 for“Improved Formulations of Oral Gastrointestinal Diagnostic X-RayContrast Agents and Oral Gastrointestinal Therapeutic Agents;” U.S. Pat.No. 5,643,552 for “Nanoparticulate Diagnostic Mixed Carbonic Anhydridesas X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;”U.S. Pat. No. 5,718,388 for “Continuous Method of GrindingPharmaceutical Substances;” U.S. Pat. No. 5,718,919 for “NanoparticlesContaining the R(−)Enantiomer of Ibuprofen;” U.S. Pat. No. 5,747,001 for“Aerosols Containing Beclomethasone Nanoparticle Dispersions;” U.S. Pat.No. 5,834,025 for “Reduction of Intravenously AdministeredNanoparticulate Formulation Induced Adverse Physiological Reactions;”U.S. Pat. No. 6,045,829 “Nanocrystalline Formulations of HumanImmunodeficiency Virus (HIV) Protease Inhibitors Using CellulosicSurface Stabilizers;” U.S. Pat. No. 6,068,858 for “Methods of MakingNanocrystalline Formulations of Human Immunodeficiency Virus (HIV)Protease Inhibitors Using Cellulosic Surface Stabilizers;” U.S. Pat. No.6,153,225 for “Injectable Formulations of Nanoparticulate Naproxen;”U.S. Pat. No. 6,165,506 for “New Solid Dose Form of NanoparticulateNaproxen;” U.S. Pat. No. 6,221,400 for “Methods of Treating MammalsUsing Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV)Protease Inhibitors;” U.S. Pat. No. 6,264,922 for “Nebulized AerosolsContaining Nanoparticle Dispersions;” U.S. Pat. No. 6,267,989 for“Methods for Preventing Crystal Growth and Particle Aggregation inNanoparticle Compositions;” U.S. Pat. No. 6,270,806 for “Use ofPEG-Derivatized Lipids as Surface Stabilizers for NanoparticulateCompositions;” U.S. Pat. No. 6,316,029 for “Rapidly Disintegrating SolidOral Dosage Form,” U.S. Pat. No. 6,375,986 for “Solid DoseNanoparticulate Compositions Comprising a Synergistic Combination of aPolymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate;” U.S.Pat. No. 6,428,814 for “Bioadhesive nanoparticulate compositions havingcationic surface stabilizers;” U.S. Pat. No. 6,431,478 for “Small ScaleMill;” and U.S. Pat. No. 6,432,381 for “Methods for targeting drugdelivery to the upper and/or lower gastrointestinal tract,” all of whichare specifically incorporated by reference. In addition, U.S. PatentApplication No. 20020012675 A1, published on Jan. 31, 2002, for“Controlled Release Nanoparticulate Compositions,” describesnanoparticulate compositions, and is specifically incorporated byreference.

The nanoparticle formulations including the compounds described herein,and also in the form of a prodrug or a salt, can be used to treat orprevent infections by coronaviruses, picornaviruses, and/or viruses inthe hepeviridae family, which includes the hepatitis E virus.

Amorphous small particle compositions are described, for example, inU.S. Pat. No. 4,783,484 for “Particulate Composition and Use Thereof asAntimicrobial Agent;” U.S. Pat. No. 4,826,689 for “Method for MakingUniformly Sized Particles from Water-Insoluble Organic Compounds;” U.S.Pat. No. 4,997,454 for “Method for Making Uniformly-Sized Particles FromInsoluble Compounds;” U.S. Pat. No. 5,741,522 for “Ultrasmall,Non-aggregated Porous Particles of Uniform Size for Entrapping GasBubbles Within and Methods;” and U.S. Pat. No. 5,776,496, for“Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.”

Controlled Release Formulations

In a preferred embodiment, the active compounds are prepared withcarriers that will protect the compound against rapid elimination fromthe body, such as a controlled release formulation, including but notlimited to implants and microencapsulated delivery systems.Biodegradable, biocompatible polymers can be used, such as ethylenevinyl acetate, polyanhydrides, polyglycolic acid, collagen,polyorthoesters and polylactic acid. For example, enterically coatedcompounds can be used to protect cleavage by stomach acid. Methods forpreparation of such formulations will be apparent to those skilled inthe art. Suitable materials can also be obtained commercially.

Liposomal suspensions (including but not limited to liposomes targetedto infected cells with monoclonal antibodies to viral antigens) are alsopreferred as pharmaceutically acceptable carriers. These can be preparedaccording to methods known to those skilled in the art, for example, asdescribed in U.S. Pat. No. 4,522,811 (incorporated by reference). Forexample, liposome formulations can be prepared by dissolving appropriatelipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoylphosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol)in an inorganic solvent that is then evaporated, leaving behind a thinfilm of dried lipid on the surface of the container. An aqueous solutionof the active compound is then introduced into the container. Thecontainer is then swirled by hand to free lipid material from the sidesof the container and to disperse lipid aggregates, thereby forming theliposomal suspension.

The terms used in describing the invention are commonly used and knownto those skilled in the art. As used herein, the following abbreviationshave the indicated meanings:

Boc₂O Di-tert-butyl dicarbonate

CbzCl Benzyl chloroformate

CDI N,N′-Carbonyldiimidazole

DCE dichloroethane

DCM Dichloromethane

DIPEA diisopropyl ethyl amine (Hünig's base)

DMSO dimethylsulfoxide

EDC 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride

Et₃N Triethylamine

EtOAc ethyl acetate

EtOH ethanol

h hour

HOBt Hydroxybenzotriazole

KOAC Potassium acetate

LiHMDS Lithium bis(trimethylsilyl)amide

M molar

mCPBA meta-Chloroperoxybenzoic acid

MeOH Methanol

MePPh₃Br Methyltriphenylphosphonium bromide

MsCl Methanesulfonyl chloride

min minute

Py.SO₃ Sulfur trioxide pyridine complex

rt or RT room temperature

TFA trifluoroacetic acid

THF tetrahydrofuran

TLC Thin layer chromatography

TMSCF₃ trimethyl(trifluoromethyl)silane

IX. General Methods for Preparing Active Compounds

Methods for the facile preparation of active compounds are known in theart and result from the selective combination of known methods. Thecompounds disclosed herein can be prepared as described in detail below,or by other methods known to those skilled in the art. It will beunderstood by one of ordinary skill in the art that variations of detailcan be made without departing from the spirit and in no way limiting thescope of the present invention.

The various reaction schemes are summarized below.

Scheme 1 is a non-limiting example of the synthesis of active compoundsof the present invention, and in particular, a synthetic approach tocompound A.

Scheme 2 is a non-limiting example of the synthesis of intermediates ofthe present invention, and in particular, a synthetic approach tocompound XVI, XVIII, XIX and XXI.

Scheme 3 is a non-limiting example of the synthesis of active compoundsof the present invention, and in particular, a synthetic approach tocompound B-D.

Scheme 4 is a non-limiting example of the synthesis of active compoundsof the present invention, and in particular, a synthetic approach tocompound E.

Compounds of formula A can be prepared by first reaction of an aminoacid derivative of general formula I with an alcohol. Intermediate IIcan be then N-protected for example, by treatment with Boc₂O in thepresence of a base such as Et₃N and then reacted with a compound ofgeneral formula IV in presence of a base such as LiHMDS. Cyanoderivative of general formula V can be then reduced and finaly cyclizedto give VII. Intermediate VII can be deprotected for example, in thepresence of TFA when Boc was used as a protecting group, and reactedwith an amino acid of general formula VIII in the presence of peptidecoupling reagents like EDC and HOBt. After deprotection for example, inthe presence of TFA when Boc was used as a protecting group, compound ofgeneral formula IX can be reacted in presence peptide coupling reagentslike EDC and HOBt with compound XII, prepared by reaction of amino acidof general formula X and halogenated reagent XI in the presence of abase such as NaHCO₃. Esters of general formula XIII can then be reducedwith, for instance, LiAlH₄ to give compounds of general formula A.

Intermediates of formula XVI, XVIII, XIX and XXI can be prepared byfirst reduction of compound of general formula VI, with a reducing agentsuch as for instance LiBH₄ followed by oxidation to form aldehyde ofgeneral formula XIV and then reaction with either compounds XV, XVII, XXor MePPh₃Br.

Compounds of formula B-D can be prepared by first deprotection ofcompound of general formula XVI, XVIII or XXI, for example, in thepresence of TFA when Boc was used as a protecting group, and reactionwith a carboxylic acid of general formula XII in the presence of peptidecoupling reagents like EDC and HOBt.

Compounds of formula E can be prepared by first deprotection of compoundof general formula XIX, for example, in the presence of TFA when Boc wasused as a protecting group; reaction with a carboxylic acid of generalformula XII in the presence of peptide coupling reagents like EDC andHOBt and epoxidation using for instance mCPBA.

SPECIFIC EXAMPLES

Specific compounds which are representative of this invention wereprepared as per the following examples and reaction sequences; theexamples and the diagrams depicting the reaction sequences are offeredby way of illustration, to aid in the understanding of the invention andshould not be construed to limit in any way the invention set forth inthe claims which follow thereafter. The present compounds can also beused as intermediates in subsequent examples to produce additionalcompounds of the present invention. No attempt has necessarily been madeto optimize the yields obtained in any of the reactions. One skilled inthe art would know how to increase such yields through routinevariations in reaction times, temperatures, solvents and/or reagents.

Anhydrous solvents were purchased from Aldrich Chemical Company, Inc.(Milwaukee, Wis.) and EMD Chemicals Inc. (Gibbstown, N.J.). Reagentswere purchased from commercial sources. Unless noted otherwise, thematerials used in the examples were obtained from readily availablecommercial suppliers or synthesized by standard methods known to oneskilled in the art of chemical synthesis. ¹H and ¹³C NMR spectra weretaken on a Bruker Ascend™ 400 MHz Fourier transform spectrometer at roomtemperature and reported in ppm downfield from internaltetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSYwere performed to confirm proton assignments. Signal multiplicities arerepresented by s (singlet), d (doublet), dd (doublet of doublets), t(triplet), q (quadruplet), br (broad), bs (broad singlet), m(multiplet). All J-values are in Hz. Mass spectra were determined on aMicromass Platform LC spectrometer using electrospray techniques.Analytic TLC were performed on Sigma-Aldrich® aluminum supported silicagel (25 μm) plates. Column chromatography was carried out on Silica Gelor via reverse-phase high performance liquid chromatography.

Example 1

Dimethyl(2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(2-cyanoethyl)pentanedioate (2)

To a solution of N-Boc-L-glutamic acid dimethyl ester (1, 16.5 g, 60.0mmol) in THF (180 mL) was added dropwise a solution of lithiumbis(trimethylsilyl)amide in THF (130 mL, 1 M, 130 mmol) at −78° C. underan argon atmosphere. The resulting mixture was stirred at −78° C. for1.5 h. At the same time, 3-bromopropionitrile (9.63 g, 71.9 mmol) wasadded dropwise to the dianion solution over a period of 1 h whilemaintaining the temperature below −70° C. The reaction mixture wasstirred at −78° C. for an additional 3 h. The reaction was quenched withaqueous NH₄Cl (80 mL). The reaction mixture was allowed to warm up toroom temperature and then EtOAc (140 mL) was added. The layers wereseparated, and the aqueous layer was extracted with EtOAc (100 mL×2).The combined organic layers were washed with brine, dried over Na₂SO₄,and filtered. The filtrate was evaporated to dryness. The crude residuewas purified by flash column chromatography (hexanes/ethyl acetate=4/1)to give product 2 (5.25 g, 27%) as a colorless oil. ¹H NMR (CDCl₃, 400MHz) δ: 5.08 (1H, d, J=8.0 Hz), 4.38 (1H, m), 3.74 (3H, s), 3.71 (3H,s), 2.62-2.65 (1H, m), 2.35-2.42 (2H, m), 1.97-2.04 (4H, m), 1.44 (9H,s). ¹³C-NMR (CDCl₃, 100 MHz) δ: 15.16, 27.31, 28.26, 34.47, 40.77,51.55, 52.20, 52.60, 80.37, 118.70, 115.38, 172.36, 174.42. ESI-MS(m/z): 329.4 (M+H)⁺.

Methyl(S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate(4)

In a hydrogenation flask was placed compound 2 (2.15 g, 6.55 mmol), 5 mLof chloroform and 60 mL of methanol before addition of PtO₂(160 mg, 0.65mmol). The resulting mixture was mechanically stirred at roomtemperature for 2 days under hydrogen pressure (50 Psi). The mixture wasthen filtered over a pad of silica gel. KOAc (1.27 g, 13 mmol) was addedto the filtrate and the resulting mixture was stirred at 60° C. for 12h. After removal of the solvents, the crude residue was purified bysilica gel column chromatography (DCM/MeOH=50:1 to 20:1) to give theproduct 4 as a colorless oil (1.21 g, 62%, over two steps). ¹H NMR(CDCl₃, 400 MHz) δ: 6.41 (1H, s), 5.64 (1H, d, J=8.0 Hz), 4.30-4.36 (1H,m), 3.31-3.33 (1H, m), 2.38-2.42 (1H, m), 2.25-2.34 (1H, m), 2.13-2.16(1H, m), 1.81-1.93 (3H, m), 1.71-1.79 (1H, m), 1.52-1.61 (1H, m), 1.47(9H, s). ¹³C-NMR (CDCl₃, 100 MHz) δ: 21.54, 26.53, 28.29, 34.28, 37.97,42.35, 51.70, 52.30, 79.81, 155.92, 173.18, 174.58. ESI-MS (m/z): 301.4(M+H)⁺.

Methyl (5S,8S, 11S)-5-(4-hydroxybenzyl)-8-isobutyl-3, 6,9-trioxo-11-(((S)-2-oxopiperidin-3-yl)methyl)-1-phenyl-2-oxa-4, 7,10-triazadodecan-12-oate (9)

To a solution of 4 (300 mg, 1.0 mmol) in dioxane was added a solution of4 M HCl in dioxane. The reaction was stirred for 2 h at room temperatureand then concentrated. The crude HCl salt was suspended in DCM (10 mL)and (tert-butoxycarbonyl)-L-leucine (254 mg, 1.1 mmol),1-hydroxybenzotriazole (169 mg, 1.25 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (240 mg,1.25 mmol) and N,N-diisopropylethyl amine (0.7 mL, 4.0 mmol) were addedat 0° C. The ice bath was removed and the reaction mixture was stirredat room temperature overnight. The reaction mixture was then dilutedwith EtOAc (100 mL) and washed with 1N HCl, NaHCO₃ (5%) and brine, driedover Na₂SO₄ and concentrated in vacuo. The residue was purified by flashchromatography (DCM/MeOH 30:1 to 10:1) to give compound 6 (262 mg, 63%).Compound 6 (200 mg, 0.48 mmol) was dissolved in a 1:2 TFA-DCM solution(10 mL) and stirred 2 h at room temperature and then concentrated undervacuum. The crude HCl salt was suspended in DCM (10 mL) and((benzyloxy)carbonyl)-L-tyrosine 8 (166 mg, 0.53 mmol),1-hydroxybenzotriazole (82 mg, 0.61 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (161 mg,0.61 mmol) and N,N-diisopropylethyl amine (0.33 mL, 1.92 mmol) at wereadded at 0° C. The ice bath was removed and the reaction mixture wasstirred at room temperature overnight. The reaction mixture was dilutedwith EtOAc (100 mL) and washed with 1N HCl, NaHCO₃ (5%) and brine. Theorganic layer was dried over Na₂SO₄ and concentrated in vacuo. Theresidue was purified by flash chromatography (DCM/MeOH 30:1 to 10:1) togive compound 9 (170 mg, 58%). ¹H NMR (400 MHz, Methanol-d₄) δ 7.39-7.20(m, 5H), 7.12-7.03 (m, 2H), 6.80-6.65 (m, 2H), 5.13-4.94 (m, 2H), 4.64(s, 1H), 4.54 (dd, J=11.5, 4.2 Hz, 1H), 4.40 (ddd, J=17.8, 9.2, 5.5 Hz,2H), 3.72 (s, 3H), 3.31-3.20 (m, 2H), 3.05 (dd, J=14.0, 4.9 Hz, 1H),2.76 (dd, J=14.0, 9.4 Hz, 1H), 2.41 (dt, J=9.9, 5.0 Hz, 1H), 2.30 (ddd,J=15.5, 11.6, 4.1 Hz, 1H), 2.04-1.88 (m, 2H), 1.88-1.80 (m, 1H),1.79-1.58 (m, 4H), 1.52 (dtt, J=13.3, 10.3, 4.4 Hz, 2H), 0.95 (dd,J=13.9, 6.1 Hz, 6H). ¹³C NMR (101 MHz, MeOD) δ 175.04, 173.48, 172.75,172.45, 156.89, 155.80, 136.77, 130.01, 128.05, 127.22, 114.83, 66.16,56.45, 51.83, 51.43, 49.83, 41.56, 40.48, 37.32, 36.82, 32.76, 25.52,24.31, 21.99, 20.85, 20.81. ESI-MS (m/z): 611.4 (M+H)⁺.

Benzyl((S)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate(10)

To a solution of 9 (120 mg, 0.2 mmol) in THF (3 mL) was added LiBH₄ (4Min THF, 0.3 mL, 1.2 mmol) dropwise at 0° C. The reaction mixture wasstirred at room temperature for 2 h and then quenched with 1N HCl (15mL). After being stirred for 1 h at room temperature, the suspension wasextracted with ethyl acetate, and washed with NaHCO₃ and brine. Theorganic layers was dried over Na₂SO₄, filtered and concentrated invacuo. The residue was purified by flash chromatography (DCM/MeOH 30:1to 10:1) to give compound. to afford 10 (83 mg, 73%). ¹H NMR (400 MHz,Methanol-d₄) δ 7.44-7.23 (m, 5H), 7.08 (d, J=8.5 Hz, 2H), 6.71 (d, J=8.5Hz, 2H), 5.18-4.97 (m, 3H), 4.62 (s, 1H), 4.43-4.28 (m, 2H), 4.09-3.91(m, 1H), 3.51 (qd, J=11.0, 5.7 Hz, 2H), 3.33 (t, J=1.7 Hz, 1H), 3.06(dd, J=14.1, 5.0 Hz, 1H), 2.80 (dd, J=14.1, 9.1 Hz, 1H), 2.30 (d, J=9.6Hz, 1H), 2.16-1.94 (m, 2H), 1.79 (d, J=9.4 Hz, 1H), 1.75-1.56 (m, 5H),1.56-1.46 (m, 1H), 1.01-0.88 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ 176.01,173.42, 172.89, 157.15, 155.87, 136.70, 129.99, 128.05, 127.62, 127.55,127.34, 114.88, 66.33, 64.15, 56.75, 52.22, 41.63, 40.51, 37.29, 36.60,32.74, 25.66, 24.38, 22.11, 20.64, 20.56. ESI-MS (m/z): 583.5 (M+H)⁺.

Benzyl((S)-3-(4-hydroxyphenyl)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxopropan-2-yl)carbamate(11)

To a solution of 10 (50 mg, 0.086 mmol) in dichloromethane-DMSO (4:1, 1mL) were added sulfur trioxide pyridine complex (55 mg, 0.34 mmol) andN,N-diisopropylethyl amine (0.06 mL, 0.34 mmol). The resulting mixturewas stirred at room temperature for 12 h and then quenched with 1N HCl(5 mL). The suspension was extracted with ethyl acetate washed with asaturated solution of NaHCO₃ and brine. The organic layer was dried overNa₂SO₄, filtered and concentrated in vacuo. The residue was purified bypreparative TLC (DCM/MeOH=12/1) to give product 11 as a white solid (28mg, 56%). ¹H NMR (400 MHz, MeOD) δ 7.39-7.23 (m, 5H), 7.08 (d, J=8.4 Hz,2H), 6.71 (d, J=8.4 Hz, 2H), 5.01 (dd, J=25.6, 12.8 Hz, 1H), 4.65 (s,1H), 4.53-4.45 (m, 1H), 4.37 (dd, J=9.5, 4.3 Hz, 2H), 4.01 (d, J=2.8 Hz,1H), 3.36 (s, 1H), 3.23 (d, J=4.1 Hz, 2H), 3.06 (dd, J=14.1, 4.3 Hz,1H), 2.77 (dd, J=13.4, 10.4 Hz, 1H), 2.27 (d, J=6.4 Hz, 1H), 2.15 (t,J=13.1 Hz, 1H), 2.01 (dd, J=6.9, 3.5 Hz, 1H), 1.84-1.43 (m, 6H),1.01-0.87 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ 176.10, 173.55, 173.46,172.89, 172.80, 157.02, 155.82, 136.75, 129.98, 128.05, 127.74, 127.51,127.25, 114.84, 98.40, 98.32, 66.21, 56.57, 54.07, 53.77, 52.22, 50.72,50.62, 41.62, 40.66, 40.59, 37.05, 37.02, 36.77, 30.50, 29.93, 25.43,24.38, 24.32, 21.97, 20.85, 20.52. ESI-MS (m/z): 581.4 (M+H)⁺.

Example 2

Methyl (5R,8S, 11S)-8-isobutyl-5-(naphthalen-1-ylmethyl)-3, 6,9-trioxo-11-(((S)-2-oxopiperidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate(13)

Compound 13 was prepared from(R)-2-(((benzyloxy)carbonyl)amino)-3-(naphthalen-1-yl)propanoic acidusing a similar procedure as that used in the synthesis of compound 9.White solid 188 mg (83% yield). ¹H NMR (400 MHz, MeOD) δ 8.17 (d, J=8.3Hz, 1H), 7.89 (d, J=8.1 Hz, 1H), 7.79 (d, J=7.4 Hz, 1H), 7.56 (t, J=7.1Hz, 1H), 7.50 (t, J=7.4 Hz, 1H), 7.44-7.24 (m, 7H), 5.08 (d, J=3.0 Hz,2H), 4.63 (s, 2H), 4.52 (dd, J=15.4, 6.8 Hz, 3H), 4.21 (dd, J=10.9, 3.8Hz, 2H), 3.66 (s, 3H), 3.50 (t, J=7.3 Hz, 2H), 3.25-3.16 (m, 2H),2.50-2.28 (m, 3H), 1.99-1.85 (m, 3H), 1.80 (d, J=13.8 Hz, 2H), 1.69 (d,J=13.5 Hz, 2H), 1.54-1.37 (m, 3H), 1.15 (t, J=11.4 Hz, 1H), 0.99 (dd,J=16.3, 5.6 Hz, 1H), 0.63-0.67 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ175.11, 173.65, 172.72, 172.29, 156.89, 136.72, 134.10, 132.56, 131.94,128.48, 128.09, 127.63, 127.58, 127.37, 125.99, 125.37, 125.15, 123.33,66.42, 56.53, 51.56, 51.36, 49.68, 41.51, 39.70, 37.24, 34.36, 32.53,25.23, 23.64, 22.03, 20.66, 20.20. ESI-MS (m/z): 645.4 (M+H)⁺.

Benzyl((R)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(14)

Prepared from 13 using a similar procedure as that used in the synthesisof compound 10. White solid 83 mg (75% yield). ¹H NMR (400 MHz, MeOD) δ8.13 (d, J=8.4 Hz, 1H), 7.88 (d, J=8.0 Hz, 1H), 7.79 (d, J=7.9 Hz, 1H),7.65 (d, J=9.2 Hz, 1H), 7.52 (dt, J=14.7, 6.9 Hz, 2H), 7.43-7.26 (m,6H), 5.12 (dd, J=29.6, 12.4 Hz, 2H), 5.07 (s, 1H), 4.48 (dd, J=9.6, 6.0Hz, 1H), 4.13 (dd, J=11.4, 3.3 Hz, 1H), 4.02-3.93 (m, 1H), 3.71 (dt,J=12.2, 6.1 Hz, 1H), 3.57-3.37 (m, 5H), 3.19 (t, J=5.8 Hz, 2H),2.26-2.02 (m, 2H), 1.93 (dd, J=6.7, 3.8 Hz, 1H), 1.77 (dd, J=12.7, 4.6Hz, 1H), 1.63 (t, J=11.3 Hz, 3H), 1.52-1.36 (m, 3H), 1.13 (d, J=6.1 Hz,7H), 0.62-0.57 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ 176.05, 173.35,173.26, 156.99, 136.61, 134.11, 132.37, 131.90, 128.53, 128.15, 127.71,127.67, 127.59, 127.46, 126.08, 125.45, 125.22, 123.32, 68.72, 66.53,64.10, 56.79, 51.82, 41.58, 39.88, 37.18, 34.07, 32.70, 25.30, 23.46,22.19, 21.74, 20.26, 20.04. ESI-MS (m/z): 617.4 (M+H)⁺.

Benzyl((R)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(15)

Prepared from compound 14 using a similar procedure as that used in thesynthesis of compound 11. White solid 13 mg (41% yield). ¹H NMR (400MHz, MeOD) δ 8.22 (d, J=8.1 Hz, 1H), 7.88 (d, J=8.0 Hz, 1H), 7.77 (d,J=7.4 Hz, 1H), 7.51 (tt, J=18.1, 9.0 Hz, 2H), 7.37 (dd, J=14.9, 7.7 Hz,2H), 7.29 (s, 2H), 7.22 (d, J=7.2 Hz, 2H), 5.05-4.92 (m, 2H), 4.59 (dt,J=21.6, 10.7 Hz, 1H), 4.48 (t, J=3.9 Hz, 1H), 4.43 (dd, J=9.9, 4.6 Hz,1H), 4.10 (dt, J=19.3, 9.6 Hz, 1H), 4.02 (ddd, J=11.3, 7.7, 3.5 Hz, 1H),3.73 (dd, J=14.5, 4.4 Hz, 1H), 3.34 (dd, J=18.8, 7.1 Hz, 4H), 3.26-3.11(m, 3H), 2.28 (s, 1H), 2.17 (t, J=12.4 Hz, 1H), 2.08-1.96 (m, 1H),1.85-1.44 (m, 8H), 1.47 (d, J=9.7 Hz, 1H), 1.25 (t, J=7.1 Hz, 1H),1.03-0.85 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ 176.08, 173.45, 173.43,172.71, 172.61, 156.86, 136.69, 134.03, 133.09, 131.99, 128.45, 128.01,127.53, 127.49, 127.27, 125.86, 125.26, 125.00, 123.28, 98.40, 98.32,98.25, 66.26, 66.17, 55.83, 55.61, 52.36, 52.28, 52.22, 50.72, 50.54,41.61, 40.64, 40.57, 40.29, 38.11, 37.08, 37.04, 34.53, 34.36, 30.44,29.89, 26.44, 25.49, 25.46, 24.44, 24.38, 22.14, 21.92, 21.13, 20.90,20.56. ESI-MS (m/z): 615.4 (M+H)⁺.

Example 3

Methyl (5S,8S, 11S)-8-isobutyl-5-(naphthalen-1-ylmethyl)-3, 6,9-trioxo-11-(((S)-2-oxopiperidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate(17)

Compound 17 was prepared from(S)-2-(((benzyloxy)carbonyl)amino)-3-(naphthalen-1-yl)propanoic acid 16using a similar procedure as that used in the synthesis of compound 9.White solid 120 mg (80% yield). ¹H NMR (400 MHz, MeOD) δ 8.21 (d, J=8.1Hz, 1H), 7.88 (d, J=7.9 Hz, 1H), 7.77 (d, J=7.1 Hz, 1H), 7.52 (dt,J=20.4, 7.1 Hz, 2H), 7.43-7.34 (m, 2H), 7.30 (d, J=7.1 Hz, 2H), 7.22 (d,J=7.2 Hz, 2H), 5.01 (2H, overlapped with water peak), 4.71-4.59 (m, 2H),4.54 (dt, J=26.7, 11.3 Hz, 1H), 4.51-4.39 (m, 1H), 3.79-3.67 (m, 4H),3.32 (t, J=5.8 Hz, 2H), 3.29-3.17 (m, 2H), 2.47-2.38 (m, 1H), 2.35-2.31(m, 1H), 2.32 (dd, J=18.3, 7.5 Hz, 1H), 2.06-1.96 (m, 1H), 1.95-1.86 (m,1H), 1.77 (d, J=16.4 Hz, 1H), 1.75-1.65 (m, 2H), 1.66-1.53 (m, 2H),1.03-0.85 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ 175.04, 173.57, 173.48,172.62, 172.48, 156.80, 136.69, 134.02, 133.05, 132.01, 128.45, 128.03,127.51, 127.25, 125.86, 125.27, 125.01, 123.29, 66.16, 55.53, 51.98,51.42, 49.92, 49.82, 41.55, 40.43, 37.33, 34.51, 32.78, 25.54, 24.36,21.95, 20.87, 20.83. ESI-MS (m/z): 645.5 (M+H)⁺.

Benzyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(19)

Compound 19 was synthesized from compound 17 using a similar procedureas that used in the synthesis of compound 11. White solid 11 mg (41%yield). ¹H NMR (400 MHz, MeOD) δ 8.22 (d, J=8.1 Hz, 1H), 7.88 (d, J=8.0Hz, 1H), 7.77 (d, J=7.4 Hz, 1H), 7.51 (tt, J=18.1, 9.0 Hz, 2H), 7.37(dd, J=15.0, 7.8 Hz, 2H), 7.27 (d, J=15.0 Hz, 2H), 7.23 (t, J=7.0 Hz,2H), 4.97 (d, J=9.8 Hz, 2H), 4.60 (dd, J=9.5, 4.4 Hz, 1H), 4.47 (dd,J=10.1, 6.1 Hz, 1H), 4.44-4.35 (m, 1H), 4.02 (ddd, J=11.3, 7.7, 3.5 Hz,1H), 3.73 (dd, J=14.5, 4.4 Hz, 1H), 3.40-3.32 (m, 3H), 3.26-3.12 (m,3H), 2.46-2.35 (m, 1H), 2.28 (s, 1H), 2.17 (t, J=12.4 Hz, 1H), 1.84-1.55(m, 7H), 1.47 (d, J=9.7 Hz, 1H), 1.02-0.83 (m, 6H). ¹³C NMR (101 MHz,MeOD) δ 176.08, 173.45, 173.43, 172.71, 172.61, 156.86, 136.69, 134.03,133.09, 131.99, 128.45, 128.01, 127.53, 127.49, 127.27, 125.86, 125.26,125.00, 123.28, 98.32, 98.25, 66.26, 66.17, 55.61, 52.36, 52.28, 52.22,50.72, 50.54, 41.61, 40.64, 40.57, 40.29, 38.11, 37.08, 37.04, 34.53,34.36, 30.44, 29.89, 26.44, 25.49, 25.46, 24.44, 24.38, 22.14, 21.92,21.13, 20.90, 20.56. ESI-MS (m/z): 615.5 (M+H)⁺.

N—((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)pyrazine-2-carboxamide(23)

Compound 23 was synthesized from compound 6 using a similar procedure asthat used in the synthesis of compound 11. ¹H NMR (400 MHz, Methanol-d4)δ 9.09 (dd, J=16.5, 1.4 Hz, 1H), 8.75 (dd, J=4.9, 2.4 Hz, 1H), 8.63 (td,J=2.5, 1.4 Hz, 1H), 8.30 (d, J=8.5 Hz, 1H), 7.85 (dd, J=8.3, 5.0 Hz,1H), 7.76 (t, J=7.3 Hz, 1H), 7.60-7.43 (m, 3H), 7.37 (dt, J=9.7, 7.5 Hz,1H), 5.14-5.00 (m, 1H), 4.59-4.37 (m, 2H), 4.25-4.12 (m, 1H), 4.08-3.99(m, 1H), 3.89 (ddd, J=19.4, 9.9, 3.8 Hz, 1H), 3.62-3.46 (m, 1H), 3.25(td, J=9.3, 8.4, 3.7 Hz, 2H), 2.41 (dt, J=10.3, 5.7 Hz, 1H), 2.31 (d,J=8.8 Hz, 1H), 2.18 (ddd, J=14.7, 8.8, 3.3 Hz, 1H), 2.04 (tt, J=9.8, 5.0Hz, 1H), 1.93-1.58 (m, 4H), 1.07-0.82 (m, 6H). ESI-MS (m/z): 587.5(M+H)+.

N—((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)pyrazine-2-carboxamide(29)

Compound 29 was synthesized from compound 24 using a similar procedureas that used in the synthesis of compound 11. ¹H NMR (400 MHz,Methanol-d₄) δ 9.09 (dd, J=20.6, 1.4 Hz, 1H), 8.75 (dd, J=6.2, 2.5 Hz,1H), 8.62 (tt, J=2.6, 1.3 Hz, 1H), 8.29 (d, J=8.5 Hz, 1H), 7.85 (t,J=7.8 Hz, 1H), 7.75 (t, J=9.2 Hz, 1H), 7.51 (dq, J=27.0, 7.3 Hz, 3H),7.37 (dt, J=15.0, 7.6 Hz, 1H), 5.16-4.97 (m, 1H), 4.58-4.36 (m, 2H),4.09 (dq, J=8.5, 4.3 Hz, 1H), 4.03-3.93 (m, 1H), 3.87 (td, J=15.6, 14.5,5.2 Hz, 1H), 3.53 (ddd, J=19.6, 14.2, 9.0 Hz, 1H), 2.60-2.43 (m, 1H),2.41-2.29 (m, 1H), 2.22 (dt, J=14.0, 4.7 Hz, 1H), 2.11-1.98 (m, 1H),1.89 (q, J=10.7, 9.9 Hz, 1H), 1.83-1.54 (m, 4H), 0.97-0.91 (m, 6H).ESI-MS (m/z): 573.5 (M+H)⁺.

(S)-2-(((Benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoicacid (31)

To a solution of p-fluoro-L-phenylalanine (2.56 g, 13.98 mmol), NaHCO₃(1.76 g, 21 mmol), K₂CO₃ (2.90 g, 21 mmol) in THF-H₂O (v/v=1:1, 50 mL)was added CbzCl (2.2 mL, 15.4 mmol). The reaction mixture was stirredovernight at room temperature. After evaporation of the volatils, thereaction mixture was washed with ethyl acetate (10 mL) and then the pHof the water phase was adjusted to pH=1 by addition of 1N HCl. The waterlayer was finally extracted with ethyl acetate (30 mL×4) and thecombined organic layers dried over Na₂SO₄, to give, after evaporation,compound 31(4.2 g, 95%). ¹H NMR (400 MHz, Methanol-d₄) δ 7.37-7.12 (m,7H), 6.96 (t, J=8.8 Hz, 2H), 5.11-4.93 (m, 2H), 4.47 (dd, J=9.3, 5.0 Hz,1H), 3.19 (dd, J=14.0, 5.0 Hz, 1H), 2.92 (dd, J=14.0, 9.3 Hz, 1H). ¹³CNMR (101 MHz, MeOD) δ 173.61, 163.03, 160.62, 156.94, 136.74, 133.08,133.05, 130.72, 130.64, 128.08, 127.61, 127.34, 114.78, 114.57, 66.20,55.37, 36.45. ¹⁹F NMR (377 MHz, Methanol-d₄) δ −119.46. LC-MS: m/z[M+H]⁺ calcd. for C₁₇H₁₇FNO₄: 318.1, found: 318.2.

Methyl(5S,8S,11S)-5-(4-fluorobenzyl)-8-isobutyl-3,6,9-trioxo-11-(((S)-2-oxopiperidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate(33)

To a solution of compound 32 (230 mg, 0.66 mmol) and amino acid 31 (250mg, 0.79 mmol) in DCM (6.0 mL) was added 1-hydroxybenzotriazole (135 mg,1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(190 mg, 1.0 mmol) and N,N-diisopropylethyl amine (0.7 mL, 4.0 mmol) at0° C. After being stirred at room temperature overnight, the reactionmixture was diluted with EtOAc (50 mL) and washed with 1N HCl, NaHCO₃(5%) and a saturated solution of NaCl. The organic layer was dried overNa₂SO₄. The solvent was concentrated in vacua and was purified by flashchromatography (DCM/MeOH 20:1) to afford compound 33 (280 mg, 69%). ¹HNMR (400 MHz, Methanol-d₄) δ 8.64 (d, J=8.0 Hz, 1H), 8.19 (d, J=7.5 Hz,1H), 7.28 (m, 4H), 7.08-6.90 (m, 3H), 5.16-4.94 (m, 2H), 4.42 (ddd,J=8.3, 5.7, 3.1 Hz, 2H), 3.72 (s, 4H), 3.29-3.20 (m, 2H), 3.14 (dd,J=14.0, 4.7 Hz, 1H), 2.82 (dd, J=14.0, 9.7 Hz, 1H), 2.47-2.18 (m, 2H),2.08-1.78 (m, 2H), 1.73-1.51 (m, J=4H), 0.93 and 0.98 (2s, 6H). ¹³C NMR(101 MHz, CD₃OD) δ 175.01, 173.60, 173.51, 172.52, 172.45, 172.43,163.01, 160.59, 156.90, 156.85, 136.79, 133.19, 133.15, 130.77, 130.69,130.61, 128.03, 127.55, 127.31, 127.28, 114.69, 114.48, 66.16, 66.07,56.19, 52.00, 51.97, 51.91, 51.87, 51.37, 49.94, 49.84, 41.56, 40.55,40.51, 37.35, 36.77, 32.83, 32.79, 25.58, 24.34, 21.97, 20.85, 20.82.¹⁹F NMR (377 MHz, Methanol-d₄) δ −119.88-−119.94 (m). LC-MS: m/z [M+H]⁺calcd. for C₃₂H₄₂FN₄O₇: 613.3, found: 613.5.

Benzyl((S)-3-(4-fluorophenyl)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)carbamate(34)

To a solution of 33 (230 mg, 0.38 mmol) in THF (2.0 mL) was added LiBH₄(4M in THF, 0.25 mL, 1.0 mmol) dropwise at 0° C. The reaction mixturewas stirred at room temperature for 2 h. Then the reaction was quenchedwith 1N HCl (5 mL) and stirred for 1 h at room temperature. Ethylacetate (30 mL) was added to the mixture, and the organic layer waswashed with 1N HCl, NaHCO₃ and brine. The organic layer was dried overNa₂SO₄, and the filtrate evaporated to dryness. The residue was purifiedby was purified by flash chromatography (DCM/MeOH 30:1 to 10:1) toafford product 34 (174 mg, 80%). ¹H NMR (400 MHz, Methanol-d₄) δ 7.88(d, J=8.9 Hz, 1H), 7.38-7.21 (m, 6H), 6.98 (t, J=8.8 Hz, 2H), 5.16-4.96(m, 2H), 4.39 (dt, J=12.9, 6.2 Hz, 3H), 4.02 (ddd, J=8.9, 5.8, 2.9 Hz,1H), 3.60-3.42 (m, 2H), 3.25 (t, J=4.7 Hz, 2H), 3.15 (dd, J=14.1, 4.7Hz, 1H), 2.85 (dd, J=14.1, 9.5 Hz, 1H), 2.31 (d, J=8.7 Hz, 1H),2.18-1.96 (m, 2H), 1.90-1.77 (m, 1H), 1.72-1.57 (m, 5H), 0.95 (d, J=5.7Hz, 3H), 0.92 (d, J=5.2 Hz, 3H). ¹³C NMR (101 MHz, MeOD) δ 175.98,173.48, 173.40, 172.53, 163.02, 160.60, 157.06, 136.71, 133.11, 130.75,130.67, 128.02, 127.56, 127.38, 127.29, 114.72, 114.50, 66.29, 64.16,56.42, 52.26, 52.22, 41.62, 40.52, 37.29, 36.57, 32.76, 25.71, 24.42,22.07, 20.62. ¹⁹F NMR (377 MHz, Methanol-d₄) δ −119.74-−119.82 (m).LC-MS: m/z [M+H]⁺ calcd. for C₃₁H₄₂FN₄O₆: 585.3, found: 585.5.

Benzyl((S)-3-(4-fluorophenyl)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-1-oxopropan-2-yl)carbamate(35)

To a solution of compound 34 (123 mg, 0.21 mmol) in dichloromethane (2.0mL) was added Dess-Martin periodinane (43 mg, 0.1 mmol). The reactionmixture was stirred at room temperature for 2 h then filtered through asilica gel pad, washed with ethyl acetate. The filtrate was evaporatedto dryness and the residue was purified by flash chromatography(DCM/MeOH 30:1 to 12:1) to afford product 35 (70 mg, 57%). ¹H NMR (400MHz, Methanol-d₄) δ 8.18 (dd, J=7.5, 4.1 Hz, 1H), 7.86 (d, J=9.3 Hz,1H), 7.42-7.15 (m, 12H), 6.98 (t, J=8.8 Hz, 3H), 5.16-4.95 (m, 3H), 4.41(qd, J=6.2, 3.8, 3.3 Hz, 3H), 4.02 (ddt, J=9.1, 5.8, 2.7 Hz, 1H), 3.23(t, J=4.9 Hz, 3H), 3.15 (dd, J=14.1, 4.9 Hz, 2H), 2.83 (dd, J=13.7, 10.0Hz, 1H), 2.35-2.24 (m, 1H), 2.23-2.11 (m, 2H), 2.02 (dt, J=10.5, 3.5 Hz,1H), 1.75-1.57 (m, 7H), 0.94 (dd, J=13.6, 6.1 Hz, 10H). ¹³C NMR (101MHz, MeOD) δ 176.05, 173.53, 173.50, 172.51, 172.42, 163.00, 160.59,156.92, 136.75, 133.17, 130.75, 130.67, 128.04, 128.02, 127.54, 127.35,127.32, 114.75, 114.71, 114.54, 114.49, 98.39, 98.32, 66.19, 56.26,54.03, 53.80, 53.73, 52.28, 52.24, 50.80, 50.62, 41.62, 40.71, 40.64,40.40, 37.07, 37.03, 36.77, 30.45, 29.92, 26.46, 25.50, 25.47, 24.41,24.35, 22.15, 21.97, 21.94, 21.14, 20.89, 20.85, 20.57, 20.54. ¹⁹F NMR(377 MHz, Chloroform-d) δ −117.12-−117.37 (m). LC-MS: m/z [M+H]⁺ calcd.for C₃₁H₄₀FN₄O₆: 583.3, found: 583.5.

Benzyl((S)-1-(((S)-1-(((S,E)-5-amino-4-cyano-5-oxo-1-((S)-2-oxopiperidin-3-yl)pent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(36)

To a solution of 2-cyanoacetamide (6.5 mg, 0.08 mmol) and 19 (50 mg,0.08 mmol) in ethanol (0.2 mL) was added piperidine (0.66 M in ethanol,12 μL, 0.008 mmol). The reaction vessel was then placed into a microwavereactor (CEM Discover), and irradiated for 25 minutes at 80° C. Afterremoval of the volatils under vacuo, the reaction mixture was purifiedby preparative TLC (EtOAc/MeOH 20/1) to give 2-cyano-3-(substitutedphenyl)acrylamide product 36 as a white solid (8 mg, 15%). ¹H NMR (400MHz, Methanol-d₄) δ 8.21 (q, J=12.1, 10.0 Hz, 1H), 7.89 (d, J=8.1 Hz,1H), 7.84-7.72 (m, 1H), 7.53 (dt, J=22.7, 7.3 Hz, 2H), 7.45-7.36 (m,1H), 7.36-7.17 (m, 6H), 5.00 (d, J=8.2 Hz, 1H), 4.62 (d, J=10.2 Hz, 1H),4.45-4.26 (m, 1H), 3.78-3.65 (m, 1H), 3.28-3.16 (m, 4H), 2.50-2.16 (m,1H), 2.04 (s, 1H), 1.85 (d, J=15.2 Hz, 1H), 1.64 (dd, J=8.4, 4.7 Hz,1H), 1.06-0.73 (m, 6H). ¹³C NMR (101 MHz, CD₃OD) δ 175.97, 175.49,173.37, 172.76, 157.28, 156.97, 136.65, 134.03, 132.99, 131.98, 128.45,128.03, 128.00, 127.51, 127.31, 127.26, 125.88, 125.27, 125.00, 123.26,114.64, 113.42, 66.27, 64.16, 55.77, 52.35, 52.19, 41.61, 41.56, 40.09,37.34, 37.30, 34.30, 24.56, 24.46, 22.06, 20.81, 20.66, 20.51. LC-MS:m/z [M+H]⁺ calcd. for C₃₈H₄₄N₆O₆: 680.3, found: 680.5.

Sodium(5S,8S,11S)-12-hydroxy-8-isobutyl-5-(naphthalen-1-ylmethyl)-3,6,9-trioxo-11-(((S)-2-oxopiperidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecane-12-sulfonate(37)

A solution of 19 (19 mg, 0.03 mmol) and sodium bisulfite (4.5 mg, 0.04mmol) in a mixture of EtOAc/EtOH/H₂O (1:0.6:0.25, 0.2 mL) was stirredfor 3 h at 55° C. and then allowed to cool down to room temperature. Theprecipitate formed was vacuum filtered and the solid was thoroughlywashed with absolute ethanol. The filtrate was then dried over anhydroussodium sulfate, filtered, and concentrated under vacuum to yield ayellowish oil which was treated with ethyl ether to form a white solid.Careful removal of the solvent using a pipette yielded compound 37 (15mg, 67%). ¹H NMR (400 MHz, DMSO-d₆) δ 8.23 (d, J=8.3 Hz, 2H), 7.92 (dd,J=7.7, 3.6 Hz, 1H), 7.85-7.74 (m, 2H), 7.70-7.49 (m, 2H), 7.30 (dt,J=9.1, 5.6 Hz, 3H), 7.24-7.13 (m, 2H), 4.45 (q, J=10.8, 9.2 Hz, 1H),4.39-4.18 (m, 1H), 3.87 (d, J=4.8 Hz, 0H), 3.21-2.97 (m, 3H), 2.17 (ddd,J=21.8, 11.5, 4.6 Hz, 1H), 2.01 (d, J=14.7 Hz, 1H), 1.96-1.79 (m, 1H),1.76-1.63 (m, 2H), 1.57-1.41 (m, 4H), 0.92 (d, J=4.8 Hz, 3H), 0.88 (d,J=4.3 Hz, 3H). ¹³C NMR (101 MHz, DMSO-d₆) δ 201.42, 173.16, 173.00,172.94, 171.82, 171.72, 156.25, 137.40, 134.19, 133.83, 132.07, 129.03,128.72, 128.08, 127.87, 127.75, 127.70, 127.48, 126.52, 126.00, 125.77,124.19, 65.63, 61.62, 56.05, 55.81, 55.69, 51.70, 41.68, 41.55, 41.40,34.98, 26.18, 24.66, 23.54, 23.37, 22.27, 22.12, 21.85, 21.77, 15.60.LC-MS: m/z [M+H]⁺ calcd. for C₃₅H₄₅N₄O₉S: 697.3, found: 697.5.

Benzyl((2S)-1-(((2S)-4-methyl-1-oxo-1-(((2S)-4,4,4-trifluoro-3-hydroxy-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(38)

To a solution of compound 19 (61 mg, 0.1 mmol) and cesium fluoride inTHF (76 mg, 0.5 mmol) was added Me₃SiCF₃ (2M in THF, 0.1 mL, 0.2 mmol)at −78° C. dropwise over 5 minutes. The reaction mixture was thenstirred at room temperature for 2 h and quenched with 1N HCl (0.5 mL).After 1 h, EtOAc (10 mL) was added to the reaction mixture and theorganic layer was washed with 1N HCl, NaHCO₃ and water. The organiclayer was dried over anhydrous sodium sulfate and concentrated underreduced pressure. The residue was purified by preparative TLC (DCM/MeOH20:1) to provide compound 38 (19 mg, 28%). ¹H NMR (400 MHz,Chloroform-d) δ 8.21 (s, 1H), 8.08 (s, 1H), 7.98-7.80 (m, 1H), 7.78 (d,J=8.0 Hz, 1H), 7.65-7.45 (m, 1H), 7.36 (d, J=15.8 Hz, 5H), 6.70-6.38 (m,2H), 5.99 (d, J=33.3 Hz, 1H), 5.66-5.40 (m, 1H), 5.04 (s, 1H), 4.66 (d,J=8.5 Hz, 1H), 4.46 (d, J=8.9 Hz, 1H), 4.33 (t, J=7.4 Hz, 1H), 3.76-3.62(m, 1H), 3.46-3.36 (m, 1H), 3.24 (s, 2H), 2.22 (s, 1H), 2.10-1.86 (m,3H), 1.75 (s, 2H), 0.98-0.78 (m, 6H). ¹³C NMR (101 MHz, CD₃OD) δ 175.83,174.65, 173.21, 172.79, 172.58, 156.79, 136.72, 134.04, 133.08, 132.87,131.99, 128.45, 128.03, 128.00, 127.51, 127.36, 127.28, 125.86, 125.26,125.00, 123.25, 66.22, 55.64, 52.55, 41.68, 41.57, 39.75, 38.56, 37.11,36.84, 34.59, 26.45, 24.52, 24.42, 22.22, 22.09, 21.54, 20.53, 20.30.¹⁹F NMR (377 MHz, Chloroform-d) δ −75.94, −77.58. LC-MS: m/z [M+H]⁺calcd. for C₃₆H₄₄F₃N₄O₆: 685.3, found: 685.5.

Benzyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-4,4,4-trifluoro-3-oxo-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(39)

A solution of compound 38 (19 mg, 0.03 mmol) and Dess-Martin periodinane(45 mg, 0.11 mmol) in dichloromethane (0.8 mL) was stirred at roomtemperature for 1 h. The reaction mixture was then filtered throughsilica gel pad, washed with ethyl acetate and concentrated under vacuum.The residue was purified by two successive preparative TLCs(DCM/methanol=20/1 then 100% ethyl acetate) to give compound 39 as awhite solid (10 mg, 53%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.22 (d, J=8.5Hz, 1H), 7.88 (d, J=8.3 Hz, 1H), 7.77 (d, J=7.7 Hz, 1H), 7.52 (dt,J=15.2, 7.6 Hz, 2H), 7.38 (d, J=9.6 Hz, 2H), 7.30 (d, J=6.3 Hz, 3H),7.21 (d, J=7.2 Hz, 2H), 4.95 (s, 1H), 4.69-4.55 (m, 1H), 4.47 (dd,J=10.2, 6.1 Hz, 1H), 4.38 (d, J=11.6 Hz, 1H), 3.73 (d, J=14.7 Hz, 1H),3.28-3.16 (m, 2H), 2.40-2.18 (m, 2H), 2.04 (s, 1H), 1.85-1.67 (m, 1H),1.60 (dt, J=13.3, 7.3 Hz, 2H), 1.44 (d, J=11.1 Hz, 1H), 1.03-0.81 (m,6H). ¹³C NMR (101 MHz, MeOD) δ 176.01, 175.84, 173.66, 173.39, 172.79,172.66, 156.79, 136.70, 134.03, 133.09, 131.99, 128.45, 128.01, 127.48,127.30, 127.22, 125.85, 125.25, 125.00, 123.25, 66.13, 66.09, 55.49,52.29, 52.05, 49.71, 49.43, 41.57, 40.32, 37.00, 36.87, 34.58, 30.12,29.99, 29.36, 25.62, 25.43, 24.35, 24.32, 22.06, 21.98, 20.76, 20.72,20.62. ¹⁹F NMR (377 MHz, CD₃OD) δ −79.48, −79.97. LC-MS: m/z [M+H]⁺calcd. for C₃₆H₄₂F₃N₄O₆: 683.3, found: 683.5 and 701.5 [M+H₂O]⁺.

tert-Butyl((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)carbamate (41)

To a solution of compound 40 (600 mg, 2.0 mmol) in MeOH (10 mL) wasadded NaBH₄ (152 mg, 4.0 mmol) at 0° C. The reaction mixture was stirredat room temperature for 3 h then quenched with 1N HCl (5 mL) and finalystirred for 1 h at room temperature. The suspension was extracted withethyl acetate (3×30 mL), and washed with NaHCO₃ and brine. The organiclayer was dried over Na₂SO₄, and then evaporated to dryness. The residuewas purified by flash chromatography on silica gel (DCM/MeOH 50:1 to10:1) to afford compound 41 (480 mg, 88%). ¹H NMR (400 MHz,Chloroform-d) δ 6.42 (s, 1H), 5.57 (d, J=8.1 Hz, 1H), 3.70 (dt, J=24.3,5.3 Hz, 2H), 3.63-3.51 (m, 2H), 3.48 (s, OH), 3.32 (qd, J=4.8, 2.2 Hz,2H), 2.38 (dt, J=11.0, 5.5 Hz, 1H), 2.17 (s, 1H), 2.01-2.1 (m, 1H),1.96-1.81 (m, 1H), 1.80-1.66 (m, 2H), 1.56 (dtd, J=13.5, 10.5, 3.0 Hz,1H), 1.44 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 175.78, 156.55, 79.31,65.64, 53.43, 50.66, 50.47, 42.45, 38.10, 32.80, 28.39, 26.90, 21.64.LC-MS: m/z [M+H]⁺ calcd. for C₁₃H₂₅N₂O₄: 273.2, found: 273.5.

Tert-Butyl ((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)carbamate(42)

A solution of compound 41 (400 mg, 1.47 mmol) and Dess-Martinperiodinane (750 mg, 1.77 mmol) in dichloromethane (10 mL) was stirredat room temperature for 2 h. The reaction mixture was filtered through acelite pad and washed with ethyl acetate (50 mL). The organic layer waswashed with a solution of sodium thiosulfate (0.4 N, 10 mL) and asolution of NaHCO₃ (5%, 10 mL). The organic layer was dried over Na₂SO₄,and filtered. The filtrate was evaporated under reduced pressure to givethe crude product 42 (364 mg, 92%). ¹H NMR (400 MHz, Chloroform-d) δ9.55 (s, 1H), 6.33-6.14 (m, 1H), 4.28-4.15 (m, 1H), 3.43-3.20 (m, 4H),2.47-2.25 (m, 1H), 2.19 (ddd, J=14.2, 8.6, 7.1 Hz, 1H), 1.88 (tt, J=8.5,4.4 Hz, 2H), 1.75 (dtd, J=13.8, 7.3, 3.3 Hz, 1H), 1.64-1.51 (m, 1H),1.45 (d, J=12.1 Hz, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 200.77, 174.84,156.18, 79.94, 60.40, 58.30, 42.39, 37.34, 31.50, 28.40, 28.32, 27.38,21.31. LC-MS: m/z [M+H]⁺ calcd. for C₁₃H₂₃N₂O₄: 271.2, found: 271.5.

tert-Butyl((2S)-4,4,4-trifluoro-3-hydroxy-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)carbamate(44)

To a solution of crude product 42 (270 mg, 1.0 mmol) and CsF (180 mg,1.18 mmol) in THF (3.0 mL) was added at −78° C., TMSCF₃ (2.0M in THF,0.7 mL, 1.4 mmol) dropwise over 10 minutes. After addition, the reactionmixture was then stirred at room temperature for 1 h, quenched byaddition of a 1 N HCl solution (10 mL) and stirred for another 30minutes. The reaction mixture was extracted with ethyl acetate (30ml×3), washed with a saturated solution of NaHCO₃ and water, dried overNa₂SO₄, filtered and concentrated under reduced pressure. The residuewas purified by flash chromatography on silica gel column (DCM/MeOH 30:1to 10:1) to afford compound 44. LC-MS: m/z [M+H]⁺ calcd. forC₁₄H₂₄F₃N₂O₄: 341.2, found: 341.5.

Benzyl((2S)-1-(((2S)-4-methyl-1-oxo-1-(((2S)-4,4,4-trifluoro-3-hydroxy-1-((S)-2-oxopiperidin-3-yl)butan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(38)

To a solution of crude product 44 (50 mg, 0.18 mmol) in DCM (1.5 mL) wasadded 4N HCl in dioxane (0.6 mL, 2.4 mmol). The reaction mixture wasstirred for 2 h at room temperature and then the volatils were removeunder reduced pressure. The residue was dissolved in DCM (1.0 mL) andcompound 46 (46 mg, 0.1 mmol), 1-hydroxybenzotriazole (28 mg, 0.2 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (38 mg, 0.2mmol) and N,N-diisopropylethyl amine (0.14 mL, 0.8 mmol) were added at0° C. The reaction mixture was stirred at room temperature overnightbefore being diluted with EtOAc (20 mL). The organic layer was washedwith a 1N HCl solution, a solution of NaHCO₃ (5%) and brine. The organiclayer was dried over Na₂SO₄. The solvent was evaporated and the residuewas purified by flash chromatography on silica gel (DCM/MeOH 30:1 to15:1) to afford product 38. LC-MS: m/z [M+H]⁺ calcd. for C₃₆H₄₄F₃N₄O₆:685.3, found: 685.5.

tert-Butyl ((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)carbamate(49)

To a solution of compound 47 (1.0 g, 3.49 mmol) in methanol (40 mL) wasadded NaBH₄ (0.53 g, 14 mmol) at room temperature. The reaction mixturewas stirred at this temperature for 2 h, then quenched with water (30mL). The suspension was extracted with EtOAc (50 mL×3) and the combinedorganic layers were dried over Na₂SO₄ and finaly evaporated undervacuum. The residue was then dissolved in dichloromethane (20 mL) andDess-Martin periodinane (1.48 g, 3.49 mmol) and NaHCO₃ (0.37 g, 3.49mmol) were added. The resulting mixture was stirred at room temperaturefor 5 h. The mixture was diluted with EtOAc (150 mL) and the organiclayer was washed with an aqueous solution of 10% Na₂S₂O₄, a saturatedsolution of NaHCO₃, a solution of 1N HCl, and brine successively. Theorganic layer was dried over Na₂SO₄ and then concentrated to giveproduct 49 as a white solid which was used in the next step withoutfurther purification. ¹H NMR (CDCl₃) δ 9.73 (1H, s), 6.02 (1H, br), 5.48(1H, d, J=7.8 Hz), 4.36-4.25 (1H, m), 3.38-3.32 (2H, m), 2.50-2.44 (2H,m), 2.11-2.03 (1H, m), 1.88-1.76 (2H, m), 1.43 (9H, s). LCMS-ESI (m/z):257 (M+H)⁺.

tert-Butyl((S)-1-((S)-2-oxopyrrolidin-3-yl)but-3-en-2-yl)carbamate (50)

To a suspension of methyltriphenylphosphonium bromide (3.29 g, 9.29mmol) in THF (10 mL) at −78° C. was added LiHMDS (30.3 g, 152 mmol). Theresulting yellow suspension was warmed up to room temperature andstirred at the same temperature for 1 hour. After the reaction mixturewas cooled down to −78° C., a solution of aldehyde 49 (1.07 g, 4.4 mmol)in THF (5 mL) was added dropwise. The mixture was stirred at 0° C.overnight. The reaction was quenched with MeOH (0.5 mL) and theresulting mixture was poured into 1 N HCl solution (20 mL). Extractionwith Et₂O (3×20 mL), drying over Na₂SO₄ and evaporation of the solventin vacuo afforded an orange semi-solid that was purified by silica gelchromatography (DCM/MeOH=20/1) to afford 50 as a white solid (0.36 g,32%). ¹H NMR (400 MHz, Chloroform-d) δ 6.89 (s, 1H), 5.72-5.80 (m, 1H),5.03-5.20 (m, 3H), 4.14 (s, br, 1H), 3.23-3.31 (m, 2H), 2.40-2.46 (m,2H), 1.72-1.77 (m, 1H), 1.45-1.52 (m, 1H), 1.40 (s, 9H).

tert-Butyl((S)-4-methyl-1-oxo-1-(((S)-1-((S)-2-oxopyrrolidin-3-yl)but-3-en-2-yl)amino)pentan-2-yl)carbamate(51)

To a solution of 50 (250 mg, 1.04 mmol) in dioxane (5 mL) was added asolution of 4 M HCl in dioxane (2 mL). The reaction was stirred at roomtemperature for 3 h and then the volatils were removed under vacuum. Theresidue was finally coevaporated with toluene the deprotecteddeprotected product as a colorless oil. To a solution of this aminoderivative in DCM (20 mL) was added EDC (250 mg, 1.3 mmol), HOBt (176mg, 1.3 mmol), Boc-L-Leu-OH (280 mg, 1.2 mmol) and DIPEA (0.84 mL, 4.8mmol). The solution was stirred at room temperature overnight beforebeing diluted with ethyl acetate (80 mL). The organic layer was washedsuccessively with aq. HCl (1M), sat. aq. NaHCO₃ and brine, dried overNa₂SO₄. After removal of the volatils under vacuum, the title compound51 was obtained as a colorless oil (250 mg, 67%). LCMS-ESI (m/z): 368(M+H)⁺.

Benzyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-((S)-2-oxopyrrolidin-3-yl)but-3-en-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate (52)

Compound 51 (370 mg, 1.0 mmol) was dissolved in DCM (6 mL) and treatedwith trifluoroacetic acid (2 mL). The solution was stirred at roomtemperature for 3 h and the solvent was removed under vacuum. The crudecompound was dried under vacuum for 5 h and used in the next stepwithout further purification. To a solution of the deprotected aminoacid in DCM (20 mL) was added EDCI (230 mg, 1.2 mmol), HOBt (160 mg, 1.2mmol), Z-L-Ala(-1-naphthyl)-OH (350 mg, 1.0 mmol) and DIPEA (0.7 mL, 4.0mmol). After being stirred at room temperature overnight, the reactionmixture was diluted with ethyl acetate (80 mL). The organic layer waswashed successively with aq. HCl (1M), sat. aq. NaHCO₃ and brine. Theorganic layer was then dried over Na₂SO₄ and the solvent removed undervacuum. The residue was purified by column chromatography(DCM:MeOH=20:1) to give title compound 52 as a white solid (320 mg,54%). ¹H NMR (400 MHz, MeOH-d4) δ 8.18 (t, J=10.1 Hz, 2H), 7.87 (d,J=7.6 Hz, 1H), 7.76 (d, J=7.3 Hz, 1H), 7.48-7.54 (m, 2H), 7.21-7.40 (m,7H), 5.80-5.85 (m, 1H), 5.21 (dt, J₁=1.4 Hz, J₂=17.2 Hz, 1H), 5.17 (dt,J₁=1.4 Hz, J₂=10.4 Hz, 1H), 4.95-4.97 (m, 2H), 4.59-4.65 (m, 1H),4.40-4.52 (m, 2H), 3.67-3.73 (m, 1H), 3.16-3.28 (m, 2H), 2.47-2.49 (m,1H), 2.24-2.27 (m, 1H), 1.47-1.77 (m, 4H), 0.91-0.96 (m, 6H); ¹³C NMR(100 MHz, MeOH-d4) δ 181.02, 172.93, 171.58, 156.92, 138.32, 136.69,134.04, 132.98, 131.98, 128.48, 128.03, 127.52, 127.29, 125.90, 125.30,125.02, 123.25, 113.62, 66.23, 60.14, 55.81, 52.43, 49.33, 40.68, 40.10,38.28, 35.58, 34.53, 27.51, 24.40, 21.97, 20.84, 19.49, 13.09; LCMS-ESI(m/z): 599 (M+H)⁺.

Benzyl((2S)-1-(((2S)-4-methyl-1-(((1S)-1-(oxiran-2-yl)-2-((S)-2-oxopyrrolidin-3-yl)ethyl)amino)-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(53)

To a solution of compound 52 (50 mg, 0.08 mmol) in DCM (5 mL) containingaq. Na₂HP₃O₄ (6 M, 40 μL, 0.24 mmol) was added mCPBA (70%, 62 mg, 0.25mmol). The reaction mixture was stirred at room temperature for 24 h.EtOAc (30 mL) was added and the solution was washed with a saturatedsolution of NaHCO₃, 1 N HCl, brine, and dried over Na₂SO₄. Afterconcentration under vacuum, the residue was purified on preparative TLCto afford compound 53 as a white solid (20 mg, 39%). ¹H NMR (400 MHz,MeOH-d4) δ 8.11-8.23 (m, 1H), 7.94-8.01 (m, 1H), 7.89 (d, J=7.7 Hz, 1H),7.78 (d, J=7.2 Hz, 1H), 7.23-7.61 (m, 8H), 4.98 (s, 2H), 4.59-4.62 (m,1H), 4.35-4.40 (m, 1H), 4.02-4.10 (m, 1H), 3.69-3.74 (m, 1H), 3.21-3.28(m, 2H), 3.04-3.07 (m, 1H), 2.75-2.77 (m, 1H), 2.58-2.60 (m, 1H),2.45-2.52 (m, 1H), 2.09-2.33 (m, 2H), 1.53-1.81 (m, 4H), 1.30-1.37 (m,1H), 0.88-0.98 (m, 6H); ¹³C NMR (100 MHz, MeOH-d4) δ 180.88, 173.64,173.56, 172.75, 156.87, 136.69, 134.03, 133.00, 132.19, 131.98, 129.67,128.44, 128.01, 127.50, 127.26, 127.20, 125.87, 125.28, 124.99, 123.24,66.20, 55.57, 53.29, 52.40, 44.06, 40.51, 40.06, 38.05, 34.38, 32.54,27.43, 24.50, 21.95, 20.66; LCMS-ESI (m/z): 615 (M+H)⁺, 633 (M+H+H₂O)⁺

Methyl((S)-2-(((benzyloxy)carbonyl)amino)-3-(naphthalen-1-yl)propanoyl)-L-leucinate(56)

To a solution of Cbz-L-Ala(1-Naphthyl)-OH 55 (0.78 g, 2.25 mmol) andL-Leu-OMe (0.45 g, 2.48 mmol) in DCM (50 mL) was added EDCI (560 mg, 2.9mmol), HOBt (400 mg, 2.9 mmol), and DIPEA (1.6 mL, 9 mmol). The reactionmixture was stirred overnight at room temperature at which time H₂O (100mL) and EtOAc (200 mL) were added. The organic layer was washedsuccessively with aq. HCl (1 M, 50 mL), sat. aq. NaHCO₃ (200 mL) andbrine (100 mL), and then dried over Na₂SO₄. The solvent was removedunder vacuum to give the title compound as a yellow solid aftercrystallization from ethyl acetate (0.9 g, 85%). ¹H NMR (400 MHz,MeOH-d4) δ 7.89 (d, J=9.0 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.49-7.58 (m,2H), 7.36-7.41 (m, 8H), 5.82 (d, J=8.0 Hz, 1H), 5.51-5.53 (m, 1H),5.08-5.16 (m, 2H), 4.60-4.65 (m, 1H), 4.44-4.59 (m, 1H), 4.09-4.23 (m,2H), 3.21-3.27 (m, 2H), 2.48-2.52 (m, 1H), 1.57-1.80 (m, 4H), 1.21-1.40(m, LCMS-ESI (m/z): 477 (M+H)⁺.

((S)-2-(((Benzyloxy)carbonyl)amino)-3-(naphthalen-1-yl)propanoyl)-L-leucine(57)

To a solution of methyl ester 56 (2.0 g, 4.2 mmol) in MeOH (19 mL) wasadded a solution of LiOH—H₂O (270 mg, 6.3 mmol) in H₂O (1 mL). Thereaction mixture was stirred overnight at room temperature. Thevolatiles were removed under vacuum to give a colourless residue thatwas partitioned between EtOAc and aq. HCl (1M). The organic layer wasseparated, washed successively with aq. HCl (1M) and brine, then driedover MgSO₄, and the solvent removed under vacuum to give a glassy solid.Recrystallization from EtOAc gave the title compound 57 as a white solid(1.86 g, 96%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.13-8.21 (m, 1H), 7.89(s, br, 1H), 7.79 (s, 1H), 7.25-7.57 (m, 9H), 5.02-5.17 (m, 1H),4.33-4.59 (m, 1H), 3.34-3.56 (m, 1H), 1.34-1.54 (m, 3H), 0.84-0.88 (m,6H); LCMS-ESI (m/z): 463 (M+H)⁺.

Methyl(5S,8S,11S,E)-8-isobutyl-5-(naphthalen-1-ylmethyl)-3,6,9-trioxo-11-(((S)-2-oxopyrrolidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazatetradec-12-en-14-oate(60)

To a solution of compound 59 (330 mg, 1.0 mmol) in dioxane (5 mL) wasadded HCl (4 M in dioxane, 2 mL). The reaction was stirred at roomtemperature for 3 h and then the volatils were removed under vacuum togive the crude deprotected amine which was used directly in the nextstep. This compound was thus dissolved in DCM (20 mL) and EDC (250 mg,1.3 mmol), HOBt (176 mg, 1.3 mmol), dipeptide 57 (460 mg, 1.0 mmol) andDIPEA (0.84 mL, 4.8 mmol) were added. The solution was stirred at roomtemperature overnight and then diluted with ethyl acetate (80 mL). Theorganic layer was washed successively with aq. HCl (1M), sat. aq. NaHCO₃and brine, dried over Na₂SO₄ and the solvent removed under vacuum. Theresidue was purified by column chromatography to give 60 as a whitesolid (460 mg, 70%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.18-8.21 (m, 1H),7.74-7.94 (m, 3H), 7.23-7.68 (m, 8H), 6.91 (dd, J=15.5, 5.3 Hz, 1H),5.90-6.02 (m, 1H), 4.95-5.01 (m, 1H), 4.60-4.65 (m, 1H), 4.32-4.86 (m,1H), 4.01-4.23 (m, 2H), 3.70-3.75 (m, 1H), 3.21-3.27 (m, 2H), 2.48-2.52(m, 1H), 2.40-2.66 (m, 1H), 1.58-1.80 (m, 4H), 1.20-1.40 (m, 6H),0.89-1.10 (m, 6H); LCMS-ESI (m/z): 657 (M+H)⁺.

Benzyl((S)-1-(((S)-1-(((R)-5-hydroxy-1-((S)-2-oxopyrrolidin-3-yl)pentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(61)

To a solution of methyl ester 60 (34 mg, 0.05 mmol) in dry THF (3 mL)was added LiBH₄ (2M in THF, 0.03 mL, 0.06 mmol) at 0° C. The resultingmixture was stirred at room temperature for 3 h and then quenched withaq. HCl (1M). Ethyl acetate (20 mL) was added and the organic layer wasfurther washed with H₂O, dried over Na₂SO₄, and the solvent removedunder vacuum to give a white solid. Recrystallization from EtOAc gave 61as a white solid (9 mg, 29%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.21 (d,J=8.3 Hz, 1H), 7.97-7.71 (m, 3H), 7.52 (dt, J=14.6, 7.5 Hz, 2H),7.45-7.20 (m, 9H), 5.10-4.94 (m, 2H), 4.58 (dd, J=9.5, 5.3 Hz, 1H),4.46-4.29 (m, 1H), 4.12 (q, J=7.1 Hz, 2H), 3.97 (d, J=10.6 Hz, 1H), 3.70(dd, J=14.0, 5.0 Hz, 1H), 3.30-3.17 (m, 2H), 2.59-2.20 (m, 5H),2.05-1.38 (m, 7H), 1.37-1.16 (m, 4H), 0.93 (td, J=12.7, 10.8, 5.7 Hz,6H); LCMS-ESI (m/z): 631 (M+H)⁺.

Benzyl((S)-1-(((S)-4-methyl-1-oxo-1-(((R)-5-oxo-1-((S)-2-oxopyrrolidin-3-yl)pentan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate (62)

To a solution of 61 (47 mg, 0.075 mmol) in DCM (4 mL) and DMSO (1 mL)was added DIPEA (50 μL, 0.3 mmol) at 0° C. The solution was stirred for30 min before addition of S03-pyridine complex (47 mg, 0.3 mmol). Thereaction mixture was stirred for 3 h at room temperature, and thendiluted with EtOAc (50 mL). The organic phase was separated and thenwashed successively with aq. HCl (1M), sat. aq. NaHCO₃, and brine, driedover Na₂SO₄. After removal of the voaltils under vacuum, the residue waspurified by preparative TLC (DCM:MeOH 20:1) to give 62 as a white solid.LCMS-ESI (m/z): 629 (M+H)⁺.

Benzyl((S)-1-(((S)-1-(((S,E)-5-hydroxy-1-((S)-2-oxopyrrolidin-3-yl)pent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(63)

To a solution of 60 (67 mg, 0.1 mmol) in DCM (3 mL) was added DIBAL (1M, 0.2 mL, 0.3 mmol) at 0° C. The reaction was stirred for 2 h at 0° C.and then quenched with 1 M HCl (0.1 mL). The reaction mixture was warmedup to room temperature and diluted with EtOAc (15 mL). The organic layerwas washed successively with 1 M HCl (5 mL), sat. aq. NaHCO₃ (5 mL), andbrine, dried over Na₂SO₄ and the solvent was removed under vacuum. Theresidue was purified by silica gel chromatography (DCM:MeOH=20:1) togive 63. ¹H NMR (400 MHz, Methanol-d₄) δ 8.22 (d, J=8.4 Hz, 1H), 7.84(dd, J=41.9, 7.7 Hz, 2H), 7.53 (dt, J=14.5, 7.6 Hz, 1H), 7.44-7.13 (m,7H), 5.81-5.63 (m, 1H), 4.68-4.27 (m, 4H), 4.07 (d, J=5.0 Hz, 1H),3.80-3.62 (m, 1H), 2.60-2.17 (m, 3H), 2.03 (dd, J=24.1, 7.1 Hz, 2H),1.82-1.45 (m, 6H), 1.31 (s, H), 1.04-0.85 (m, 6H); LCMS-ESI (m/z): 629(M+H)⁺.

Benzyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S,E)-5-oxo-1-((S)-2-oxopyrrolidin-3-yl)pent-3-en-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(64)

To a solution of alcohol 63 (56 mg, 0.09 mmol) in DCM (4 mL) and DMSO (1mL) was added DIPEA (0.13 mL, 0.36 mmol) at 0° C. The solution wasstirred for 30 min before addition of SO₃-pyridine complex (60 mg, 0.36mmol). The reaction mixture was then stirred at 0° C. overnight and thendiluted with EtOAc (25 mL). The organic phase was separated and thenwashed successively with aq. HCl (1M, 10 mL), sat. aq. NaHCO₃ (10 mL),and brine, dried over Na₂SO₄. After removal of the volatils undervacuum, the residue was purified by preparative TLC to give 64 as awhite solid (mg, 75%). ¹H NMR (400 MHz, Methanol-d₄) δ 9.55 (dd, J=1.6,7.8 Hz, 1H), 8.21 (d, J=8.4 Hz, 1H), 7.88 (d, J=7.4 Hz, 1H), 7.78 (d,J=6.6 Hz, 1H), 7.48-7.57 (m, 2H), 7.23-7.41 (m, 7H), 6.91-6.97 (m, 1H),6.14-6.20 (m, 1H), 4.99 (s, 2H), 4.74-4.85 (m, 1H), 4.59-4.63 (m, 1H),4.37-4.41 (m, 1H), 3.68-3.74 (m, 1H), 3.24-3.29 (m, 2H), 2.45-2.61 (m,1H), 2.24-2.32 (m, 1H), 1.62-1.84 (m, 5H), 0.89-0.98 (m, 6H); LCMS-ESI(m/z): 627 (M+H)⁺.

tert-Butyl((S,E)-4-(methylsulfonyl)-1-((S)-2-oxopyrrolidin-3-yl)but-3-en-2-yl)carbamate(65)

To a solution of diethyl ((methylsulfonyl)methyl)phosphonate (1.46 g,6.3 mmol) in THF (60 mL) was added BuLi (1 M, 6.5 mL, 6.5 mmol) dropwiseat −78° C. After stirred for 30 min, aldehyde 49 (1.35 g, 5.3 mmol) inTHF (10 mL) was added over 30 min. The reaction mixture was warmed up tort over 1 h and stirred for further 3 h. Quenched the reaction byaddition of MeOH (1 mL), and the solvent was removed in vacuum. Theresidue was partitioned between EtOAc (150 mL) and aq. 1N HCl (80 mL),and the organic phase was washed respectively with aq. NaHCO₃ and brine,dried (Na₂SO₄), concentrated, and the residue was purified by silica gelchromatography (DCM:MeOH=20:1) to afford 65 (25%). LCMS-ESI (m/z): 333[M+H].

Benzyl((S)-1-(((S)-4-methyl-1-(((S,E)-4-(methylsulfonyl)-1-((S)-2-oxopyrrolidin-3-yl)but-3-en-2-yl)amino)-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(66)

A solution of compound 65 (330 mg, 1 mmol) and trifluoroacetic acid (2mL) in DCM (6 mL) was stirred at room temperature for 3 h. The solventwas removed under vacuum and the residue coevaporated three times withtoluene. The residue was then dissolved in DCM (30 mL) and dipeptide 57(480 mg, 1.05 mmol), EDCI (250 mg, 1.3 mmol), HOBt (180 mg, 1.3 mmol),and DIPEA (0.7 mL, 4 mmol) were added. The solution was stirred at roomtemperature overnight before being diluted with EtOAc (80 mL). Theorganic layer was washed successively with aq. HCl (1M), sat. aq. NaHCO₃and brine, dried over Na₂SO₄. Removal of the volatils under vacuum andrecristalization of the residue from EtOAc gave 66 as a white solid (27mg, 31%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.21 (d, J=8.72 Hz, 1H), 7.89(d, J=7.76 Hz, 1H), 7.79 (d, J=4.84 Hz, 1H), 7.48-7.59 (m, 2H),7.25-7.40 (m, 7H), 6.86 (dd, J=4.8, 15.32 Hz, 1H), 6.7 (d, J=15.16 Hz,1H), 5.01-5.05 (m, 2H), 4.70-4.72 (m, 1H), 4.56-4.60 (m, 1H), 4.31-4.34(m, 1H), 3.66-3.73 (m, 1H), 2.99 (s, 3H), 2.51-2.54 (m, 1H), 2.27-2.29(m, 1H), 1.61-1.84 (m, 4H), 0.91-0/98 (m, 6H); LCMS-ESI (m/z): 677(M+H)⁺.

Benzyl((2S)-1-(((2S)-4-methyl-1-(((1S)-1-(3-(methylsulfonyl)oxiran-2-yl)-2-((S)-2-oxopyrrolidin-3-yl)ethyl)amino)-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(67)

To a solution of TBHP (5.5 M, 50 μL, 0.27 mmol) in THF (5 mL) was addedMeLi (2.5 M, 0.1 mL, 0.25 mmol) at −78° C. The resulting mixture wasstirred at −78° C. for 15 min and then a solution of compound 66 (123mg, 0.18 mmol) in THF (1 mL) was added dropwise. The resulting mixturewas stirred at 0° C. overnight. Solid Na₂SO₃ (200 mg) was added and thesuspension was stirred for 15 min. After dilution with sat. aq. NH₄Clsolution, extraction with EtOAc (30 mL×3), the combined organic layerswere washed with brine, dried over Na₂SO₄, and concentrated undervacuum. The crude oil was purified by column chromatography(DCM:MeOH=20:1) to give 67 as a pale yellow solid. ¹H NMR (400 MHz,Methanol-d₄) δ 8.23 (d, J=8.6 Hz, 1H), 7.88 (d, J=8.2 Hz, 1H), 7.78 (d,J=7.3 Hz, 1H), 7.53 (dd, J=17.7, 7.7 Hz, 1H), 7.45-7.18 (m, 6H), 4.98(d, J=3.6 Hz, 1H), 4.72 (q, J=7.2, 6.7 Hz, 1H), 4.60 (q, J=3.8 Hz, 1H),4.47 (dd, J=26.2, 3.5 Hz, 1H), 4.19-4.05 (m, 2H), 3.69 (dt, J=13.1, 6.2Hz, 1H), 3.38 (d, J=6.7 Hz, 1H), 2.58 (d, J=10.3 Hz, 1H), 2.43-2.30 (m,1H), 2.05-1.92 (m, 1H), 1.82 (ddd, J=13.2, 8.8, 4.4 Hz, 1H), 1.75-1.44(m, 2H), 1.40-1.21 (m, 2H), 0.94 (hept, J=6.7 Hz, 6H); LCMS-ESI (m/z):693 (M+H)⁺.

S—((S)-2-((tert-Butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propyl)ethanethioate (32)

To a solution of N-[1-(hydroxymethyl)cyclopropyl]carbamic acid-t-butylester 2 (3.74 g, 20.0 mmol) and NEt₃ (3.4 mL, 24.0 mmol) in CH₂Cl₂ (100mL), methanesulfonyl chloride (1.9 mL, 24.0 mmol) was added dropwise at0° C. The reaction mixture was stirred for 20 h at 0° C. and afterremoval of the volatile components under reduced pressure, the residuewas diluted with H₂O (60 mL). The aqueous phase was extracted with EtOAc(3×60 mL) and the combined organic layers were dried over Na₂SO₄ andconcentrated under vacuum. To a solution of the residue in DMF (90 mL)was added K₂CO₃ (6.78 g, 20.8 mmol) and thioacetic acid (1.5 mL, 20.8mmol). The reaction mixture was stirred for 24 h at room temperature andthen the volatile components were removed under reduced pressure. 1N HCl(90 mL) was added to the residue and the aqueous phase was extractedwith EtOAc (3×100 mL). The combined organic phases were dried overNa₂SO₄ and concentrated under vacuum. Recrystallization of the residuefrom hexane/Et₂O yielded 68 (2.97 g, 12.1 mmol, 61%) as pale yellowsolid. LCMS-ESI (m/z): 317 [M+H].

S-((5S,8S,11S)-8-Isobutyl-5-(naphthalen-1-ylmethyl)-3,6,9-trioxo-11-(((S)-2-oxopyrrolidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecan-12-yl)ethanethioate (69)

A solution of compound 68 (130 mg, 0.41 mmol) in DCM (6 mL) andtrifluoroacetic acid (2 mL) was stirred at room temperature for 2 h. Thesolvent was removed under vacuum, the residue coevaporated three timeswith toluene. To a solution of the dry residue in DCM (20 mL) was addeddipeptide 57 (200 mg, 0.43 mmol), EDCI (103 mg, 0.54 mmol), HOBt (73 mg,0.54 mmol), and DIPEA (0.3 mL, 1.72 mmol). The solution was stirred atroom temperature overnight before being diluted with EtOAc (80 mL). Theorganic layer was washed successively with aq. HCl (1M), sat. aq. NaHCO₃and brine, dried over Na₂SO₄. After removal of the solvent under vacuumand reccrystalization from EtOAc, the thioacetate 69 was obtained as awhite solid (227 mg, 50%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.13 (d,J=8.4 Hz, 1H), 7.89 (d, J=8.0 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.48-7.59(m, 2H), 7.30-7.44 (m, 7H), 5.32 (d, J=12.4 Hz, 1H), 5.13 (d, J=12.4 Hz,1H), 4.42-4.47 (m, 1H), 3.97-4.07 (m, 2H), 3.45-3.51 (m, 1H), 3.24-3.30(m, 1H), 3.16-3.20 (m, 1H), 2.87-2.93 (m, 1H), 2.29 (s, 3H), 1.67-1.73(m, 1H), 1.48-1.52 (m, 1H), 1.35-1.42 (m, 1H), 1.09-1.16 (m, 1H),0.92-0.97 (m 1H), 0.60 (d, J=6.4 Hz, 3H), 0.52 (d, J=6.4 Hz, 3H);LCMS-ESI (m/z): 661 [M+H].

Benzyl((S)-1-(((S)-1-(((S)-1-mercapto-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(70)

A solution of thioacetate 60 (21 mg, 0.03 mmol) and LiOH (2.4 mg, 0.1mmol) in methanol (1 ml), and the mixture was stirred for 3 days in roomtemperature. The solvent was removed under vacuum and the residue waspurified by preparative TLC (DCM:MeOH=20:1) to give solid thiol 70 inquantitative yield. ¹H NMR (400 MHz, Methanol-d₄) δ 8.13 (d, J=8.4 Hz,1H), 7.89 (d, J=8.0 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.48-7.59 (m, 2H),7.30-7.44 (m, 7H), 5.32 (d, J=12.4 Hz, 1H), 5.13 (d, J=12.4 Hz, 1H),4.42-4.47 (m, 1H), 3.97-4.07 (m, 2H), 3.45-3.51 (m, 1H), 3.24-3.30 (m,1H), 3.16-3.20 (m, 1H), 2.87-2.93 (m, 1H), 1.67-1.73 (m, 1H), 1.48-1.52(m, 1H), 1.35-1.42 (m, 1H), 1.09-1.16 (m, 1H), 0.92-0.97 (m 1H), 0.60(d, J=6.4 Hz, 3H), 0.52 (d, J=6.4 Hz, 3H); LCMS-ESI (m/z): 619 [M+H].

(S)-3-(naphthalen-1-yl)-2-((phenethoxycarbonyl)amino)propanoic acid (71)

To a mixture of amino acid 54 (545 mg, 2.53 mmol), NaHCO₃ (320 mg, 3.8mmol) in THF-H₂O (2:3, 20 mL) was added PhCH₂CH₂OCOCl (0.33 mL, 2.78mmol) at 0° C. The reaction mixture stirred at rt for 5 h and theacidified with 1 N HCl (8-10 mL) to pH 2.0. organic solvents were thenremoved under vacuum and the remaining aqueous phase extracted withEtOAc (20 mL×3). The combined organic layers were washed with brine,dried, and concentrated under vacuum to give 71 as a white solid afterrecrystallization from EtOAc. ¹H NMR (400 MHz, Chloroform-d) δ 8.12 (d,J=8.4 Hz, 1H), 7.90 (d, J=8.0 Hz, 1H), 7.82 (d, J=8.2 Hz, 1H), 7.54 (q,J=8.1, 7.1 Hz, 2H), 7.15-7.48 (m, 7H), 5.13 (m, 1H), 4.79 (m, 1H), 4.27(m, 2H), 3.76 (d, J=13.7 Hz, 1H), 3.50 (m, 1H), 2.89 (m, 2H). LCMS-ESI(m/z): 364 [M+H].

Methyl(S)-2-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate(24)

To a solution of compound 47 (4.14 g, 14.47 mmol) in dioxane (30 mL) wasadded HCl (4 M in dioxane, 20 mL). The reaction mixture was stirred atroom temperature for 2 h and the solvent removed under vacuum. Theresidue was carfully dried in vacuo for 5 h and then used directely inthe next step without further purification. The residue was dissolved inDCM (100 mL) and Boc-L-Leu-OH (4.02 g, 17.4 mmol), EDCI (3.61 g, 18.8mmol), HOBt (2.54 g, 18.8 mmol), and DIPEA (10.4 mL, 60 mmol) wereadded. The solution was stirred at room temperature overnight beforesolvents were removed under vacuum. EtOAc (200 mL) was then added andthe organic layer was washed successively with aq. HCl (1M), sat. aq.NaHCO₃ and brine and finaly dried over Na₂SO₄. After removal of thesolvent under vacuum and recrystallization from EtOAc, compound 24 wasobtained as a white solid (72%). LCMS-ESI (m/z): 400 [M+H].

Methyl(6S,9S,12S)-9-isobutyl-6-(naphthalen-1-ylmethyl)-4,7,10-trioxo-12-(((S)-2-oxopyrrolidin-3-yl)methyl)-1-phenyl-3-oxa-5,8,11-triazatridecan-13-oate(72)

A solution of compound 24 (520 mg, 1.3 mmol) and TFA (5 mL) in DCM (20mL) was stirred at room temperature for 3 h. The solvent was removedunder vacuum and the residue used in the next step without furtherpurification. The residue was dissolved in DCM (40 mL) and compound71(494 mg, 1.2 mmol mmol), EDCI (310 mg, 1.62 mmol), HOBt (220 mg, 1.62mmol), and DIPEA (0.88 mL, 5 mmol) were added The solution was stirredat room temperature overnight before solvents were removed under vacuum.EtOAc (100 mL) was then added and the organic layer was washedsuccessively with aq. HCl (1M), sat. aq. NaHCO₃ and brine and finalydried over Na₂SO₄. After removal of the solvent under vacuum andrecrystallization from EtOAc, compound 72 was obtained as a white solid(62%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.16 (d, J=8.4 Hz, 1H), 7.89 (d,J=8.1 Hz, 1H), 7.80 (d, J=7.9 Hz, 1H), 7.54 (dt, J=27.5, 7.3 Hz, 2H),7.44-7.20 (m, 7H), 4.64 (m, 1H), 4.52-4.40 (m, 1H), 4.34-4.11 (m, 3H),3.72 (d, J=15.2 Hz, 1H), 3.64 (s, 2H), 3.47 (d, J=7.8 Hz, 1H), 3.30-3.18(m, 1H), 2.91 (t, J=6.9 Hz, 1H), 2.50 (d, J=10.7 Hz, 1H), 2.28 (ddd,J=34.9, 17.0, 7.3 Hz, 2H), 1.92-1.37 (m, 2H), 1.14 (d, J=6.0 Hz, 1H),0.64 (d, J=12.8 Hz, 6H); LCMS-ESI (m/z): 645 [M+H].

Phenethyl((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(74)

To a solution of methyl ester 72 (420 mg, 0.65 mmol) in THF-EtOH (2:3,10 mL) were added LiBH₄ (4M, 250 μL, 1 mmol) at 0° C. The resultingmixture was stirred at room temperature for 3 h and then quenched withaq. HCl (1 M). Ethyl acetate (50 mL) was added and the organic phase wasfurther washed with brine and dried over Na₂SO₄ After removal of thesolvent under vacuum compound 73 was obtained as a white solid. To asolution of alcohol 73 in a mixture of DCM (16 mL) and DMSO (4 mL) wasadded at 0° C. DIPEA (360 μL, 2.07 mmol). The resulting solution wasstirred for 30 min before addition of S03-pyridine complex (330 mg, 2.06mmol). The reaction mixture was stirred overnight at 0° C. and thendiluted with EtOAc (100 mL). The organic phase was then washedsuccessively with aq. HCl (1M), sat. aq. NaHCO₃, and brine and driedover Na₂SO₄. After removal of the solvent under vacuum andrecrystallization from EtOAc, compound 74 was obtained as a white solid(68%). ¹H NMR (400 MHz, Methanol-d₄) δ 8.16 (d, J=8.4 Hz, 1H), 7.89 (d,J=7.8 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.64-7.44 (m, 2H), 7.15-7.46 (m,7H), 4.53-4.41 (m, 1H), 4.31-4.14 (m, 3H), 3.69 (s, 1H), 3.64 (s, 2H),3.51-3.44 (m, 1H), 3.29-3.14 (m, 2H), 2.90 (q, J=7.2 Hz, 2H), 2.59-2.44(m, 1H), 2.39-2.14 (m, 1H), 1.91-1.64 (m, 1H), 1.64-1.37 (m, 1H),0.72-0.51 (m, 6H); LCMS-ESI (m/z): 615 [M+H].

(S)-2-Dodecanamido-3-(naphthalen-1-yl)propanoic acid (75)

To a mixture of amino acid 54 (215 mg, 1 mmol), NaHCO₃ (125 mg, 1.5mmol) in THF-H₂O (2:3, 10 mL) was added C₁₁H₂₃COCl (0.33 mL, 2.78 mmol)at 0° C. The reaction mixture was stirred at rt for 2 h and thenacidified with 1 N HCl (8-10 mL) to reach pH 2.0. After removal of thesolvent the aqueous layer was extracted with EtOAc (20 mL×3), and thecombined organic phases were washed with brine, dried over Na₂SO₄. Afterremoval of the solvent under vacuum and recrystallization from EtOAc,compound 75 (73%) was obtained as a white solid. LCMS-ESI (m/z): 398[M+H].

Methyl ((S)-2-dodecanamido-3-(naphthalen-1-yl)propanoyl)-L-leucinate(76)

To a solution of compound 75 (380 mg, 1.05 mmol) and L-Leu-OMe (230 mg,1.27 mmol) in DCM (30 mL) were added EDCI (260 mg, 1.35 mmol), HOBt (185mg, 1.34 mmol), and DIPEA (0.73 mL, 4.2 mmol). The reaction mixture wasstirred overnight at room temperature and then H₂O (800 mL) and EtOAc(100 mL) were added. The organic phase was washed successively with aq.HCl (1 M, 50 mL), sat. aq. NaHCO₃ (50 mL) and brine (500 mL), and thendried over Na₂SO₄. After removal of the solvent under vacuum andrecrystallization from EtOAc, compound 76 (350 mg, 65%) was obtained.LCMS-ESI (m/z): 525 [M+H].

((S)-2-Dodecanamido-3-(naphthalen-1-yl)propanoyl)-L-leucine (77)

To a solution of methyl ester 76 (345 mg, 0.66 mmol) in THF-MeOH—H₂O(3:1:1, 10 mL) was added a solution of LiOH—H₂O (32 mg, 1.33 mmol) inH₂O (1 mL). The reaction mixture was stirred overnight at roomtemperature. The volatiles were removed under vacuum to give acolourless residue that was partitioned between EtOAc and aq. HCl (1M).The organic layer was separated, washed successively with aq. HCl (1M)and brine, then dried over Na₂SO₄, After removal of the solvent undervacuum and recrystallization from EtOAc, compound 77 was obtained as awhite solid (430 mg, 96%). LCMS-ESI (m/z): 692 [M+H].

N—((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxocyclohexyl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)dodecanamide(79)

To a solution of methyl ester 4 (466 mg, 0.67 mmol) in THF-EtOH (2:3, 20mL) was added LiBH₄ (2 M, 440 μL, 0.88 mmol) at 0° C. The resultingmixture was stirred at room temperature for 3 h and then quenched withaq. HCl (1 M). After addition of ethyl acetate (50 mL) the organic phasewas separated and further washed with brine and dried over Na₂SO₄.Removal of the solvent under vacuum afforded compound 78 as a whitesolid which was used directly in the next without further purification.To a solution of alcohol 78 (70 mg, 0.11 mmol) in a mixture of DCM (3mL) and DMSO (1 mL) was added at 0° C. DIPEA (90 μL, 0.5 mmol). Thesolution was stirred at this temperature for 10 min before addition ofSO₃-pyridine complex (70 mg, 0.43 mmol). The reaction mixture wasstirred overnight at 0° C. and then diluted with EtOAc (50 mL). Theorganic phase was separated and then washed successively with aq. HCl(1M), sat. aq. NaHCO₃, and brine, dried over Na₂SO₄. After removal ofthe solvent under vacuum and recrystallization from EtOAc, compound 79was obtained as a white solid (48%). ¹H NMR (400 MHz, Methanol-d₄) δ8.23 (d, J=6.4 Hz, 1H), 7.87 (d, J=6.8 Hz, 1H), 7.75-7.78 (m, 1H),7.48-7.59 (m, 2H), 7.37-7.42 (m, 2H), 4.37-4.44 (m, 1H), 3.95-4.04 (m,1H), 3.67-3.75 (m, 1H), 3.45-3.55 (m, 2H), 3.21-3.28 (m, 2H), 2.27-2.35(m, 1H), 2.08-2.18 (m, 4H), 1.60-1.82 (m, 7H), 1.19-1.43 (m, 18H),0.90-0.98 (m, 9H); LCMS-ESI (m/z): 662 [M+H].

Methyl(S)-2-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-3-((S)-2-oxocyclohexyl)propanoate (80)

To a solution of compound 4 (630 mg, 2.1 mmol) in dioxane (8 mL) wasadded HCl (4M in dioxane, 8 mL). The solution was stirred at roomtemperature for 3 h and the solvent was removed under reduced pressure.The obtained residue was used in the next step without furtherpurification. To a solution of the residue in DCM (80 mL) was addedL-Phe-OH (725 mg, 2.73 mmol), EDCI (564 mg, 2.94 mmol), HOBt (400 mg,2.94 mmol), and DIPEA (1.54 mL, 8.83 mmol). The reaction mixture wasstirred at room temperature overnight before evaporation of the solventunde vacuum. EtOAc (200 mL) was added to the residue and the organiclayer was washed successively with aq. HCl (1 M), sat. aq. NaHCO₃, brineand dried over Na₂SO₄. After removal of the solvent under vacuum andrecrystallization from EtOAc, compound 80 was obtained as a white solid(72%). ¹H NMR (400 MHz, Chloroform-d) δ 7.69 (d, J=7.5 Hz, 1H),7.34-7.16 (m, 7H), 6.36 (s, 1H), 5.19 (d, J=8.4 Hz, 1H), 4.56 (dd,J=19.2, 10.7 Hz, 2H), 3.71 (s, 3H), 3.16 (dd, J=13.9, 5.5 Hz, 1H), 3.03(dd, J=14.1, 7.0 Hz, 1H), 2.35 (ddd, J=14.0, 11.3, 5.1 Hz, 1H), 2.24(dq, J=14.9, 5.7 Hz, 1H), 2.15-2.00 (m, 2H), 1.88 (dtd, J=14.3, 7.9, 3.9Hz, 2H), 1.80-1.61 (m, 1H), 1.60-1.46 (m, 1H), 1.37 (d, J=17.7 Hz, 9H);LCMS-ESI (m/z): 413 [M+H].

Methyl(5S,8S,11S)-8-benzyl-5-(naphthalen-1-ylmethyl)-3,6,9-trioxo-11-(((S)-2-oxopiperidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazadodecan-12-oate(81)

A solution of compound 80 (592 mg, 1.28 mmol) and TFA (5 mL) in DCM (15mL) was stirred at room temperature for 2 h. The solvent was removedunder vacuum and the residue used in the next step without furtherpurification. The residue was dissolved in DCM (50 mL) and compound 9(540 mg, 1.54 mmol mmol), EDCI (320 mg, 1.68 mmol), HOBt (225 mg, 1.67mmol), and DIPEA (0.9 mL, 5.2 mmol) were added. The solution was stirredat room temperature overnight before removal of the solvent under vacuumand addition of EtOAc (150 mL). The organic layer was washedsuccessively with aq. HCl (1M), sat. aq. NaHCO₃, brine and dried overNa₂SO₄. After removal of the solvent under vacuum and recrystallizationfrom EtOAc, compound 81 was obtained as a white solid (62%). LCMS-ESI(m/z): 679 [M+H].

Benzyl((S)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(82)

To a solution of methyl ester 81 (870 mg, 1.28 mmol) in THF-EtOH (2:3,30 mL) was added LiBH₄ (2 M, 1 mL, 2 mmol) at 0° C. The resultingmixture was stirred at room temperature for 3 h and then quenched withaq. HCl (1 M). Ethyl acetate (50 mL) was added and the organic phase waswashed with brine and dried over Na₂SO₄. Removal of the solvent undervacuum gave 82 as a white solid which was used in the next step withoutfurther purification. ¹H NMR (400 MHz, Methanol-d₄) δ 8.14 (d, J=8.5 Hz,1H), 7.85 (d, J=8.3 Hz, 2H), 7.74 (d, J=8.1 Hz, 1H), 7.49 (dq, J=14.6,7.2 Hz, 2H), 7.27 (tdd, J=16.9, 11.8, 7.9 Hz, 12H), 4.96 (d, J=4.2 Hz,2H), 4.58 (dt, J=19.6, 7.1 Hz, 2H), 4.02-3.89 (m, 1H), 3.55 (dd, J=14.3,5.4 Hz, 1H), 3.48-3.06 (m, 4H), 2.98 (dd, J=13.6, 8.0 Hz, 1H), 2.24 (h,J=5.7, 4.5 Hz, 1H), 1.98 (dtq, J=12.7, 6.3, 3.5 Hz, 3H), 1.79-1.53 (m,4H), 1.50-1.35 (m, 1H); LCMS-ESI (m/z): 651 [M+H].

Benzyl((S)-3-(naphthalen-1-yl)-1-oxo-1-(((S)-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)propan-2-yl)carbamate(83)

To a solution of 82 (70 mg, 0.11 mmol) in a mixture of DCM (3 mL) andDMSO (1 mL) was added at 0° C. DIPEA (90 μL, 0.5 mmol). After 10 minutesat this temperature, S03-pyridine complex (70 mg, 0.43 mmol) was addedand the reaction mixture was stirred overnight at 0° C. After additionof EtOAc (50 mL), the organic layer was washed successively with aq. HCl(1M), sat. aq. NaHCO₃, brine and dried over Na₂SO₄. After removal of thesolvent under vacuum and recrystallization from EtOAc, compound 83 as awhite solid (56%). ¹H NMR (400 MHz, Methanol-d₄) δ 9.22 (s, 0.3H),8.22-8.07 (m, 1H), 7.87 (d, J=8.1 Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.51(dq, J=14.6, 7.1 Hz, 2H), 7.39-7.12 (m, 12H), 5.06-4.94 (m, 2H),4.69-4.46 (m, 1H), 4.35-4.21 (m, 1H), 3.98 (d, J=12.3 Hz, 1H), 3.57 (dt,J=14.2, 7.7 Hz, 1H), 3.28-2.95 (m, 5H), 2.29-1.93 (m, 1H), 1.81 (d,J=14.4 Hz, 1H), 1.66 (s, 1H), 1.46 (q, J=11.5, 10.3 Hz, 1H), 1.35-1.18(m, 1H); LCMS-ESI (m/z): 649 [M+H].

Benzyl((S)-1-(((S)-1-(((S)-1-chloro-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(84)

A solution of 82 (32 mg, 0.05 mmol), Ph₃P (50 mg, 0.19 mmol), CCl₄ (0.1mL) in 1,2-dichloroethane (0.5 mL) was heated at 80° C. for 3 min undermicrowave irradiation. After removal of the solvent under vacuum, theresidue was purified by preparative TLC to give 84 (78%) as a whitesolid. ¹H NMR (400 MHz, Methanol-d₄) δ 8.15 (d, J=8.1 Hz, 1H), 7.87 (d,J=8.0 Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.51 (dq, J=15.3, 7.5 Hz, 2H),7.27 (tdd, J=20.7, 9.9, 5.4 Hz, 13H), 4.96 (d, J=19.5 Hz, 2H), 4.57 (dq,J=21.7, 6.2, 5.1 Hz, 2H), 4.19-4.09 (m, 1H), 3.67-3.37 (m, 2H),3.27-2.96 (m, 5H), 2.27 (s, 1H), 2.19-1.88 (m, 2H), 1.85-1.52 (m, 3H);LCMS-ESI (m/z): 669 [M+H].

Benzyl((S)-3-(naphthalen-1-yl)-1-oxo-1-(((S)-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)propan-2-yl)carbamate(85)

To a solution of 82 (41 mg, 0.06 mmol) and NEt₃ (30 μL, 0.2 mmol) inCH₂Cl₂ (5 mL) was added methanesulfonyl chloride (9 μL, 0.09 mmol) at 0°C. The reaction mixture was stirred for 1 h at this temperature. Afterremoval of the volatile components under reduced pressure, the residuewas subjected to preparative TLC to give 85 as a white solid. ¹H NMR(400 MHz, Methanol-d₄) δ 8.20-8.05 (m, 2H), 7.87 (d, J=7.9 Hz, 1H), 7.77(t, J=8.2 Hz, 1H), 7.51 (dd, J=13.4, 7.6 Hz, 2H), 7.27 (tt, J=17.2, 7.0Hz, 6H), 5.06-4.96 (m, 2H), 4.64-4.44 (m, 1H), 4.07 (q, J=7.7, 5.7 Hz,1H), 3.65-3.49 (m, 1H), 3.23 (d, J=5.0 Hz, 3H), 3.04 (s, 3H), 2.37-2.21(m, 2H), 2.22-1.94 (m, 1H).

Methyl(6S,9S,12S)-9-isobutyl-2,2-dimethyl-6-(naphthalen-1-ylmethyl)-4,7,10-trioxo-12-(((S)-2-oxopiperidin-3-yl)methyl)-3-oxa-5,8,11-triazatridecan-13-oate(88)

To a solution of 86 (930 mg, 2.25 mmol) (Y. Zhai, Y. Ma, F. Ma, Q. Nie,X. Ren, Y. Wang, L. Shang, Z. Yin, Eur. J. Med. Chem, 2016, 124,559-573) in CH₂Cl₂ (10 mL) was added 4 M HCl in dioxane (2.3 mL)dropwise. The reaction mixture was stirred for 2 h at room temperatureand then concentrated under vacuum. The resulting amine was suspended inDCM (10 mL) and (S)—N-Boc-L-(1-naphthyl)alanine 87 (710 mg, 2.25 mmol),1-hydroxybenzotriazole (405 mg, 3.0 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (575 mg, 3.0mmol) and N,N-diisopropylethyl amine (2.1 mL, 12.0 mmol) were added at0° C. After being stirred at room temperature overnight, the reactionmixture was diluted with EtOAc (80 mL) and the organic layer washed with1 M HCl, 5% aqueous NaHCO₃ and brine. The organic layer was dried overNa₂SO₄. After removal of the volatiles under vacuum, the residue waspurified by flash chromatography (CH₂Cl₂/MeOH, 20/1 to 10/1) to afford88 (1.02 g, 74%).

¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, J=8.3 Hz, 1H), 8.05 (d, J=7.3 Hz,1H), 7.84 (dd, J=8.0, 1.5 Hz, 1H), 7.74 (dd, J=8.0, 1.4 Hz, 1H), 7.50(dddd, J=20.7, 8.0, 6.8, 1.3 Hz, 2H), 7.40-7.29 (m, 2H), 7.17 (d, J=8.5Hz, 1H), 6.79 (s, 1H), 5.09 (d, J=8.1 Hz, 1H), 4.67 (td, J=8.8, 4.7 Hz,1H), 4.59-4.41 (m, 2H), 3.70 (s, 3H), 3.37 (dd, J=14.5, 8.2 Hz, 1H),3.23 (d, J=11.8 Hz, 2H), 2.47-2.22 (m, 2H), 2.05 (m, 1H), 1.83 (dp,J=11.5, 3.6 Hz, 2H), 1.67 (ddt, J=19.1, 15.7, 6.1 Hz, 3H), 1.56-1.42 (m,2H), 1.34 (s, 9H), 1.05 (s, 1H), 0.93-0.90 (overlap two s, 6H). ¹³C NMR(101 MHz, CDCl₃) δ 174.4, 172.7, 172.5, 171.5, 155.5, 133.9, 133.2,132.2, 128.8, 127.6, 127.5, 126.3, 125.6, 125.4, 125.6, 123.7, 80.0,55.3, 52.3, 51.8, 50.1, 42.3, 42.1, 37.7, 34.9, 33.5, 28.2, 28.0, 26.2,24.6, 22.9, 22.1, 21.4. ESI-MS (m/z): 611.4 (M+H)⁺.

Methyl(S)-2-((S)-4-methyl-2-((S)-2-(5-methylisoxazole-3-carboxamido)-3-(naphthalen-1-yl)propanamido)pentanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate(89)

To a solution of 88 (610 mg, 1.0 mmol) in CH₂Cl₂ (5 mL) was added 4 MHCl in dioxane (1.0 mL) dropwise. The reaction mixture was stirred for 2h at room temperature and then concentrated under vacuum. The residuewas suspended in CH₂Cl₂ (10 mL) before addition of5-methylisoxazole-3-carboxylic acid (165 mg, 1.3 mmol),1-hydroxybenzotriazole (176 mg, 1.3 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (248 mg, 1.3mmol) and N,N-diisopropylethyl amine (0.7 mL, 4.0 mmol) at 0° C. Afterbeing stirred at room temperature overnight, the reaction mixture wasdiluted with EtOAc (60 mL) and the organic layer washed with 1M HCl, 5%aqueous NaHCO₃ and brine and finally dried over Na₂SO₄. After removal ofthe volatile under vacuum, the residue was purified by flashchromatography (CH₂Cl₂/MeOH, 30/1 to 15/1) to afford 89 (396 mg, 64%).

¹H NMR (400 MHz, CDCl₃) δ 8.29-8.21 (m, 1H), 8.16 (d, J=7.0 Hz, 1H),7.83 (dd, J=8.1, 1.4 Hz, 1H), 7.78-7.69 (m, 1H), 7.65 (d, J=8.0 Hz, 1H),7.53 (ddd, J=8.4, 6.8, 1.5 Hz, 1H), 7.47 (ddd, J=8.0, 6.8, 1.2 Hz, 1H),7.42-7.31 (m, 2H), 7.16 (d, J=8.3 Hz, 1H), 6.81 (s, 1H), 6.35 (d, J=1.1Hz, 1H), 5.03 (td, J=7.8, 6.3 Hz, 1H), 4.62 (td, J=8.5, 5.4 Hz, 1H),4.50 (ddd, J=11.4, 7.0, 3.7 Hz, 1H), 3.70 (s, 3H), 3.55 (dd, J=14.3, 7.6Hz, 1H), 3.36-3.20 (m, 2H), 2.43 (d, J=0.9 Hz, 3H), 2.39-2.27 (m, 2H),2.10-2.03 (m, 1H), 1.89-1.82 (m, 2H), 1.72-1.43 (m, 5H), 0.88 (d, J=1.8Hz, 3H), 0.87 (d, J=1.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.6,172.3, 171.2, 170.1, 159.1, 158.2, 133.9, 132.5, 132.0, 128.8, 127.9,127.7, 126.4, 125.7, 125.3, 123.7, 101.4, 54.0, 52.3, 52.00, 50.8, 42.2,41.8, 38.0, 35.4, 33.4, 26.8, 24.6, 22.8, 22.1, 21.5, 12.3. ESI-MS(m/z): 620.4 (M+H)⁺.

N—((S)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide(90)

To a solution of 89 (370 mg, 0.6 mmol) in methanol (6.0 mL) was addedNaBH₄ (46 mg, 1.2 mmol) at 0° C. The reaction mixture was stirred atroom temperature for 2 h, then quenched with a saturated solution ofNH₄Cl and finally stirred for another hour at room temperature. Afterevaporation of the volatiles under vacuum, ethyl acetate (60 mL) wasadded. The organic layer was washed with a saturated solution of NH₄Cland water and finally dried over Na₂SO₄. After removal of the volatilesunder vacuum, the residue was purified by flash chromatography(CH₂Cl₂/MeOH, 30/1 to 12/1) to afford 90 (245 mg, 69%).

¹H NMR (400 MHz, MeOD) δ 8.26 (dd, J=8.5, 1.1 Hz, 1H), 7.93 (d, J=8.9Hz, 1H), 7.90-7.83 (m, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.56 (ddd, J=8.4,6.8, 1.4 Hz, 1H), 7.52-7.47 (m, 1H), 7.46-7.41 (m, 1H), 7.37 (dd, J=8.1,7.0 Hz, 1H), 6.33 (d, J=1.0 Hz, 1H), 5.02 (dd, J=9.3, 5.1 Hz, 1H), 4.41(dd, J=8.6, 6.2 Hz, 1H), 4.03 (ddq, J=11.3, 5.6, 2.8 Hz, 1H), 3.82 (dd,J=14.4, 5.1 Hz, 1H), 3.60-3.40 (m, 3H), 3.27-3.18 (m, 2H), 2.43 (s, 3H),2.40-2.28 (m, 1H), 2.15-2.01 (m, 2H), 1.84-1.74 (m, 1H), 1.72-1.57 (m,4H), 1.54-1.43 (m, 1H), 0.96 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).¹³C NMR (101 MHz, MeOD) δ 176.0, 173.4, 173.3, 171.7, 171.6, 160.0,158.06, 134.0, 132.7, 132.0, 128.4, 127.4, 127.3, 125.9, 125.3, 125.0,123.2, 100.5, 64.2, 54.0, 52.5, 52.5, 41.6, 40.5, 37.3, 34.3, 32.6,25.7, 24.5, 22.0, 20.7, 10.6. ESI-MS (m/z): 592.4 (M+H)⁺.

5-Methyl-N—((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)isoxazole-3-carboxamide(91)

To a solution of 90 (150 mg, 0.25 mmol) in CH₂Cl₂ (3.0 mL) was slowlyadded Dess-Martin periodinane (161 mg, 0.38 mmol). The resulting mixturewas stirred at room temperature for 2 h and then quenched with 5%aqueous NaHCO₃ (3 mL) and 10% aqueous Na₂SO₃ (3 mL). The mixture wasextracted with dichloromethane (15 mL×2) and the combined organic layerswere washed with brine, dried over Na₂SO₄, and concentrated undervacuum. The residue was purified by flash chromatography (CH₂Cl₂/MeOH,30/1 to 10/1) and then preparative TLC (DCM/MeOH, 15/1) to give 91 (79mg, 53%).

¹H NMR (400 MHz, MeOD) δ 8.31-8.22 (m, 1H), 7.86 (dt, J=8.2, 2.0 Hz,1H), 7.75 (dd, J=8.2, 4.0 Hz, 1H), 7.56 (ddd, J=8.4, 6.9, 1.3 Hz, 1H),7.52-7.42 (m, 2H), 7.37 (ddd, J=8.2, 7.0, 5.9 Hz, 1H), 6.33 (dd, J=1.5,0.9 Hz, 0.4H), 6.31 (d, J=1.0 Hz, 0.6H), 5.06-5.01 (m, 1H), 4.54-4.48(m, 1H), 4.46-4.41 (m, 1H), 4.20-4.12 (m, 0.4H), 4.06-4.0 (m, 0.6H),3.89-3.79 (m, 1H), 3.53-3.40 (m, 1H), 3.37-3.34 (overlap two d, J=0.9Hz, 3H), 2.44-2.41 (overlap two d, J=0.9 Hz, 3H), 2.33-2.29 (m, 1H),2.22-2.14 (m, 1H), 2.07-2.0 (m, 0.6H), 1.96-1.92 (m, 0.4H), 1.81-1.60(m, 5H), 1.01-0.88 (m, 6H). ¹³C NMR (101 MHz, MeOD) δ 176.1, 173.4,171.7, 171.6, 171.5, 159.8, 158.0, 134.0, 134.0, 132.7, 132.0, 128.4,127.4, 125.9, 125.9, 125.3, 125.0, 123.3, 100.6, 100.5, 98.4, 98.3,54.0, 53.8, 53.7, 52.5, 52.3, 50.7, 50.5, 40.6, 40.5, 38.1, 37.1, 34.4,30.3, 29.8, 26.4, 25.5, 24.5, 24.4, 22.1, 21.9, 21.9, 21.1, 20.9, 20.9,20.6, 20.6, 10.6. ESI-MS (m/z): 590.3 (M+H)⁺.

Methyl(6S,9S,12S)-6-(4-fluorobenzyl)-9-isobutyl-2,2-dimethyl-4,7,10-trioxo-12-(((S)-2-oxopiperidin-3-yl)methyl)-3-oxa-5,8,11-triazatridecan-13-oate(93)

A solution of compound 32 (350 mg, 1.0 mmol) and(S)-2-((tert-butoxycarbonyl)amino)-3-(4-fluorophenyl)propanoic acid(compound 92, 286 mg, 1.0 mmol) in DCM (10 mL) was treated with1-hydroxybenzotriazole (200 mg, 1.5 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (287 mg, 1.5mmol) and N,N-diisopropylethyl amine (0.7 mL, 4.0 mmol) at 0° C. The icebath was removed, and the reaction mixture was stirred at roomtemperature overnight. The reaction mixture was diluted with EtOAc (70mL) and the organic layer washed with 1N HCl, NaHCO₃ (5%) and saturatedbrine and dried over Na₂SO₄. The solvent was evaporated and the crudemixture was purified on silica gel, eluting with mixtures of DCM/MeOH(30:1 to 20:1) to give product 93 (450 mg, 78%).

¹H NMR (400 MHz, Chloroform-d) δ 8.06 (d, J=7.2 Hz, 1H), 7.24-7.10 (m,3H), 6.94 (t, J=8.6 Hz, 3H), 5.15 (d, J=8.4 Hz, 1H), 4.65 (td, J=8.8,4.7 Hz, 1H), 4.56-4.44 (m, 1H), 4.45-4.32 (m, 1H), 3.71 (s, 3H), 3.28(dt, J=9.4, 3.0 Hz, 2H), 3.10 (dd, J=14.0, 5.8 Hz, 1H), 2.94 (dd,J=14.1, 7.3 Hz, 1H), 2.46-2.21 (m, 2H), 2.12-1.98 (m, 1H), 1.95-1.79 (m,2H), 1.78-1.59 (m, 3H), 1.59-1.44 (m, 2H), 1.38 (s, 9H), 0.92 (s, 3H),0.91 (s, 3H). ¹⁹F NMR (377 MHz, CDCl₃) δ −116.22 (s). ¹³C NMR (101 MHz,CDCl₃) δ 174.51, 172.50, 172.30, 170.94, 161.79 (d, J=244.6 Hz), 155.40,132.45, 130.92, 130.84, 115.22 (d, J=21.2 Hz), 80.15, 55.45, 52.27,51.66, 50.46, 42.20, 37.92, 37.31, 33.39, 28.22, 26.56, 24.54, 22.88,22.05, 21.45. ESI-MS (m/z): 579.3 (M+H)⁺.

Methyl(S)-2-((S)-2-((S)-3-(4-fluorophenyl)-2-(5-methylisoxazole-3-carboxamido)propanamido)-4-methylpentanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate(95)

To a solution of compound 93 (139 mg, 0.24 mmol) in DCM (2.5 mL) wasadded 4N HCl in dioxane (0.25 mL, 1.0 mmol) dropwise. The reactionmixture was stirred for 1 h at room temperature and then concentrated toyield compound 94 as a crude HCl salt. A solution of the crude HCl saltand 5-methylisoxazole-3-carboxylic acid (38 mg, 0.3 mmol) in DCM (3 mL)was treated with 1-hydroxybenzotriazole (40 mg, 0.3 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (57 mg, 0.3mmol) and N,N-diisopropylethyl amine (0.21 mL, 1.2 mmol) at 0° C. Theice bath was removed, and the reaction mixture was stirred at roomtemperature overnight. The reaction mixture was diluted with EtOAc (30mL) and the organic layer washed with 1N HCl, NaHCO₃ (5%) and saturatedbrine and then dried over Na₂SO₄. The solvent was evaporated, and thecrude mixture was purified on silica gel, eluting with mixtures ofDCM/MeOH (30:1 to 20:1) to afford product 95 (86 mg, 61%).

¹H NMR (400 MHz, Chloroform-d) δ 8.28 (d, J=6.9 Hz, 1H), 7.58 (d, J=8.4Hz, 1H), 7.41 (d, J=8.5 Hz, 1H), 7.23-7.10 (m, 2H), 6.99-6.85 (m, 3H),6.39 (d, J=1.0 Hz, 1H), 4.90 (ddd, J=8.4, 7.3, 5.7 Hz, 1H), 4.67 (td,J=8.6, 5.3 Hz, 1H), 4.49 (ddd, J=11.3, 6.9, 3.7 Hz, 1H), 3.71 (s, 3H),3.33-3.24 (m, 2H), 3.19 (dd, J=14.1, 5.7 Hz, 1H), 3.06 (dd, J=14.0, 7.3Hz, 1H), 2.61 (s, 1H), 2.45 (d, J=0.9 Hz, 3H), 2.44-2.37 (m, 1H),2.37-2.28 (m, 1H), 2.05 (ddt, J=12.8, 5.7, 2.7 Hz, 1H), 1.86 (ddd,J=13.6, 7.9, 3.6 Hz, 2H), 1.78-1.56 (m, 2H), 1.51 (ddd, J=12.5, 6.3, 2.9Hz, 2H), 0.89 (d, J=4.0 Hz, 3H), 0.89 (d, J=4.0 Hz, 3H). ¹⁹F NMR (377MHz, CDCl₃) δ −115.92 (s). ¹³C NMR (101 MHz, CDCl₃) δ 174.54, 172.68,172.33, 171.23, 169.84, 161.83 (d, J=244.9 Hz), 158.94, 158.20, 132.07,130.92 (d, J=7.9 Hz), 115.27 (d, J=21.2 Hz), 101.40, 54.15, 52.27,51.78, 50.78, 42.21, 41.93, 37.99, 37.47, 33.34, 26.66, 24.59, 22.77,22.09, 21.48, 12.30. ESI-MS (m/z): 588.3 (M+H)⁺.

N—((S)-3-(4-fluorophenyl)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide(96)

To a solution of compound 95 (60 mg, 0.1 mmol) in methanol (2 mL) wasadded NaBH₄ (38 mg, 1.0 mmol) dropwise at 0° C. The reaction mixture wasstirred at room temperature for 2 h and quenched with 1N HCl (5 mL). Theresolution mixture was stirred for 1 h at room temperature before beingextracted with ethyl acetate. The organic layer was washed with NaHCO₃and brine and then dried over Na₂SO₄. The filtrate was evaporated todryness and the crude product was purified on silica gel, eluting withmixtures of DCM/MeOH (20:1 to 15:1) to afford product 96 as a whitesolid (45 mg, 81%).

¹H NMR (400 MHz, Chloroform-d) δ 7.91 (d, J=7.3 Hz, 1H), 7.59 (d, J=8.1Hz, 1H), 7.52 (d, J=8.2 Hz, 1H), 7.21-7.10 (m, 2H), 6.97-6.86 (m, 2H),6.60 (s, 1H), 6.36 (d, J=1.0 Hz, 1H), 4.94 (td, J=7.6, 5.8 Hz, 1H), 4.54(td, J=8.5, 5.4 Hz, 1H), 4.00 (tt, J=6.9, 4.3 Hz, 1H), 3.90 (t, J=6.4Hz, 1H), 3.59 (d, J=4.8 Hz, 2H), 3.27 (dq, J=7.4, 3.8, 2.9 Hz, 2H), 3.19(dd, J=14.1, 5.8 Hz, 1H), 3.09 (dd, J=14.0, 7.3 Hz, 1H), 2.45 (d, J=0.9Hz, 3H), 2.36 (s, 1H), 2.29 (dd, J=10.4, 5.6 Hz, 1H), 2.22-1.96 (m, 2H),1.85 (dt, J=13.7, 4.9 Hz, 1H), 1.77-1.59 (m, 2H), 1.53 (tq, J=12.4, 4.8,3.5 Hz, 3H), 0.89 (s, 3H), 0.86 (s, 3H). ¹⁹F NMR (377 MHz, CDCl₃) δ−115.76 (s). ¹³C NMR (101 MHz, CDCl₃) δ 175.71, 172.94, 171.35, 170.03,161.86 (d, J=245.0 Hz), 159.21, 158.13, 132.03, 130.90 (d, J=7.8 Hz),115.34 (d, J=21.2 Hz), 101.35, 65.64, 54.28, 52.40, 50.40, 42.38, 41.83,38.29, 37.23, 32.73, 27.17, 24.83, 22.85, 22.00, 21.50, 12.31. ESI-MS(m/z): 560.3 (M+H)⁺.

N—((S)-3-(4-fluorophenyl)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide(97)

The procedure described for the synthesis of compound 91 was used withcompound 96 (37 mg, 0.067 mmol) as a starting material to give compound97 (18 mg, 49%).

¹H NMR (400 MHz, Methanol-d₄) δ 7.25-7.15 (m, 2H), 6.94-6.82 (m, 2H),6.28 (d, J=1.0 Hz, 1H), 4.74-4.68 (m, 1H), 4.36 (t, J=4.0 Hz, 1H), 4.27(ddd, J=8.2, 6.9, 2.9 Hz, 1H), 3.97-3.81 (m, 1H), 3.14 (dt, J=8.9, 4.6Hz, 3H), 2.89 (dd, J=14.0, 9.3 Hz, 1H), 2.35 (s, 3H), 2.19 (dddd,J=11.4, 9.0, 6.0, 3.2 Hz, 1H), 2.11-1.97 (m, 1H), 1.91 (ddt, J=9.7, 6.3,3.2 Hz, 1H), 1.77-1.66 (m, 1H), 1.64-1.44 (m, 4H), 1.43-1.32 (m, 1H),0.87 (d, J=6.4 Hz, 3H), 0.83 (d, J=6.4 Hz, 3H). ¹⁹F NMR (377 MHz, MeOD)δ −118.43 (s). ¹³C NMR (101 MHz, MeOD) δ 176.10, 173.37, 171.66, 171.36,161.88 (d, J=243.6 Hz), 159.80, 158.14, 132.76, 130.77 (d, J=7.9 Hz),114.64 (d, J=21.4 Hz), 100.52, 54.31, 52.39, 50.61, 41.61, 40.60, 37.03,36.55, 29.79, 25.52, 24.40, 21.86, 20.83, 20.60, 10.57. ESI-MS (m/z):558.3 (M+H)⁺.

5-(Trifluoromethyl)isoxazole-3-carboxylic acid (101)

A solution of triethylamine (1.48 mL, 8.0 mmol) in diethyl ether (8.0mL) was added dropwise with syringe pump over 7 h to a solution of ethylchlorooximidoacetate 98 (500 mg, 3.3 mmol) and3,3,3-trifluoro-2-bromopropene 99 (1.2 mL, 11 mmol) in diethyl ether (11mL). After addition, the reaction mixture was stirred overnight at roomtemperature and then quenched with water. The layers were separated andthe aqueous layer was extracted with diethyl ether. The combined organiclayers were dried over Na₂SO₄, filtered and partially concentrated. MeOH(7.0 mL) and 1N NaOH (7.0 mL) were added. The resulting mixture wasstirred at room temperature for 1 h. The reaction mixture waspartitioned between 1N HCl and CH₂Cl₂. The layers were separated, andthe aqueous layer was extracted with CH₂Cl₂. The combined organic layerswere dried over Na₂SO₄, filtered and partially concentrated to give thecrude product 101.

¹H NMR (400 MHz, Chloroform-d) δ 11.10 (s, 1H), 7.11 (s, 1H). ¹⁹F NMR(377 MHz, Chloroform-d) 6-64.34 (s). ESI-MS (m/z): 204.2 (M+Na)⁺.

Methyl(S)-2-((S)-4-methyl-2-((S)-3-(naphthalen-1-yl)-2-(5-(trifluoromethyl)isoxazole-3-carboxamido)propanamido)pentanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate(102)

Compound 102 was prepared by following the protocol described for thepreparation of compound 89.

¹H NMR (400 MHz, Acetone-d6) δ 8.35 (dd, J=16.6, 7.7 Hz, 2H), 8.28 (dd,J=8.4, 1.2 Hz, 1H), 7.94-7.84 (m, 2H), 7.78 (d, J=8.2 Hz, 1H), 7.59-7.47(m, 3H), 7.43-7.34 (m, 2H), 6.98 (s, 1H), 5.22-5.07 (m, 1H), 4.64-4.55(m, 1H), 4.49 (ddd, J=11.3, 7.2, 4.1 Hz, 1H), 3.88 (dd, J=14.4, 5.0 Hz,1H), 3.67 (s, 3H), 3.56 (dd, J=14.4, 9.0 Hz, 1H), 3.30-3.21 (m, 2H),2.90 (d, J=5.1 Hz, 2H), 2.44-2.24 (m, 2H), 2.15 (s, 1H), 1.82 (ddd,J=10.6, 6.4, 4.4 Hz, 1H), 1.77-1.63 (m, 2H), 1.62-1.45 (m, 2H), 0.91 (d,J=4.9 Hz, 3H), 0.89 (d, J=4.9 Hz, 3H). ¹⁹F NMR (377 MHz, Acetone-d6) δ−64.81 (s). ESI-MS (m/z): 674.2 (M+H)⁺.

N—((S)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-5-(trifluoromethyl)isoxazole-3-carboxamide(103)

Compound 103 was prepared by following the protocol described for thepreparation of compound 90.

¹H NMR (400 MHz, Methanol-d₄) δ 8.28-8.18 (m, 1H), 7.96 (d, J=8.8 Hz,1H), 7.83 (dd, J=8.2, 1.4 Hz, 1H), 7.74 (d, J=8.2 Hz, 1H), 7.52 (ddd,J=8.4, 6.8, 1.5 Hz, 1H), 7.49-7.41 (m, 2H), 7.37 (dd, J=8.2, 7.0 Hz,1H), 7.25 (d, J=1.1 Hz, 1H), 5.09 (dd, J=9.5, 5.0 Hz, 1H), 4.45 (dd,J=8.3, 6.3 Hz, 1H), 4.04 (ddq, J=8.8, 6.2, 3.3 Hz, 1H), 3.83 (dd,J=14.4, 5.0 Hz, 1H), 3.61-3.42 (m, 3H), 3.20 (dd, J=7.9, 5.0 Hz, 2H),2.42-2.28 (m, 1H), 2.12-2.07 (m, 1H), 2.05-1.96 (m, 1H), 1.86-1.74 (m,1H), 1.65 (qd, J=10.1, 8.9, 5.7 Hz, 4H), 1.53-1.40 (m, 1H), 0.95 (d,J=6.1 Hz, 3H), 0.91 (d, J=6.1 Hz, 3H). ¹⁹F NMR (377 MHz, Methanol-d₄) δ−65.62 (s). ESI-MS (m/z): 646.2 (M+H)⁺.

N—((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-5-(trifluoromethyl)isoxazole-3-carboxamide(104)

Compound 104 was prepared by following the protocol described for thepreparation of compound 91.

¹H NMR (400 MHz, Methanol-d₄) δ 8.25 (d, J=8.4 Hz, 1H), 7.85 (d, J=8.0Hz, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.59-7.51 (m, 1H), 7.51-7.42 (m, 2H),7.37 (t, J=7.6 Hz, 1H), 7.25 (s, 1H), 5.08 (dd, J=9.7, 4.8 Hz, 1H),4.54-4.40 (m, 2H), 4.04 (ddq, J=11.6, 7.2, 3.8 Hz, 1H), 3.84 (dd,J=14.4, 4.8 Hz, 1H), 3.46 (dd, J=14.5, 9.7 Hz, 1H), 3.40-3.30 (m, 1H),3.27-3.16 (m, 2H), 2.32 (dtd, J=11.8, 5.7, 3.0 Hz, 1H), 2.26-2.14 (m,1H), 2.10-1.98 (m, 1H), 1.84-1.57 (m, 4H), 1.48 (qt, J=9.8, 3.4 Hz, 1H),0.97 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H). ¹⁹F NMR (377 MHz, MeOD)δ −65.69 (s). ESI-MS (m/z): 644.2 (M+H)⁺.

Methyl(S)-2-(5-methylisoxazole-3-carboxamido)-3-(naphthalen-1-yl)propanoate(106)

A solution of compound 105 (530 mg, 2.0 mmol) and5-methylisoxazole-3-carboxylic acid (254 mg, 2.0 mmol) in DCM (10 mL)was treated with 1-hydroxybenzotriazole (350 mg, 2.6 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (497 mg, 2.6mmol) and N,N-diisopropylethyl amine (1.48 mL, 8.0 mmol) at 0° C. Theice bath was removed, and the reaction mixture was stirred at roomtemperature overnight. The reaction mixture was then diluted with EtOAc(60 mL) and the organic layer washed with 1N HCl, NaHCO₃ (5%) and brineand finally dried over Na₂SO₄. The solvent was evaporated, and the crudemixture was purified on silica gel, eluting with mixtures of DCM/MeOH(50:1 to 30:1) to afford product 106 (470 mg, 70%). ¹H NMR (400 MHz,Chloroform-d) δ 8.17 (d, J=8.4 Hz, 1H), 7.93-7.82 (m, 1H), 7.77 (d,J=8.1 Hz, 1H), 7.62-7.31 (m, 4H), 6.40 (s, 1H), 5.17 (q, J=7.2 Hz, 1H),3.77-3.65 (m, 2H), 3.63 (s, 3H), 2.42 (s, 3H). ¹³C NMR (101 MHz, CDCl₃)δ 171.58, 171.26, 158.88, 158.15, 133.91, 132.07, 131.98, 128.92,128.10, 127.53, 126.45, 125.81, 125.31, 123.35, 101.33, 53.16, 52.38,35.53, 12.26. ESI-MS (m/z): 339.2 (M+H)⁺.

Methyl 2-(5-methylisoxazole-3-carboxamido)-3-(naphthalen-1-yl)propanoate(107)

To a solution of compound 106 (450 mg, 1.33 mmol) in THF (7.0 mL) wasadded 2N LiOH (1.33 mL, 2.66 mmol) dropwise at 0° C. The reaction wasmixture was then stirred at room temperature for 2 h before addition of1N HCl (adjusted to pH=1-2). The reaction mixture was extracted withethyl acetate, dried over Na₂SO₄, filtered and concentrated to givecompound 107 (358 mg, 83%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.05 (s, 1H), 9.02 (t, J=6.4 Hz, 1H), 8.16(d, J=8.2 Hz, 1H), 7.93 (d, J=7.8 Hz, 1H), 7.79 (d, J=7.8 Hz, 1H),7.72-7.25 (m, 4H), 6.45 (d, J=4.8 Hz, 1H), 4.77 (dp, J=12.2, 4.1 Hz,1H), 3.92-3.67 (m, 1H), 3.52 (td, J=12.1, 10.2, 3.7 Hz, 1H), 2.43 (d,J=5.4 Hz, 3H). ¹³C NMR (101 MHz, DMSO) δ 172.97, 171.68, 159.23, 158.83,134.23, 133.91, 131.85, 129.23, 127.81, 127.70, 126.76, 126.10, 125.82,123.66, 101.69, 53.41, 33.69, 12.25. ESI-MS (m/z): 325.2 (M+H)⁺.

N—((R)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide(111)

A solution of compound 108 (112 mg, 0.32 mmol) and compound 107 (105 mg,0.32 mmol) in DCM (3 mL) was treated with 1-hydroxybenzotriazole (47 mg,0.35 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(67 mg, 0.35 mmol) and N,N-diisopropylethyl amine (0.26 mL, 1.4 mmol) at0° C. The reaction mixture was stirred at room temperature overnightbefore being diluted with EtOAc (30 mL). The solution was then washedwith 1N HCl, NaHCO₃ (5%) and brine and dried over Na₂SO₄. The solventwas evaporated, and the crude mixture was purified with preparative TLC(DCM/MeOH=25:1) to afford the less polar compound 109 (57 mg, 29%) andthe more polar compound 89 (90 mg, 45%).

Compound 109: ¹H NMR (400 MHz, Chloroform-d) δ 8.91 (d, J=4.9 Hz, 1H),8.78 (d, J=9.1 Hz, 1H), 8.28-8.18 (m, 1H), 7.87-7.79 (m, 1H), 7.70 (d,J=8.1 Hz, 1H), 7.55-7.39 (m, 3H), 7.35 (dd, J=8.2, 7.0 Hz, 1H), 6.66 (s,1H), 6.40 (d, J=1.0 Hz, 1H), 6.11 (d, J=9.3 Hz, 1H), 5.30 (dt, J=8.9,6.5 Hz, 1H), 4.70 (td, J=9.9, 4.4 Hz, 1H), 4.10 (ddd, J=12.0, 4.9, 3.3Hz, 1H), 3.88 (dd, J 14.0, 6.1 Hz, 1H), 3.74 (s, 3H), 3.71-3.65 (m, 1H),3.36-3.22 (m, 2H), 2.46 (d, J=0.9 Hz, 3H), 2.18-2.09 (m, 1H), 2.07-1.84(m, 3H), 1.78-1.65 (m, 2H), 1.56 (td, J=12.2, 3.2 Hz, 1H), 1.43 (ddt,J=11.4, 6.6, 3.3 Hz, 1H), 1.30-1.13 (m, 1H), 0.86 (dd, J=18.5, 6.6 Hz,7H). ¹³C NMR (101 MHz, CDCl₃) δ 175.14, 172.26, 172.03, 171.11, 169.93,159.14, 158.48, 133.87, 133.25, 132.47, 128.57, 128.41, 127.47, 126.25,125.59, 125.46, 124.09, 102.00, 54.46, 53.40, 52.30, 51.52, 42.05,40.93, 39.88, 35.02, 33.01, 28.73, 24.60, 23.07, 21.82, 21.48, 12.32.

Compound 110 (37 mg, 67%) was prepared from compound 109 (57 mg, 0.093mmol) by following the protocol described for the preparation ofcompound 90.

Compound 110: ¹H NMR (400 MHz, Chloroform-d) δ 8.75 (d, J=8.4 Hz, 1H),8.49 (d, J=5.8 Hz, 1H), 8.22-8.10 (m, 1H), 7.80 (dd, J=6.9, 2.6 Hz, 1H),7.70 (d, J=7.9 Hz, 1H), 7.46 (ddt, J=9.6, 6.8, 3.5 Hz, 2H), 7.41-7.31(m, 2H), 6.75 (s, 1H), 6.55 (d, J=8.8 Hz, 1H), 6.36 (d, J=1.2 Hz, 1H),5.15 (q, J=7.3 Hz, 1H), 4.53 (dq, J=12.7, 4.1 Hz, 1H), 4.17 (d, J=6.3Hz, 1H), 3.83 (dd, J=14.0, 6.3 Hz, 1H), 3.79-3.69 (m, 1H), 3.62 (dd,J=14.1, 7.3 Hz, 1H), 3.54 (p, J=6.3, 5.8 Hz, 2H), 3.34-3.15 (m, 2H),2.43 (s, 3H), 2.10-1.94 (m, 1H), 1.94-1.75 (m, 2H), 1.65 (dtd, J=13.1,10.1, 8.4, 4.6 Hz, 2H), 1.56-1.34 (m, 2H), 1.34-1.16 (m, 3H), 0.81 (d,J=6.3 Hz, 3H), 0.78 (d, J=6.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ175.90, 173.25, 171.24, 170.37, 159.29, 158.29, 133.83, 133.01, 132.26,128.62, 128.24, 127.58, 126.23, 125.53, 125.43, 123.95, 101.88, 66.45,54.68, 52.66, 52.18, 42.17, 40.64, 39.16, 34.87, 33.01, 28.41, 24.59,23.11, 21.69, 21.30, 12.30. ESI-MS (m/z): 592.3 (M+H)⁺.

5-Methyl-N—((R)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)isoxazole-3-carboxamide(111)

Compound 111 (17 mg, 48%) was prepared from compound 110 (35 mg, 0.06mmol) by following the protocol described for the preparation ofcompound 91.

¹H NMR (400 MHz, Methanol-d₄) δ 8.29-8.18 (m, 1H), 7.89 (dd, J=8.1, 1.6Hz, 1H), 7.83-7.76 (m, 1H), 7.61-7.44 (m, 2H), 7.44-7.35 (m, 2H), 6.50(ddd, J=9.5, 2.4, 1.0 Hz, 1H), 4.51-4.38 (m, 1H), 4.21-4.01 (m, 1H),4.00-3.86 (m, 1H), 3.64 (td, J=9.1, 3.0 Hz, 2H), 3.33 (m, 1H), 3.29-3.25(m, 2H), 3.26 (s, 1H), 3.20 (dt, J=8.9, 6.2 Hz, 2H), 2.49 (dt, J=2.1,1.0 Hz, 3H), 2.38-2.11 (m, 2H), 1.95 (ddt, J=13.3, 6.4, 3.2 Hz, 1H),1.88-1.54 (m, 2H), 1.52-1.33 (m, 1H), 1.25-1.04 (m, 1H), 0.68 (d, J=5.3Hz, 3H), 0.65 (d, J=5.3 Hz, 3H). ESI-MS (m/z): 590.3 (M+H)⁺.

Methyl(S)-2-((S)-4-methyl-2-((S)-2-(3-methylthiophene-2-carboxamido)-3-(naphthalen-1-yl)propanamido)pentanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate(113)

A solution of compound 112 (162 mg, 0.3 mmol) and3-methylthiophene-2-carboxylic acid (43 mg, 0.3 mmol) in DCM (3.5 mL)was treated with 1-hydroxybenzotriazole (55 mg, 0.4 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (78 mg, 0.4mmol) and N,N-diisopropylethyl amine (0.22 mL, 1.26 mmol) at 0° C. Thereaction mixture was stirred at room temperature overnight before beingdiluted with EtOAc (30 mL). The solution was washed with 1N HCl, NaHCO₃(5%) and brine and the organic layer was dried over Na₂SO₄. The solventwas evaporated, and the crude mixture was purified on silica gel,eluting with mixtures of DCM/MeOH (50:1 to 20:1) to afford compound 113(142 mg, 75%).

¹H NMR (400 MHz, Chloroform-d) δ 8.33-8.17 (m, 1H), 8.07 (d, J=7.5 Hz,1H), 7.82 (dd, J=8.0, 1.6 Hz, 1H), 7.79-7.69 (m, 1H), 7.55-7.43 (m, 3H),7.42-7.32 (m, 2H), 7.21 (d, J=4.9 Hz, 1H), 6.84 (s, 1H), 6.78 (d, J=5.0Hz, 1H), 6.60 (d, J=7.3 Hz, 1H), 5.02 (td, J=7.5, 6.2 Hz, 1H), 4.59(dtd, J=22.8, 8.1, 7.5, 4.4 Hz, 2H), 3.75 (dd, J=4.2, 1.6 Hz, 1H), 3.70(d, J=2.3 Hz, 3H), 3.66-3.53 (m, 2H), 3.18 (ddd, J=7.4, 4.3, 2.0 Hz,2H), 2.48-2.30 (m, 2H), 2.25 (s, 3H), 2.14-2.01 (m, 1H), 1.84 (ddt,J=15.7, 13.3, 4.3 Hz, 2H), 1.66 (tdd, J=12.9, 6.9, 2.4 Hz, 2H),1.59-1.45 (m, 2H), 0.89 (d, J=4.0 Hz, 3H), 0.87 (d, J=4.0 Hz, 3H). ¹³CNMR (101 MHz, CDCl₃) δ 174.50, 172.45, 172.38, 170.90, 163.02, 140.99,133.87, 132.82, 132.19, 131.85, 130.87, 128.74, 127.83, 127.35, 126.45,125.75, 125.32, 123.85, 67.08, 54.40, 52.29, 52.18, 50.50, 42.19, 41.82,37.99, 34.87, 33.70, 26.64, 24.68, 22.88, 22.03, 21.44, 15.56. ESI-MS(m/z): 635.2 (M+H)⁺.

N—((S)-1-(((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-3-methylthiophene-2-carboxamide(114)

Compound 114 (103 mg, 85%) was prepared from compound 113 (130 mg, 0.2mmol) by following the protocol described for the preparation ofcompound 90.

¹H NMR (400 MHz, Methanol-d₄) δ 8.24-8.08 (m, 1H), 7.86 (d, J=8.7 Hz,1H), 7.72 (dd, J=8.0, 1.4 Hz, 1H), 7.63 (d, J=8.1 Hz, 1H), 7.37 (dddd,J=24.4, 8.1, 6.8, 1.3 Hz, 3H), 7.31-7.21 (m, 2H), 6.69 (d, J=5.0 Hz,1H), 4.90 (dd, J=9.5, 5.0 Hz, 1H), 4.33 (dd, J=8.9, 6.0 Hz, 1H),4.06-3.83 (m, 1H), 3.69 (dd, J=14.4, 5.0 Hz, 1H), 3.50-3.28 (m, 3H),3.27-3.15 (m, 1H), 3.05 (dd, J=7.6, 5.1 Hz, 2H), 2.32-2.13 (m, 1H), 2.05(s, 3H), 1.71-1.57 (m, 2H), 1.51 (ddt, J=12.6, 10.3, 4.1 Hz, 3H), 1.33(ddt, J=13.4, 10.1, 5.2 Hz, 1H), 1.20-1.06 (m, 1H), 0.84 (d, J=6.5 Hz,3H), 0.82 (d, J=6.4 Hz, 3H). ¹³C NMR (101 MHz, MeOD) δ 175.93, 173.50,172.26, 164.07, 140.98, 134.03, 133.00, 132.10, 131.19, 130.30, 128.47,127.49, 127.38, 125.98, 125.36, 125.05, 123.38, 64.22, 60.15, 54.42,52.50, 52.46, 41.62, 40.75, 37.31, 34.00, 32.69, 32.66, 25.78, 24.51,22.10, 20.69, 14.21. ESI-MS (m/z): 607.2 (M+H)⁺.

3-Methyl-N—((S)-1-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)thiophene-2-carboxamide(115)

Compound 115 (61 mg, 64%) was prepared from compound 114 (95 mg, 0.16mmol) by following the protocol described for the preparation ofcompound 91.

¹H NMR (400 MHz, Methanol-d₄) δ 8.14 (dd, J=8.5, 5.5 Hz, 1H), 7.73 (ddd,J=8.2, 3.3, 1.3 Hz, 1H), 7.64 (dd, J=8.2, 4.3 Hz, 1H), 7.41 (tdd, J=7.0,3.7, 1.4 Hz, 1H), 7.35 (ddt, J=8.4, 6.9, 3.4 Hz, 2H), 7.31-7.17 (m, 2H),6.70 (t, J=5.2 Hz, 1H), 4.90 (dt, J=9.2, 4.6 Hz, 1H), 4.46-4.30 (m, 2H),4.12-3.86 (m, 1H), 3.80-3.64 (m, 1H), 3.43-3.28 (m, 1H), 3.20 (p, J=1.6Hz, 1H), 3.06 (dd, J=7.6, 4.8 Hz, 2H), 2.31-2.14 (m, 1H), 2.05 (m, 4H),1.94-1.80 (m, 1H), 1.73-1.43 (m, 4H), 1.16 (s, 1H), 0.84 (d, J=6.4 Hz,3H), 0.82 (d, J=6.4 Hz, 3H). ESI-MS (m/z): 605.2 (M+H)⁺.

Methyl ((benzyloxy)carbonyl)-L-leucinate (117)

To a solution of compound 116 (360 mg, 2.0 mmol) in DCM (10 mL) wasadded benzyl carbonochloridate (340 mg, 2.0 mmol) and Et₃N (0.54 mL, 4.0mmol). The reaction mixture was stirred overnight at room temperatureand then diluted with DCM (30 mL). The solution was washed with 1N HCl,NaHCO₃ (5%) and brine and the organic layer was dried over Na₂SO₄. Thesolvent was evaporated, and the crude mixture was purified on silicagel, eluting with mixtures of Hex/EA (5:1 to 2:1) to afford compound 117(447 mg, 80%).

¹H NMR (400 MHz, Chloroform-d) δ 7.39-7.28 (m, 5H), 5.29 (d, J=7.4 Hz,1H), 5.10 (s, 2H), 4.40 (td, J=9.1, 5.1 Hz, 1H), 3.72 (s, 3H), 1.77-1.58(m, 2H), 1.52 (ddd, J=13.5, 9.3, 5.5 Hz, 1H), 0.94 (t, J=6.9 Hz, 6H).¹³C NMR (101 MHz, CDCl₃) δ 173.65, 156.00, 136.29, 128.50, 128.14,128.08, 66.96, 52.48, 52.26, 41.72, 24.73, 22.82, 21.82. ESI-MS (m/z):280.1 (M+H)⁺.

((Benzyloxy)carbonyl)-L-leucine (118)

To a solution of compound 117 (430 mg, 1.54 mmol) in THF (10 mL) wasadded LiOH (1M, 1.85 mL, 1.85 mmol). The reaction mixture was stirredfor 1.5 h at room temperature. The pH of the solution was then adjustedto ˜1-2 by addition of 1N HCl. The reaction mixture was extracted withethyl acetate, dried over Na₂SO₄, filtrated and concentrated to givecompound 118 (335 mg, 82%).

¹H NMR (400 MHz, Chloroform-d) δ 10.20 (s, 1H), 7.49-7.30 (m, 6H),5.26-5.06 (m, 3H), 4.42 (td, J=9.1, 4.7 Hz, 1H), 1.85-1.64 (m, 2H), 1.56(ddd, J=13.4, 9.4, 5.3 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 178.24,156.15, 136.10, 128.55, 128.24, 128.12, 67.19, 52.39, 41.46, 24.77,22.83, 21.73. ESI-MS (m/z): 266.1 (M+H)⁺.

Methyl(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate(119)

A solution of compound 37 280 mg (1.06 mmol) and compound 118 (350 mg,1.0 mmol) in DCM (5 mL) was treated with 1-hydroxybenzotriazole (176 mg,1.3 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(250 mg, 1.3 mmol) and N,N-diisopropylethyl amine (0.74 mL, 4.0 mmol) at0° C. The reaction mixture was stirred at room temperature overnightbefore being diluted with EtOAc (40 mL). The solution was then washedwith 1N HCl, NaHCO₃ (5%) and brine and the organic layer dried overNa₂SO₄. The solvent was evaporated, and the residue was purified onsilica gel, eluting with mixtures of DCM/MeOH (50:1 to 20:1) to affordcompound 119 (312 mg, 70%).

¹H NMR (400 MHz, Chloroform-d) δ 8.05 (d, J=7.3 Hz, 1H), 7.39-7.29 (m,5H), 6.81 (s, 1H), 5.73 (d, J=8.9 Hz, 1H), 5.08 (s, 2H), 4.52 (ddd,J=11.5, 7.3, 3.8 Hz, 1H), 4.42 (td, J=8.9, 5.4 Hz, 1H), 3.69 (s, 3H),3.28-3.16 (m, 3H), 2.48-2.18 (m, 2H), 2.11-1.98 (m, 1H), 1.85 (dtd,J=17.2, 8.6, 4.7 Hz, 2H), 1.78-1.59 (m, 2H), 1.59-1.47 (m, 2H), 0.96 (s,3H), 0.94 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.54, 173.03, 172.44,156.06, 136.45, 128.47, 128.05, 127.91, 66.74, 53.34, 52.24, 50.39,42.51, 42.15, 37.86, 33.30, 26.47, 24.59, 22.91, 22.15, 21.47. ESI-MS(m/z): 448.2 (M+H)⁺.

Benzyl((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate(120)

Compound 120 (161 mg, 64%) was prepared from compound 119 (270 mg, 0.6mmol) by following the protocol described for the preparation ofcompound 90.

¹H NMR (400 MHz, Chloroform-d) δ 7.70 (d, J=8.1 Hz, 1H), 7.31 (m, 5H),6.79 (s, 1H), 5.99 (d, J=8.4 Hz, 1H), 5.07 (d, J=4.0 Hz, 2H), 4.27 (td,J=9.0, 5.0 Hz, 1H), 4.05 (td, J=7.1, 3.8 Hz, 2H), 3.55 (q, J=5.6 Hz,2H), 3.19 (dt, J=7.7, 4.1 Hz, 2H), 2.32-2.13 (m, 3H), 2.04-1.98 (m, 1H),1.82-1.76 (m, 1H), 1.71-1.44 (m, 5H), 0.93 (s, 3H), 0.91 (s, 3H). ¹³CNMR (101 MHz, CDCl₃) δ 175.84, 173.39, 156.20, 136.41, 128.47, 128.06,127.92, 66.77, 65.58, 53.92, 49.38, 42.24, 37.87, 32.70, 26.66, 24.76,23.02, 22.01, 21.33. ESI-MS (m/z): 420.2 (M+H)⁺.

Benzyl((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)carbamate(121)

Compound 121 (17 mg, 48%) was prepared from compound 120 (35 mg, 0.084mmol) by following the protocol described for the preparation ofcompound 91.

¹H NMR (400 MHz, Methanol-d₄) δ 7.30-7.14 (m, 5H), 5.08-4.89 (m, 2H),4.34 (dd, J=4.1, 2.1 Hz, 1H), 4.03 (dt, J=8.1, 4.2 Hz, 1H), 3.89 (tt,J=9.3, 3.7 Hz, 1H), 3.24-3.18 (m, 1H), 3.18-3.02 (m, 2H), 2.16 (dtd,J=11.6, 5.8, 2.9 Hz, 1H), 2.10-1.98 (m, 1H), 1.95-1.81 (m, 1H),1.74-1.40 (m, 4H), 1.39-1.27 (m, 1H), 0.86 (d, J=6.4 Hz, 3H), 0.82 (d,J=6.4 Hz, 3H). ¹³C NMR (101 MHz, MeOD) δ 176.15, 174.40, 156.95, 136.88,128.07, 127.58, 127.39, 127.37, 98.36, 66.15, 53.92, 50.60, 41.60,40.82, 36.97, 29.80, 25.34, 24.42, 21.95, 20.55. ESI-MS (m/z): 418.2(M+H)⁺.

Methyl(S)-2-((S)-4-methyl-2-(5-methylisoxazole-3-carboxamido)pentanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate(123)

A solution of compound 122 (139 mg, 0.4 mmol) and5-methylisoxazole-3-carboxylic acid (51 mg, 0.4 mmol) in DCM (5 mL) wastreated with 1-hydroxybenzotriazole (68 mg, 0.5 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (96 mg, 0.5mmol) and N,N-diisopropylethyl amine (0.35 mL, 2.0 mmol) at 0° C. Thereaction mixture was stirred at room temperature overnight before beingdiluted with EtOAc (40 mL). The solution was washed with 1N HCl, NaHCO₃(5%) and brine and the organic layer was dried over Na₂SO₄. The solventwas evaporated, and the residue was purified on silica gel, eluting withmixtures of DCM/MeOH (30:1 to 20:1) to afford compound 123 (145 mg,86%).

¹H NMR (400 MHz, Chloroform-d) δ 8.09 (d, J=7.3 Hz, 1H), 7.49 (d, J=8.7Hz, 1H), 6.82 (s, 1H), 6.40 (d, J=1.0 Hz, 1H), 4.81 (td, J=8.8, 5.1 Hz,1H), 4.54 (ddd, J=11.5, 7.3, 3.9 Hz, 1H), 3.71 (s, 3H), 3.30 (ddd,J=7.5, 4.5, 2.4 Hz, 2H), 2.47 (s, 3H), 2.45-2.28 (m, 2H), 2.13-2.00 (m,2H), 1.88 (ddd, J=13.4, 7.7, 3.8 Hz, 2H), 1.83-1.61 (m, 3H), 1.61-1.47(m, 1H), 0.98 (m, 3H), 0.96 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.82,172.32, 172.14, 171.08, 158.88, 158.46, 101.41, 52.30, 51.65, 50.61,42.25, 42.11, 37.90, 33.33, 26.61, 24.71, 22.87, 22.10, 21.40, 12.31.ESI-MS (m/z): 423.2 (M+H)⁺.

N—((S)-1-(((S)-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-5-methylisoxazole-3-carboxamide(124)

Compound 124 (86 mg, 82%) was prepared from compound 123 (110 mg, 0.27mmol) by following the protocol described for the preparation ofcompound 90.

¹H NMR (400 MHz, Chloroform-d) δ 7.85 (d, J=7.9 Hz, 1H), 7.63 (d, J=8.6Hz, 1H), 6.69 (d, J=2.3 Hz, 1H), 6.41 (d, J=1.1 Hz, 1H), 4.72 (td,J=8.5, 4.2 Hz, 1H), 4.06 (td, J=7.5, 3.9 Hz, 1H), 3.59 (t, J=4.4 Hz,2H), 3.39-3.20 (m, 2H), 2.46 (d, J=0.9 Hz, 3H), 2.37-2.26 (m, 1H), 2.19(ddd, J=14.1, 10.9, 4.6 Hz, 1H), 2.05 (ddq, J=11.1, 5.9, 2.9 Hz, 1H),1.92-1.78 (m, 1H), 1.79-1.59 (m, 6H), 1.58-1.38 (m, 1H), 0.95 (s, 3H),0.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.81, 172.46, 171.09, 158.98,158.49, 101.50, 65.63, 52.17, 49.61, 42.35, 41.98, 38.00, 32.62, 26.78,24.86, 22.98, 21.99, 21.43, 12.30. ESI-MS (m/z): 395.2 (M+H)⁺.

5-Methyl-N—((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)pentan-2-yl)isoxazole-3-carboxamide(125)

Compound 125 (26 mg, 53%) was prepared from compound 124 (52 mg, 0.13mmol) by following the protocol described for the preparation ofcompound 91.

¹H NMR (400 MHz, Methanol-d₄) δ 6.56-6.44 (m, 1H), 4.60 (tdd, J=8.5,5.6, 2.6 Hz, 1H), 4.56-4.39 (m, 1H), 4.24-3.88 (m, 1H), 3.36 (d, J=3.7Hz, 2H), 3.30-3.20 (m, 2H), 2.50 (dd, J=2.2, 0.9 Hz, 3H), 2.34 (dddd,J=20.4, 11.7, 6.6, 3.3 Hz, 1H), 2.23-2.09 (m, 1H), 2.03 (ddt, J=13.1,6.4, 3.2 Hz, 1H), 1.89-1.60 (m, 3H), 1.57-1.40 (m, 1H), 1.01 (d, J=6.2Hz, 3H), 0.99 (d, J=6.2 Hz, 3H). ¹³C NMR (101 MHz, MeOD) δ 176.10,173.19, 171.63, 159.95, 158.32, 100.64, 98.33, 53.80, 52.39, 50.56,41.61, 40.55, 37.01, 29.80, 25.40, 24.62, 21.90, 20.83, 10.62. ESI-MS(m/z): 393.2 (M+H)⁺.

Ethyl(S,E)-4-((S)-4-methyl-2-((S)-2-(5-methylisoxazole-3-carboxamido)-3-(naphthalen-1-yl)propanamido)pentanamido)-5-((S)-2-oxopiperidin-3-yl)pent-2-enoate(126)

To a solution of triethyl phosphonoacetate (20 mg, 0.09 mmol) inanhydrous THF (0.5 mL), at −78° C. under an argon atmosphere, was addedsodium hydride (2.0 mg, 0.05 mmol). The suspension was stirred for 30min at the same temperature, and a solution of compound 91(12.5 mg,0.021 mmol) in anhydrous THF was added dropwise. The reaction wasgradually warmed to −30° C. and stirred for 1 h and upon completion wasquenched by the addition of saturated aqueous NH₄Cl. The mixture wasdiluted with AcOEt (15 mL) and the water layer was extracted with AcOEt.The combined organic layer was dried over Na₂SO₄, and the solvent wasevaporated under reduced pressure. The residue was purified bypreparative TLC (DCM/MeOH, 20/1) to give compound 126 (8.1 mg, 58%).

¹H NMR (400 MHz, Chloroform-d) δ 8.28 (d, J=8.3 Hz, 1H), 7.90 (d, J=6.8Hz, 1H), 7.84 (dd, J=8.2, 1.4 Hz, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.55(ddd, J=8.3, 6.8, 1.4 Hz, 2H), 7.48 (ddd, J=8.0, 6.8, 1.2 Hz, 1H),7.44-7.33 (m, 2H), 6.80 (dd, J=15.7, 5.4 Hz, 1H), 6.64 (d, J=8.1 Hz,1H), 6.37 (d, J=1.0 Hz, 1H), 6.01 (s, 1H), 5.91 (dd, J=15.7, 1.5 Hz,1H), 4.98 (q, J=7.3 Hz, 1H), 4.46 (td, J=8.7, 8.2, 4.7 Hz, 2H),3.78-3.72 (m, 4H), 3.59 (dd, J=14.3, 7.2 Hz, 1H), 3.32-3.18 (m, 2H),2.45 (s, 3H), 2.22 (dd, J=10.6, 5.5 Hz, 1H), 2.02-1.96 (m, 2H),1.84-1.79 (m, 2H), 1.70-1.62 (m, 2H), 1.53-1.42 (m, 4H), 1.40-1.25 (m,3H), 0.86 (d, J=4.4 Hz, 3H), 0.84 (d, J=4.4 Hz, 3H). ¹³C NMR (101 MHz,CDCl₃) δ 174.93, 171.81, 171.28, 170.02, 166.77, 159.39, 158.14, 147.83,133.94, 132.45, 132.00, 128.85, 128.02, 127.84, 126.45, 125.75, 125.47,123.75, 120.66, 101.32, 54.22, 52.30, 51.57, 49.50, 42.32, 41.49, 38.71,35.86, 35.04, 27.93, 24.79, 22.92, 21.83, 21.50, 12.32. ESI-MS (m/z):660.3 (M+H)⁺.

N—((S)-1-(((S)-1-(((S)-1,1-dimethoxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide(127)

To a solution of compound 91 (23 mg, 0.039 mmol) in MeOH (2 mL) wasadded TsOH (0.5 mg). The reaction mixture was stirred overnight at roomtemperature. After removal of the solvent, the residue was purified withpreparative TLC (DCM/MeOH=20:1) to give compound 127 (16.3 mg, 66%).

¹H NMR (400 MHz, Methanol-d₄) δ 8.27 (d, J=8.4 Hz, 1H), 7.86 (dd, J=8.1,1.4 Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.56 (ddd, J=8.5, 6.8, 1.4 Hz, 1H),7.53-7.41 (m, 2H), 7.37 (dd, J=8.2, 7.0 Hz, 1H), 6.32 (d, J=1.1 Hz, 1H),5.03 (ddd, J=9.5, 5.0, 1.9 Hz, 1H), 4.42 (t, J=7.5 Hz, 1H), 4.31-4.22(m, 1H), 4.22-4.09 (m, 1H), 3.82 (dd, J=14.4, 4.9 Hz, 1H), 3.41 (s, 3H),3.39 (s, 3H), 3.38-3.36 (m, 1H), 3.23 (tt, J=7.2, 3.8 Hz, 3H), 2.43 (d,J=0.9 Hz, 3H), 2.31 (dddd, J=11.8, 9.2, 5.9, 3.1 Hz, 1H), 2.16 (ddd,J=14.2, 12.2, 3.3 Hz, 1H), 2.10-2.03 (m, 1H), 1.84-1.54 (m, 4H),1.53-1.41 (m, 1H), 1.37 (dd, J=7.0, 5.1 Hz, 1H), 0.98 (dd, J=6.4 Hz,3H), 0.95 (dd, J=6.4 Hz, 3H). ¹³C NMR (101 MHz, MeOD) δ 175.92, 173.39,173.31, 171.61, 171.57, 159.89, 158.08, 134.04, 132.72, 131.99, 128.44,127.39, 127.34, 125.92, 125.31, 124.99, 123.24, 105.88, 100.52, 54.62,53.83, 52.55, 41.61, 40.57, 37.05, 34.38, 30.70, 25.50, 24.41, 21.83,20.93, 20.70, 10.55. ESI-MS (m/z): 604.2 (M−OCH₃)⁺.

Benzyl((S)-1-(((S)-1-(((1R,2S)-1-cyano-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamateand benzyl((S)-1-(((S)-1-(((1S,2S)-1-cyano-1-hydroxy-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamate(128 and 129)

To a solution of 18 (31 mg, 0.05 mmol) in DCM (0.5 mL) was added NaHSO₃(1M, 0.06 mL, 0.06 mmol). The mixture was stirred at room temperaturefor 30 minutes, and then a solution of KCN (1M, 0.06 mL, 0.06 mmol) wasadded. The mixture was stirred overnight at room temperature. Thereaction mixture was diluted with DCM (30 mL) and washed with water. Theorganic layer was dried over Na₂SO₄, and the solvent was evaporatedunder reduced pressure. The residue was purified by preparative TLC(DCM/MeOH, 20/1) to give the less polar isomer 128 (11 mg, 34%) and themore polar isomer 129 (14 mg, 43%).

Compound 128: ¹H NMR (400 MHz, Methanol-d₄) δ 8.10 (d, J=8.3 Hz, 1H),7.76 (dt, J=8.1, 1.8 Hz, 1H), 7.66 (dt, J=7.1, 3.1 Hz, 1H), 7.49-7.34(m, 2H), 7.34-7.24 (m, 2H), 7.21-7.16 (m, 2H), 7.16-7.02 (m, 3H),4.90-4.87 (m, 1H), 4.60-4.40 (m, 1H), 4.40-4.20 (m, 2H), 4.15-4.08 (m,1H), 3.67-3.56 (m, 1H), 3.18-2.98 (m, 3H), 2.37-2.02 (m, 2H), 1.97-1.85(m, 1H), 1.78-1.42 (m, 7H), 1.34 (t, J=11.2 Hz, 1H), 0.92-0.75 (m, 6H).¹³C NMR (101 MHz, MeOD) δ 175.51, 175.44, 173.86, 172.71, 156.88,136.69, 134.06, 133.11, 132.01, 128.48, 128.04, 127.50, 127.27, 125.86,125.27, 125.00, 123.33, 118.89, 66.19, 63.62, 55.91, 52.30, 49.58,41.55, 40.59, 37.62, 36.97, 34.46, 31.42, 25.77, 24.47, 21.26, 20.52.ESI-MS (m/z): 642.3 (M+H)⁺.

Compound 129: ¹H NMR (400 MHz, Methanol-d₄) δ 8.22 (d, J=8.3 Hz, 1H),7.88 (d, J=8.1 Hz, 1H), 7.77 (dd, J=6.7, 2.9 Hz, 1H), 7.61-7.46 (m, 2H),7.45-7.36 (m, 2H), 7.34-7.28 (m, 3H), 7.26-7.14 (m, 2H), 5.06-4.97 (m,2H), 4.85-4.77 (m, 1H), 4.63 (dq, J=15.8, 6.1, 5.4 Hz, 1H), 4.50-4.33(m, 1H), 4.22 (dt, J=12.1, 3.8 Hz, 1H), 4.02 (ddd, J=9.7, 5.2, 2.6 Hz,1H), 3.73 (dt, J=14.5, 4.2 Hz, 1H), 3.36 (d, J=4.0 Hz, 1H), 3.28-3.12(m, 3H), 2.37 (tdd, J=17.6, 10.4, 4.0 Hz, 1H), 2.24-2.09 (m, 1H),2.08-1.96 (m, 1H), 1.87-1.52 (m, 4H), 1.52-1.40 (m, 1H), 0.98-0.91 (m,6H). ¹³C NMR (101 MHz, MeOD) δ 176.09, 175.51, 173.96, 172.67, 156.81,136.70, 134.03, 133.11, 132.03, 128.44, 128.01, 127.49, 127.28, 127.25,125.83, 125.26, 125.00, 123.33, 123.28, 118.68, 66.16, 62.90, 55.61,52.29, 49.58, 41.55, 40.60, 37.09, 34.46, 30.66, 25.77, 24.38, 21.90,20.72. ESI-MS (m/z): 642.3 (M+H)⁺.

N-((2S)-1-(((2S)-1-(((2S)-1-cyano-1-hydroxy-3-((2S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide(130 and 131)

Cyanohydrins 130 and 131 were synthesized from 91 by following theprocedure described for the preparation of compound 128 and 129. Afterpurification, one fraction was isolated as a single isomer (130,configuration unknown) while the other fractions were mixtures of (R)-and (S)-isomers (131).

Compound 130: ¹H NMR (400 MHz, Chloroform-d) δ 8.28 (d, J=7.2 Hz, 1H),8.16 (d, J=8.2 Hz, 1H), 7.89-7.64 (m, 3H), 7.46 (dtd, J=10.1, 6.8, 1.7Hz, 3H), 7.38-7.28 (m, 2H), 6.64 (s, 1H), 6.27 (s, 1H), 5.98 (d, J=7.7Hz, 1H), 5.06 (td, J=8.0, 6.0 Hz, 1H), 4.56 (dd, J=7.7, 3.7 Hz, 1H),4.49 (td, J=8.2, 5.5 Hz, 1H), 4.22 (ddt, J=11.5, 7.5, 3.7 Hz, 1H), 3.70(dd, J=14.5, 5.9 Hz, 1H), 3.51 (dd, J=14.4, 8.3 Hz, 1H), 3.29-3.10 (m,2H), 2.38 (s, 3H), 2.29 (ddd, J=22.3, 12.0, 4.6 Hz, 2H), 1.97 (tt,J=8.9, 4.0 Hz, 1H), 1.77 (dt, J=13.5, 4.2 Hz, 1H), 1.71-1.38 (m, 5H),0.82 (dd, J=2.2 Hz, 3H), 0.80 (dd, J=2.2 Hz, 3H). ¹³C NMR (101 MHz,CDCl₃) δ 175.17, 173.96, 171.34, 170.79, 159.45, 158.04, 133.87, 132.51,131.97, 128.82, 127.86, 127.70, 126.44, 125.76, 125.42, 123.62, 118.45,101.31, 65.16, 54.07, 52.77, 51.78, 42.24, 41.12, 37.79, 34.93, 31.49,27.09, 24.75, 22.75, 21.96, 21.24, 12.27. ESI-MS (m/z): 617.3 (M+H)⁺.

Ethyl(E)-4-((S)-4-methyl-2-((S)-2-(3-methylthiophene-2-carboxamido)-3-(naphthalen-1-yl)propanamido)pentanamido)-5-((S)-2-oxopiperidin-3-yl)pent-2-enoate(132 and 133)

Compounds 132 and 133 were synthesized from 115 by following theprocedure described for the preparation of compound 126.

Compound 132: ¹H NMR (400 MHz, Chloroform-d) δ 8.29 (d, J=8.5 Hz, 1H),7.89-7.79 (m, 2H), 7.79-7.70 (m, 1H), 7.51 (dddd, J=23.8, 8.0, 6.8, 1.3Hz, 2H), 7.46-7.34 (m, 2H), 6.94 (d, J=8.2 Hz, 1H), 6.87-6.76 (m, 2H),6.50 (d, J=7.2 Hz, 1H), 5.93 (ddd, J=17.2, 13.9, 3.0 Hz, 2H), 5.00 (q,J=7.2 Hz, 1H), 4.48 (td, J=9.3, 8.8, 4.8 Hz, 2H), 4.18 (qd, J=7.2, 2.9Hz, 3H), 3.83-3.56 (m, 2H), 3.22 (s, 1H), 2.97 (dd, J=21.6, 6.4 Hz, 1H),2.33 (d, J=2.2 Hz, 3H), 2.28-2.15 (m, 1H), 2.06-1.89 (m, 1H), 1.81 (dd,J=9.0, 4.5 Hz, 1H), 1.69 (ddt, J=13.3, 9.1, 4.5 Hz, 1H), 1.58-1.41 (m,3H), 1.35 (t, J=7.1 Hz, 1H), 1.30-1.22 (m, 4H), 0.88 (s, 3H), 0.86 (s,3H). ¹³C NMR (101 MHz, CDCl₃) δ 174.88, 171.95, 170.84, 166.34, 163.26,147.48, 141.24, 133.96, 132.75, 132.19, 131.97, 130.76, 128.84, 128.00,127.92, 127.47, 126.49, 125.78, 125.49, 123.93, 121.16, 60.41, 54.60,52.31, 49.36, 42.34, 41.44, 38.66, 36.03, 34.78, 27.88, 24.83, 23.03,21.73, 21.43, 15.66, 14.25. ESI-MS (m/z): 675.3 (M+H)⁺.

Compound 133: 1H NMR (400 MHz, Chloroform-d) δ 8.35 (d, J=8.4 Hz, 1H),8.22 (d, J=7.2 Hz, 1H), 7.86 (dd, J=8.0, 1.3 Hz, 1H), 7.76 (d, J=7.7 Hz,1H), 7.57 (ddd, J=8.4, 6.8, 1.5 Hz, 1H), 7.54-7.48 (m, 1H), 7.46-7.35(m, 2H), 7.00-6.79 (m, 2H), 6.62 (d, J=8.1 Hz, 1H), 6.48 (d, J=7.1 Hz,1H), 5.90 (dd, J=15.6, 1.7 Hz, 1H), 5.82 (s, 1H), 5.07 (q, J=7.2 Hz,1H), 4.71 (d, J=6.9 Hz, 1H), 4.43 (td, J=9.3, 4.4 Hz, 1H), 4.18 (qd,J=7.1, 1.0 Hz, 2H), 3.80 (dd, J=14.4, 6.6 Hz, 1H), 3.76-3.63 (m, 2H),3.22 (d, J=7.0 Hz, 3H), 2.32 (s, 3H), 2.02-1.94 (m, 2H), 1.93-1.81 (m,1H), 1.77-1.56 (m, 4H), 1.50-1.40 (m, 2H), 1.27 (t, J=7.1 Hz, 3H), 0.85(dd, J=1.7 Hz, 3H), 0.82 (dd, J=1.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ174.88, 171.34, 171.31, 166.28, 163.56, 147.12, 141.49, 134.00, 132.90,132.15, 132.02, 130.52, 128.91, 127.97, 127.91, 127.54, 126.66, 125.89,125.52, 123.85, 121.72, 60.45, 54.53, 52.48, 48.36, 42.52, 41.22, 37.84,34.68, 34.14, 27.60, 24.81, 23.05, 21.87, 21.52, 15.64, 14.26. ESI-MS(m/z): 675.3 (M+H)⁺.

Ethyl(E)-4-((S)-4-methyl-2-((S)-3-(naphthalen-1-yl)-2-(5-(trifluoromethyl)isoxazole-3-carboxamido)propanamido)pentanamido)-5-((S)-2-oxopiperidin-3-yl)pent-2-enoate(134 and 135)

Compounds 134 and 135 were synthesized from 104 by following theprocedure described for the preparation of compound 126.

Compound 134: ¹H NMR (400 MHz, Chloroform-d) δ 8.28 (d, J=8.4 Hz, 1H),7.95 (d, J=6.6 Hz, 1H), 7.90-7.83 (m, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.67(d, J=7.5 Hz, 1H), 7.52 (dddd, J=26.4, 8.0, 6.8, 1.3 Hz, 2H), 7.45-7.32(m, 2H), 7.08 (t, J=0.9 Hz, 1H), 6.79 (dd, J=15.7, 5.4 Hz, 1H), 6.63 (d,J=8.1 Hz, 1H), 5.92 (d, J=1.6 Hz, 1H), 5.01 (q, J=7.2 Hz, 1H), 4.45 (td,J=10.4, 8.3, 5.0 Hz, 2H), 4.18 (q, J=7.1 Hz, 2H), 3.79-3.56 (m, 2H),3.26 (d, J=12.9 Hz, 3H), 2.35-2.23 (m, 1H), 2.09-1.91 (m, 2H), 1.87-1.60(m, 4H), 1.60-1.37 (m, 3H), 1.27 (t, J=7.1 Hz, 3H), 0.88 (dd, J=1.7 Hz,3H), 0.86 (dd, J=1.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.17, 171.74,169.67, 166.31, 158.17, 157.27, 147.31, 133.97, 132.13, 131.98, 128.93,128.23, 127.99, 126.55, 125.85, 125.48, 123.65, 121.22, 105.33, 105.30,60.45, 54.39, 52.35, 49.88, 42.39, 41.62, 38.85, 36.13, 35.35, 28.22,24.80, 22.90, 21.87, 21.44, 14.24. ¹⁹F NMR (377 MHz, CDCl₃) δ −64.01.ESI-MS (m/z): 714.3 (M+H)⁺.

Compound 135: ¹H NMR (400 MHz, Chloroform-d) δ 8.62 (d, J=7.0 Hz, 1H),8.29 (s, 1H), 8.21 (d, J=8.0 Hz, 1H), 7.85 (dd, J=8.2, 1.5 Hz, 1H), 7.76(d, J=8.2 Hz, 1H), 7.73-7.65 (m, 1H), 7.60-7.53 (m, 2H), 7.51-7.46 (m,2H), 7.41-7.37 (m, 1H), 6.86 (dd, J=15.6, 4.4 Hz, 1H), 6.22 (d, J=7.8Hz, 1H), 6.10 (s, 1H), 5.96 (dd, J=15.6, 1.8 Hz, 1H), 5.16 (q, J=7.4 Hz,1H), 4.70 (d, J=6.2 Hz, 1H), 4.31 (ddd, J=9.8, 7.9, 4.8 Hz, 1H),4.26-4.12 (m, 3H), 3.77 (dd, J=14.3, 7.3 Hz, 1H), 3.68 (dd, J=14.4, 7.0Hz, 1H), 3.25 (s, 3H), 2.35-2.25 (m, 1H), 1.96-1.87 (m, 2H), 1.70 (ddt,J=16.6, 12.5, 6.3 Hz, 3H), 1.28 (t, J=7.2 Hz, 3H), 0.81 (d, J=4.2 Hz,3H), 0.79 (d, J=4.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.30, 170.83,169.81, 166.31, 158.36, 157.28, 146.91, 133.99, 132.42, 132.16, 131.97,128.99, 128.45, 128.13, 127.99, 126.63, 125.89, 125.57, 123.53, 122.05,105.47, 60.53, 54.19, 52.86, 48.51, 42.49, 40.70, 37.48, 35.16, 28.33,24.74, 22.94, 21.64, 21.60, 14.26. ¹⁹F NMR (377 MHz, CDCl₃) δ −64.01.ESI-MS (m/z): 714.3 (M+H)⁺.

Example 2

Cellular Toxicity Assays

The toxicity of the compounds was assessed in Vero, human PBM, CEM(human lymphoblastoid), MT-2, and HepG2 cells, as described previously(see Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D. L., XieM.-Y., Hart G. C., Smith G. A. & Hahn E. F. Antimicrob. AgentsChemother. 1990, 34, 1061-67). Cycloheximide was included as positivecytotoxic control, and untreated cells exposed to solvent were includedas negative controls. The cytotoxicity CC₅₀ was obtained from theconcentration-response curve using the median effective method describedpreviously (see Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22,27-55; Belen'kii M. S. & Schinazi R. F. Antiviral Res. 1994, 25, 1-11).The results are shown in Table 1 below:

TABLE 1 Cytotoxicity, CC₅₀, μM ( % inhibition) Compound PBM CEM VEROHuh7 11 >100 >100 >100 >10 19  24  32  20 >10 23 >100  39 >100 >1029 >100  38 >100 >10 35  52  35 >100  60 36  45   9 >100  8 37  44 18 >100  11 38  18   6  22  13 39  39   2  11  14 67 >100  64 >100 ND

In the Table, compounds 11, 19, 28, 29, 35-39 and 67 have the followingstructures:

Example 3

Mitochondrial Toxicity Assays in HepG2 Cells:

i) Effect of Compounds on Cell Growth and Lactic Acid Production: Theeffect on the growth of HepG2 cells was determined by incubating cellsin the presence of 0 μM, 0.1 μM, 1 μM, 10 μM and 100 μM drug. Cells(5×10⁴ per well) were plated into 12-well cell culture clusters inminimum essential medium with nonessential amino acids supplemented with10% fetal bovine serum, 1% sodium pyruvate, and 1%penicillin/streptomycin and incubated for 4 days at 37° C. At the end ofthe incubation period the cell number was determined using ahemocytometer. Also taught by Pan-Zhou X-R, Cui L, Zhou X-J, SommadossiJ-P, Darley-Usmer V M. “Differential effects of antiretroviralnucleoside analogs on mitochondrial function in HepG2 cells,”Antimicrob. Agents Chemother. 2000; 44: 496-503.

To measure the effects of the compounds on lactic acid production, HepG2cells from a stock culture were diluted and plated in 12-well cultureplates at 2.5×10⁴ cells per well. Various concentrations (0 μM, 0.1 μM,1 μM, 10 μM and 100 μM) of compound were added, and the cultures wereincubated at 37° C. in a humidified 5% CO₂ atmosphere for 4 days. At day4, the number of cells in each well was determined and the culturemedium collected. The culture medium was then filtered, and the lacticacid content in the medium was determined using a colorimetric lacticacid assay (Sigma-Aldrich). Since lactic acid product can be considereda marker for impaired mitochondrial function, elevated levels of lacticacid production detected in cells grown in the presence of testcompounds would indicate a drug-induced cytotoxic effect.

ii) Effect of Compounds on Mitochondrial DNA Synthesis: a real-time PCRassay to accurately quantify mitochondrial DNA content has beendeveloped (see Stuyver L J, Lostia S, Adams M, Mathew J S, Pai B S,Grier J, Tharnish P M, Choi Y, Chong Y, Choo H, Chu C K, Otto M J,Schinazi R F. Antiviral activities and cellular toxicities of modified2′,3′-dideoxy-2′,3′-didehydrocytidine analogs. Antimicrob. AgentsChemother. 2002; 46: 3854-60). This assay was used in all studiesdescribed in this application that determine the effect of compounds onmitochondrial DNA content. In this assay, low-passage-number HepG2 cellswere seeded at 5,000 cells/well in collagen-coated 96-well plates. Testcompounds were added to the medium to obtain final concentrations of 0μM, 0.1 μM, 10 μM and 100 μM. On culture day 7, cellular nucleic acidswere prepared by using commercially available columns (RNeasy 96 kit;Qiagen). These kits co-purify RNA and DNA, and hence, total nucleicacids are eluted from the columns. The mitochondrial cytochrome coxidase subunit II (COXII) gene and the β-actin or rRNA gene wereamplified from 5 μl of the eluted nucleic acids using a multiplex Q-PCRprotocol with suitable primers and probes for both target and referenceamplifications. For COXII the following sense, probe and antisenseprimers were used, respectively: 5′-TGCCCGCCATCATCCTA-3′, SEQ ID No: 2,5′-tetrachloro-6-carboxyfluorescein-TCCTCATCGCCCTCCCATCCC-TAMRA-3′, SEQID No: 3, and 5′-CGTCTGTTATGTAAAGGATGCGT-3′, SEQ ID No: 4. For exon 3 ofthe β-actin gene (GenBank accession number E01094) the sense, probe, andantisense primers are 5′-GCGCGGCTACAGCTTCA-3′, SEQ ID No: 5,5′-6-FAMCACCACGGCCGAGCGGGATAMRA-3′, SEQ ID No: 6, and5′-TCTCCTTAATGTCACGCACGAT-3′, SEQ ID No: 7, respectively. The primersand probes for the rRNA gene are commercially available from AppliedBiosystems. Since equal amplification efficiencies are obtained for allgenes, the comparative CT method was used to investigate potentialinhibition of mitochondrial DNA synthesis. The comparative CT methoduses arithmetic formulas in which the amount of target (COXII gene) isnormalized to the amount of an endogenous reference (the β-actin or rRNAgene) and is relative to a calibrator (a control with no drug at day 7).The arithmetic formula for this approach is given by 2-ΔΔCT, where ΔΔCTis (CT for average target test sample−CT for target control)−(CT foraverage reference test−CT for reference control) (see Johnson M R, KWang, J B Smith, M J Heslin, R B Diasio. Quantitation ofdihydropyrimidine dehydrogenase expression by real-time reversetranscription polymerase chain reaction. Anal. Biochem. 2000;278:175-184). A decrease in mitochondrial DNA content in cells grown inthe presence of drug indicated mitochondrial toxicity.

Example 4

Mitochondrial Toxicity Assays in Neuro2A Cells

To estimate the potential of the compounds of this invention to causeneuronal toxicity, mouse Neuro2A cells (American Type Culture Collection131) can be used as a model system (see Ray A S, Hernandez-Santiago B I,Mathew J S, Murakami E, Bozeman C, Xie M Y, Dutschman G E, Gullen E,Yang Z, Hurwitz S, Cheng Y C, Chu C K, McClure H, Schinazi R F, AndersonK S. Mechanism of anti-human immunodeficiency virus activity ofbeta-D-6-cyclopropylamino-2′,3′-didehydro-2′,3′-dideoxyguanosine.Antimicrob. Agents Chemother. 2005, 49, 1994-2001). The concentrationsnecessary to inhibit cell growth by 50% (CC₅₀) can be measured using the3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide dye-basedassay, as described. Perturbations in cellular lactic acid andmitochondrial DNA levels at defined concentrations of drug can becarried out as described above. ddC and AZT can be used as controlnucleoside analogs.

Example 5

Assay for Bone Marrow Cytotoxicity

Primary human bone marrow mononuclear cells can be obtained commerciallyfrom Cambrex Bioscience (Walkersville, Md.). CFU-GM assays is carriedout using a bilayer soft agar in the presence of 50 units/mL humanrecombinant granulocyte/macrophage colony-stimulating factor, whileBFU-E assays used a ethylcellulose matrix containing 1 unit/mLerythropoietin (see Sommadossi J P, Carlisle R. Toxicity of3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guaninefor normal human hepatopoietic progenitor cells in vitro. Antimicrob.Agents Chemother. 1987; 31: 452-454; Sommadossi, J P, Schinazi, R F,Chu, C K, and Xie, M Y. Comparison of cytotoxicity of the (−) and (+)enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrowprogenitor cells. Biochem. Pharmacol. 1992; 44:1921-1925). Eachexperiment can be performed in duplicate in cells from three differentdonors. AZT is used as a positive control. Cells can be incubated in thepresence of the compound for 14-18 days at 37° C. with 5% CO₂, andcolonies of greater than 50 cells can be counted using an invertedmicroscope to determine the IC₅₀. The 50% inhibitory concentration(IC₅₀) can be obtained by least-squares linear regression analysis ofthe logarithm of drug concentration versus BFU-E survival fractions.Statistical analysis can be performed with Student's t test forindependent non-paired samples.

Example 6

Anti-Enterovirus Activity

Compounds are tested for cytotoxicity using a MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)method and the CC₅₀ (IC₅₀) values (cytotoxic concentrations of drugrequired to reduce cell viability by 50%) are determined for each testcompound in human rhabdomyosarcoma (RD) cell line. In addition, themaximum non-toxic concentrations (MNTC) are also determined for eachcompound. To avoid potential drug toxicity that would interfere withviral cytopathic effect (CPE), compounds are evaluated at nontoxicconcentrations. The resultant inhibitory effect of each test compound iscalculated as a percentage of decrease in EV-71 CPE. Briefly, amonolayer of RD cells is prepared in a 96-well plates. The cells arethen infected with 1 MOI of EV-71 (BrCr strain) followed by treatmentwith a single non-toxic dose of each compound in triplicate. The vehiclecontrol wells are treated with 0.1% DMSO diluted in the working media.The plate is then incubated for 48 h at which time the virus-controlwells produced detectable CPE. To determine the probable CPE inhibitoryeffect of test compounds, an MTS assay is performed and effectivecompounds are chosen for further studies to identify the potency of thecompounds and their concentration-dependent manner. The dose-responseantiviral activity of each compound is determined by a virus yieldreduction assay method. Briefly, confluent monolayers of RD cells in96-wells microplate are infected with 0.1 MOI of EV-71 followed bytreatment with compounds. Effective compounds are further quantified andconfirmed with a virus-yield-reduction assay using an optimized in houseqRT-PCR to determine the EV-71 RNA copy number after 2 dayspost-treatment from collected supernatants. qRT-PCR is performed usingthe EV-71 specific probe/primer mix and qScript-Tough master mix(Quantibio, USA). Quantitative PCR measurement was performed usingStepOnePlus real time PCR system (Roche, Germany) according tomanufacturer's protocol. The median effective concentration (EC₅₀) andthe concentration with 90% of inhibitory effect (EC₉₀) are calculatedusing GraphPad PRISM for Windows, version 5 (GraphPad Software Inc., SanDiego, Calif., 2005) as the means±standard deviation (SD) of the meanfrom triplicate assay from three independent experiments.

The median effective concentrations (EC₅₀) ranges of several of thecompounds described herein against Enterovirus EV-71 (BrCr strain) isshown below:

Thus, numerous compounds within the formulas described herein havenanomolar EC₅₀ values, and excellent therapeutic windows (i.e., CC₅₀values>100 μM).

Example 7

In Vitro Assay for SARS

A fusion protein, prepared by fusing a severe acute respiratory syndrome3CL protease to E. coli maltose-binding protein (MBP), can be expressedin E coli BL21 (DE3) pLys S cells (Novagen, Oakland, Calif.). Fusionprotein thus obtained can be purified by amylose-affinity chromatographyand cleaved with factor Xa to release the severe acute respiratorysyndrome 3CL protease. Subsequently, the recombinant protease can bepurified to homogeneity using phenyl Sepharose CL-4B column (Pharmacia,Uppsala, Sweden) and concentrated to form a 25 μM solution.

The enzymatic activity of severe acute respiratory syndrome 3CL protease(75 nM) can be determined by incubation with a solution containing 15 μMof a substrate peptide (SITSAVLQSGFRKMA, SEQ ID

No: 1) at 25° C. for 30 minutes in a medium containing 20 mM Tris-HCl(pH 7.5), 200 mM NaCl, 1 mM EDTA, 1 mM dithiothretol, and 1 mg/mL bovineserum albumin. The reaction can be terminated by adding an equal volumeof 0.2% trifluoroacetic acid. The reaction mixture can be analyzed byreverse-phase HPLC using a C18 column. Cleaved products can be resolvedusing a 5-95% linear gradient of acetonitrile in 0.9% trifluoroaceticacid. Quantification of peak areas can be used to determine the extentof substrate conversion.

Compounds can be tested for their efficacy in inhibiting severe acuterespiratory syndrome 3CL protease. Specifically, a test compound and thesevere acute respiratory syndrome 3CL protease can be pre-incubated at25° C. for 20 minutes before they are incubated with the substratepeptide.

Example 8

In Vitro Assay for SARS-CoV-2 and HCoV (OC43):

In order to determine the potential effect of each selected compoundagainst in vitro replication of SARS-CoV-2 in Vero cells or HCoV (OC43)in Huh7 cells, a confluent cell monolayer in a 96-wells cell culturemicroplate can be infected at a multiplicity of infection (MOI) of 0.1and treated with a maximum non-toxic concentration (MNTC) of eachcompound. To assess the antiviral activity, a virus yield reductionassay using specific qRT-PCR for each virus can be performed.

Dose-Dependent Antiviral Assay. The antiviral effect of each compoundselected through the antiviral evaluation assay can be further confirmedby virus yield reduction assay using the optimized qRT-PCR by measuringthe RNA copy number for each virus in the supernatant oftreated-infected cells. A positive control, such as remdesivir, can beused for each assay.Statistical analysis. The half-maximal effective concentration (EC₅₀)and the concentration with 90% of inhibitory effect (EC₉₀) can becalculated using GraphPad PRISM for Windows, version 5 (GraphPadSoftware Inc., San Diego, Calif., 2005) or the Chou and Talalay Method.

These methods were used to evaluate certain of the compounds describedherein.

SARS-CoV-2 strain was provided by BEI Resources (NR-52281: USA-WA/2020).The virus was propagated in Vero cells (African Green Monkey Kidney:ATCC) and titrated by median tissue culture infectious dose (TCID₅₀)method. Viral stock was stored as aliquots at −80° C. until further use.

A qRT-PCR assay was used to specifically to quantify the yield ofSARS-CoV-2 in the cell-based assays. A one-step qRT-PCR was carried outin a final volume of 20 μl containing extracted viral RNA, probe/primermix (Forward Primer: 5′-GAC CCC AAA ATC AGC GAA AT-3′, SEQ ID No: 8;Reverse Primer: 5′-TCT GGT TAC TGC CAG TTG AAT CTG-3′, SEQ ID No: 10;Probe: 5′-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1-3′, SEQ ID No: 9)recommended by CDC and synthesized by IDT DNA Technology, andqScript-Tough master mix. Quantitative PCR measurement was performedusing StepOnePlus real time PCR system (Roche, Germany).

Virus kinetic replication assay: To determine the best time point forvirus yield assay a kinetic replication of SARS-CoV-2 in Vero cells wasperformed and the yield of progeny virus production was assessed fromsupernatants at interval time points using a specific q-RT PCR forSARS-CoV-2. It was observed that 48 h post-infection, a significantincrease in virus yield was achieved.

SARS- OC43 CoV-2 Inhibition Inhibition at 10 μM at 10 μM CompoundStructure (%) (%) 37

99.9 99.9 36

99.9 99.8 38

95 85.1 35

99.9 99.8 39

99.4 68.0 136

99.3 99.8 128

100 99.9 129

99.9 99.9 97

99.9 99.8 43

99.9 99.9 44

99.7 99.5

Activity against SARS- CoV-2 Compound Structure EC₅₀ EC₉₀ 37

0.3 4.5 91

0.6 2.3

Various publications are cited herein, the disclosures of which areincorporated by reference in their entireties for all purposes.

The present invention is not to be limited in scope by the specificembodiments described herein. Indeed, various modifications of theinvention in addition to those described will become apparent to thoseskilled in the art from the foregoing description and accompanyingfigures. Such modifications are intended to fall within the scope of theappended claims.

We claim:
 1. A method for treating a coronavirus infection or reducingthe biological activity of an infection with a coronavirus, comprisingadministering an effective antiviral amount of a compound to a patientin need of treatment thereof, wherein the compound has any of FormulasIII or V:

or

or a pharmaceutically acceptable salt thereof, wherein: R¹ is anoptionally substituted 5-membered ring heteroaryl, R³ is an optionallysubstituted C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₈ alkoxyalkyl, arylalkyl,alkylaryl, heteroarylalkyl, or alkylheteroaryl, —CH2-(hydroxy)phenyl, orCH₂-(halo)phenyl, R⁴ is an optionally substituted C₁₋₆ alkyl, R⁵ is—C(O)H, CH═C(CN)C(O)NH₂, —C(O)CF₃, —CH(OH)CF₃, —C(OH)SO₃ ⁻ (and anassociated cation), or an optionally-substituted epoxide ring, R²,R^(2′), R¹⁰ and R^(10′) are, independently, hydrogen, CF₃, C₁₋₆ alkyl,C₁₋₆ haloalkyl, or C₂₋₆ alkenyl, X is a bond, m is 1 and n is 0, 1, 2,or 3; p is 0; R⁶ and R^(6′) are, independently, hydrogen, halogen, CF₃,hydroxy, N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆ alkenyl,cyano, C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl,alkoxycarbonylalkyl, C₁₋₆ alkyl, aryl alkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; or R⁶ and R^(6′),together with the carbon to which they are attached, form a carbonyl,each R′ is, independently, H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, aryl, heteroaryl,alkylaryl, or arylalkyl, the R′ groups can optionally be substitutedwith one or more substituents, which substituents are, independently,halo, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, hydroxyl, carboxyl, acyl, aryl,acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino,arylamino, alkoxy, alkoxyalkyl, aryloxy, nitro, cyano, sulfonic acid,thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester,carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine,thioester, thioether, acid halide, anhydride, oxime, hydrozine,carbamate, phosphonic acid, or phosphonate; two R′ residing on the samecarbon or nitrogen atom can come together to form a C₃₋₆ ring optionallycontaining a N, O, or S heteroatom; R⁶ and R^(6′) can come together toform an optionally substituted double bond or a C₃₋₆ ring optionallycontaining a N, O, or S heteroatom; R⁷ and R^(7′) are, independently,hydrogen, CF₃, N(R′)S(O)₂R′, S(O)₂R′, S(O)₂N(R′)₂, C₁₋₆ alkoxy, C₂₋₆alkenyl, cyano, C₂₋₆ alkynyl, C₃₋₆ alkoxyalkyl, alkoxycarbonyl,alkoxycarbonylalkyl, C₁₋₆ alkyl, arylalkoxycarbonyl, carboxy, C₁₋₆haloalkyl, heterocyclylalkyl, or C₁₋₆ hydroxyalkyl; and R⁷ and R^(7′)can come together to form an optionally substituted double bond or aC₃₋₆ ring optionally containing a N, O, or S heteroatom, and R¹ is afive or six membered ring heteroaryl.
 2. The method of claim 1, whereinR⁵ is C(O)H.
 3. The method of claim 1, wherein R³ is alkylaryl oralkylheteroaryl, R¹ is


4. The method of claim 1, wherein the compound has one of the followingformulas:

and pharmaceutically acceptable salts thereof.
 5. A method for treatinga coronavirus infection or reducing the biological activity of aninfection with a coronavirus, comprising administering an effectiveantiviral amount of a compound to a patient in need of treatmentthereof, wherein the compound has one of the following structures:


6. The method of claim 1, wherein R³ is phenyl, halo-substituted phenyl,or naphthyl.
 7. The method of claim 1, wherein the virus is SARS, MERS,or COVID-19.
 8. The method of claim 1, wherein the virus is a causativeagent for a respiratory infection.
 9. The method of claim 1, wherein themethod further comprising administering another anti-coronavirus agentin combination or alternation with the compound of any of Formulas IIIor V.
 10. The method of claim 9, wherein the one or more additionalactive compounds are selected from the group consisting of JAKinhibitors, NOX inhibitors, CYP-450 inhibitors, fusion inhibitors, entryinhibitors, protease inhibitors, polymerase inhibitors, antiviralnucleosides, viral entry inhibitors, viral maturation inhibitors,angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specifichuman monoclonal antibodies, platelet aggregation inhibitors,anticoagulant, and agents of distinct or unknown mechanism.
 11. Themethod of claim 9, wherein the one or more additional active agentscomprise remdesivir, GS-441524, N-hydroxy cytidine, Jakafi, Tofacitinib,Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof.12. The method of claim 1, wherein the virus is SARS-CoV-2.
 13. Themethod of claim 1, wherein the compound has one of the followingformulas: